{"PMC7092805": [], "d94a9c03a0dc9134e2a8928719f66827ff8f8fbf": [["IntroductionThe SARS-CoV-2 pandemic has reached over 2,054,000 diagnosed cases and 114,000 COVID-19 deaths in the United States (US) as of June 13, 2020 [1] .", [["SARS-CoV-2 pandemic", "DISEASE", 16, 35], ["deaths", "DISEASE", 100, 106], ["SARS-CoV-2", "ORGANISM", 16, 26], ["SARS-CoV", "SPECIES", 16, 24], ["The SARS", "TEST", 12, 20]]], ["New York State, especially the New York City metropolitan area, has been the geographic area in the US with the largest cumulative number of diagnosed cases (381,714) and COVID-19 deaths (30,758) as of the same date [1, 2] .IntroductionThe racial and ethnic disparities in COVID-19 fatalities have received substantial attention.", [["deaths", "DISEASE", 180, 186], ["fatalities", "DISEASE", 282, 292], ["COVID", "TEST", 171, 176], ["New", "OBSERVATION_MODIFIER", 31, 34], ["geographic", "OBSERVATION_MODIFIER", 77, 87], ["area", "OBSERVATION_MODIFIER", 88, 92], ["largest", "OBSERVATION_MODIFIER", 112, 119], ["racial", "OBSERVATION_MODIFIER", 240, 246]]], ["For example, in a large health system in California, Black patients were hospitalized for COVID-19 at 2.7 times the rate for white patients even after adjustment for sex, age, income and comorbidities [3] .", [["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 131, 139], ["COVID", "TEST", 90, 95], ["large", "OBSERVATION_MODIFIER", 18, 23], ["Black", "OBSERVATION_MODIFIER", 53, 58]]], ["In a study of COVID-19 racial and ethnic disparities among over 5.8 million US veterans, Black and Hispanic persons were more likely to be tested for COVID-19, and at increased odds of testing positive though mortality at 30 days did not appear to differ [4] .", [["persons", "ORGANISM", 108, 115], ["persons", "SPECIES", 108, 115], ["a study", "TEST", 3, 10], ["COVID", "TEST", 14, 19], ["COVID", "TEST", 150, 155], ["testing positive", "PROBLEM", 185, 201]]], ["In a large health care system in Louisiana, 31% of the patients are Black, but comprised 76.9% of the hospitalizations and 70.6% of the COVID-19 deaths [5] .", [["deaths", "DISEASE", 145, 151], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["the COVID", "TEST", 132, 141], ["large", "OBSERVATION_MODIFIER", 5, 10]]], ["A study of the county-level disparities in the US found that 22% of the counties were \"disproportionatelyIntroductionBlack\" yet accounted for 52% of diagnoses and 58% of deaths related to COVID-19 [6] .", [["deaths", "DISEASE", 170, 176], ["COVID-19", "CHEMICAL", 188, 196], ["A study", "TEST", 0, 7], ["the US", "TEST", 43, 49], ["diagnoses", "TEST", 149, 158], ["COVID", "TEST", 188, 193]]], ["Besides empirical observations of racial and ethnic disparities in the COVID-19 pandemic, other recent papers draw lessons from the history of infectious diseases as to why such disparities may exist, and how these lessons may provide a path forward to building health equity [7] [8] [9] .IntroductionThe racial and ethnic minority disparities in COVID-19 fatalities in New York State (excluding New York City) are clear and pronounced with the age-adjusted death rates per 100,000 population for Black, Hispanic, Asian American and white communities being 112, 101, 60 and 28, respectively, as of mid-June 2020 (further information on the impact of SARS-CoV-2 is Native American communities is lacking and much needed) [10, 11] .IntroductionIn order to address racial and ethnic disparities in COVID-19 fatalities, it is crucial to define and compare competing metrics for fatalities, as well as better understand their upstream determinants.IntroductionFirst, it is important to separate Population Fatality Rate (COVID-19 deaths divided by population size, PFR), Infection Fatality Rate (deaths divided by estimated number of SARS-CoV-2 infections in the population, IFR), and Case Fatality Rate (deaths divided by estimated number of diagnoses cases in the population, CFR).", [["infectious diseases", "DISEASE", 143, 162], ["fatalities", "DISEASE", 356, 366], ["death", "DISEASE", 458, 463], ["SARS", "DISEASE", 650, 654], ["fatalities", "DISEASE", 874, 884], ["deaths", "DISEASE", 1025, 1031], ["Fatality", "DISEASE", 1076, 1084], ["deaths", "DISEASE", 1091, 1097], ["SARS", "DISEASE", 1129, 1133], ["infections", "DISEASE", 1140, 1150], ["deaths", "DISEASE", 1200, 1206], ["SARS-CoV", "SPECIES", 1129, 1137], ["racial and ethnic disparities", "PROBLEM", 34, 63], ["the COVID", "TEST", 67, 76], ["infectious diseases", "PROBLEM", 143, 162], ["Infection Fatality Rate (deaths", "PROBLEM", 1066, 1097], ["SARS", "TEST", 1129, 1133], ["CoV", "TEST", 1134, 1137], ["racial", "OBSERVATION_MODIFIER", 34, 40], ["infectious", "OBSERVATION", 143, 153], ["racial", "OBSERVATION_MODIFIER", 305, 311]]], ["When stratified by race and ethnicity, PFR, IFR and CFR potentially portray different lenses through which to view and understand the disparities in COVID-19 deaths.", [["deaths", "DISEASE", 158, 164], ["PFR", "TEST", 39, 42], ["IFR", "TEST", 44, 47]]], ["These various fatality rates by race and ethnicity are not currently available in the literature to our knowledge, in part because of limited availability of appropriately stratified data sources, such as population-based seroprevalence studies or case registries.IntroductionSecond, to better understand the sources of racial and ethnic disparities in the various COVID-19 fatality rate metrics, we construct a continuum analogous to the well-known \"care continuum\" in the HIV literature which traces the fraction of the population diagnosed as living with HIV, the percentage of diagnosed persons accessing HIV-related medical care; and the fraction of persons who experience HIV viral suppression [12] [13] [14] .", [["HIV", "DISEASE", 558, 561], ["HIV viral suppression", "DISEASE", 678, 699], ["persons", "ORGANISM", 591, 598], ["persons", "ORGANISM", 655, 662], ["persons", "SPECIES", 591, 598], ["HIV", "SPECIES", 609, 612], ["persons", "SPECIES", 655, 662], ["HIV", "SPECIES", 474, 477], ["HIV", "SPECIES", 558, 561], ["HIV", "SPECIES", 609, 612], ["HIV", "SPECIES", 678, 681], ["seroprevalence studies", "TEST", 222, 244], ["racial and ethnic disparities", "PROBLEM", 320, 349], ["HIV viral suppression", "PROBLEM", 678, 699]]], ["For COVID-19, such a continuum might trace the following steps, which are key, routinely-reported health quantities and events: (a) population size; (b) infection experience with SARS-CoV-2; (c) diagnosis; (d) hospitalization; and (e) fatality.", [["infection", "DISEASE", 153, 162], ["SARS", "DISEASE", 179, 183], ["COVID", "TEST", 4, 9], ["SARS", "PROBLEM", 179, 183], ["fatality", "PROBLEM", 235, 243], ["size", "OBSERVATION_MODIFIER", 143, 147], ["infection", "OBSERVATION", 153, 162]]], ["By constructing such a continuum for COVID-19 and stratifying by race and ethnicity, one can better determine if the racial and ethnic disparities seen in fatality metrics are also seen at other steps, and importantly at which steps and to what degree.", [["COVID-19", "DNA", 37, 45], ["COVID", "TEST", 37, 42], ["the racial and ethnic disparities", "PROBLEM", 113, 146]]], ["These insights can inform policy decisions as to how best to intervene to reduce disparities and promote health equity related to COVID-19.IntroductionIn the present paper, we estimate the New York State COVID-19 outcomes continuum by race and ethnicity.", [["COVID", "TEST", 130, 135]]], ["An important challenge to address in the construction of a COVID-19 continuum is the establishment of an analytic framework for synthesizing data sources that allows valid and meaningful movement from one step to the next in the continuum, as opposed to simply identifying individual, not comparable sources in estimating each step [14] .", [["a COVID-19 continuum", "TREATMENT", 57, 77], ["synthesizing data sources", "PROBLEM", 128, 153]]], ["Using recently-available population-based data sources, we propose such an analytic framework.Continuum constructionThe COVID-19 outcomes continuum for adults ages \u226518 years was conceptualized and estimated in five distinct steps: population, infection-experience (cumulative incidence), diagnosis, hospitalization, and fatality.", [["infection", "DISEASE", 243, 252], ["infection", "PROBLEM", 243, 252], ["fatality", "PROBLEM", 320, 328], ["infection", "OBSERVATION", 243, 252]]], ["We used both publicly available and peer-reviewed data sources (Table 1) to estimate the absolute number and relative racial and ethnic distribution of individuals within these steps.", [["racial", "OBSERVATION_MODIFIER", 118, 124]]], ["We estimated the continuum for the cohort of adults in the time-period defined for a statewide seroprevalence study in NYS, which estimated cumulative incidence of SARS-CoV-2 by race and ethnicity through approximately March 29 [15] .", [["SARS", "DISEASE", 164, 168], ["SARS-CoV", "SPECIES", 164, 172], ["a statewide seroprevalence study", "TEST", 83, 115], ["SARS", "PROBLEM", 164, 168]]], ["Calculations were performed for the four racial and ethnic groupings of white non-Hispanic, Black non-Hispanic, Hispanic, and \"all other races and ethnicities combined\" so as to address the entire adult population, however, we present detailed results on the first 3 due to greater data robustness, completeness, and interpretability.", [["Calculations", "TEST", 0, 12]]], ["Importantly, we note that for Asian, Native Hawaiian and other Pacific Islander, American Indian, Alaska Native, multi-racial, multiethnic, and other communities the completeness of the available data and the size of each specific community prohibited construction of separate continua, and we identify these as key data gaps to urgently address in the future.PopulationThe continuum is estimated here for all adults including institutionalized persons (i.e. including incarcerated persons and nursing home residents; Table 1 , Source A) who are disproportionally affected by COVID-19 while making up a small portion (1.3%) of the general adult population.", [["continua", "DISEASE", 277, 285], ["persons", "ORGANISM", 445, 452], ["persons", "SPECIES", 445, 452], ["persons", "SPECIES", 482, 489], ["COVID", "TEST", 576, 581], ["size", "OBSERVATION_MODIFIER", 209, 213]]], ["This population is represented in all data sources utilized here, other than the seroprevalence study [16].Infection experienceThe probabilities of a history of SARS-Cov-2 infection by race-ethnicity observed in the NYS seroprevalence study (Table 1 , Source B) were applied to the adult population estimates [15] .DiagnosisInformation on the race and ethnicity of COVID-19 diagnoses is not publicly available statewide, but is reported for residents of NYC, with 41% completeness (Source C) [17] .", [["SARS", "DISEASE", 161, 165], ["infection", "DISEASE", 172, 181], ["the seroprevalence study", "TEST", 77, 101], ["Infection experience", "PROBLEM", 107, 127], ["SARS", "PROBLEM", 161, 165], ["Cov", "PROBLEM", 166, 169], ["2 infection", "PROBLEM", 170, 181], ["the NYS seroprevalence study", "TEST", 212, 240]]], ["Next, for each racial and ethnic-group, the percent diagnosed within NYC was estimated by dividing the diagnosed case counts by the number of individuals who experienced SARS-CoV-2 infection (\"infection experienced\"), as previously done for age and sex stratifications [15] .DiagnosisWe next applied this distribution to the rest of NYS (ROS) by multiplying the within-group diagnosis rates in NYC by the total number of infections by each group in ROS, thus accounting for differences in racial/ethnic composition of adults in ROS compared to NYC.", [["SARS-CoV-2 infection", "DISEASE", 170, 190], ["infection", "DISEASE", 193, 202], ["ROS", "CHEMICAL", 338, 341], ["infections", "DISEASE", 421, 431], ["ROS", "CHEMICAL", 449, 452], ["ROS", "CHEMICAL", 528, 531], ["CoV-2", "ORGANISM", 175, 180], ["NYS", "SIMPLE_CHEMICAL", 333, 336], ["ROS", "SIMPLE_CHEMICAL", 338, 341], ["ROS", "SIMPLE_CHEMICAL", 449, 452], ["adults", "ORGANISM", 518, 524], ["ROS", "SIMPLE_CHEMICAL", 528, 531], ["SARS-CoV-2", "SPECIES", 170, 180], ["SARS", "PROBLEM", 170, 174], ["CoV-2 infection", "PROBLEM", 175, 190], ["\"infection", "PROBLEM", 192, 202], ["infections", "PROBLEM", 421, 431], ["infection", "OBSERVATION", 181, 190], ["infections", "OBSERVATION", 421, 431]]], ["As the overall percent diagnosed was previously found significantly higher in ROS than in NYC (12.9% vs. 7.1%), diagnoses were next equally scaled across racial/ethnic groups to match the total overall number of diagnoses in ROS through April 9 th (Source B).", [["ROS", "SIMPLE_CHEMICAL", 78, 81], ["ROS", "SIMPLE_CHEMICAL", 225, 228], ["significantly", "OBSERVATION_MODIFIER", 54, 67], ["higher", "OBSERVATION_MODIFIER", 68, 74]]], ["The sum within-group diagnoses for NYC and ROS diagnoses then yielded the statewide estimates.HospitalizationThe racial/ethnic distribution among hospitalizations was calculated from a random sample of medical records from patients admitted to hospitals in metropolitan New York City counties, which represented 88% of diagnosed COVID-19 patients in NYS from March 15-30 (Source D) [18] .", [["COVID", "DISEASE", 329, 334], ["ROS", "SIMPLE_CHEMICAL", 43, 46], ["patients", "ORGANISM", 223, 231], ["patients", "ORGANISM", 338, 346], ["patients", "SPECIES", 223, 231], ["patients", "SPECIES", 338, 346], ["COVID", "TEST", 329, 334]]], ["These proportions were multiplied by the cumulative number of individuals hospitalized for COVID-19 in NYS as of April 9 th (42,852) (Source E), reflecting that 85% of hospitalized patients were diagnosed concurrent with admission during this time period, then multiplied by the percent of hospitalized individuals 18 years old or older (98.3%) from the sample study, to yield the total number of hospitalized adults (42,124) for each racial and ethnic group [19].FatalityThough racial and ethnic data on fatalities are available publicly from both NYC and ROS, they differ in completeness and methodology, and are likely underestimates due to missingness in race and ethnicity collection.", [["patients", "ORGANISM", 181, 189], ["ROS", "SIMPLE_CHEMICAL", 557, 560], ["patients", "SPECIES", 181, 189], ["COVID", "TEST", 91, 96], ["the sample study", "TEST", 350, 366], ["missingness in race and ethnicity collection", "PROBLEM", 644, 688]]], ["Therefore, we estimated in-hospital fatality by multiplying, for each racial/ethnic group, the probability of in-hospital death observed in the hospital sample study by the estimated number of persons hospitalized (Source D).", [["death", "DISEASE", 122, 127], ["persons", "ORGANISM", 193, 200], ["persons", "SPECIES", 193, 200], ["sample study", "TEST", 153, 165]]], ["These total deaths were finally scaled to allow the resulting estimated total in-hospital deaths (8, 580) to match the total officially-reported number of COVID-19 fatalities in NYS (12,822) as of April 17 th , which were then multiplied by the percent of fatalities attributed to adults 18 years or older (99.94%), to yield the total number of adult fatalities (12,814) by race and ethnicity (Source E).Assessment of outcomes and disparitiesFollowing estimation of adults at each step of the continuum, we computed the percent at each step per population.", [["deaths", "DISEASE", 12, 18], ["deaths", "DISEASE", 90, 96], ["fatalities", "DISEASE", 164, 174], ["fatalities", "DISEASE", 256, 266], ["fatalities", "DISEASE", 351, 361], ["COVID", "TEST", 155, 160]]], ["In addition to overall fatality per population (\"PFR\"), we estimated race-specific infection-fatality rates (per infection-experienced individuals, \"IFR\") and case-fatality rates (per diagnosed persons, \"CFR\").", [["infection", "DISEASE", 83, 92], ["infection", "DISEASE", 113, 122], ["persons", "SPECIES", 194, 201], ["specific infection", "PROBLEM", 74, 92], ["fatality rates", "PROBLEM", 93, 107], ["infection", "OBSERVATION", 83, 92]]], ["We also present additional conditional percentages to assess where along the continuum racial/ethnic disparities emerge: severity (hospitalization, among those infected) and fatalities-to-hospitalizations (total fatalities, per person hospitalized).", [["fatalities", "DISEASE", 174, 184], ["fatalities", "DISEASE", 212, 222], ["person", "SPECIES", 228, 234]]], ["Disparities in these quantities were summarized using risk-ratios.ResultsIn the population of adult New York residents, through late March 2020, 8.0% of white non-Hispanic, 18.7% of Black non-Hispanic, and 28.4% of Hispanic adults were estimated to have experienced infection with SARS-CoV-2 ( Figure 1 ).", [["infection", "DISEASE", 266, 275], ["SARS", "DISEASE", 281, 285], ["adults", "ORGANISM", 224, 230], ["SARS-CoV", "SPECIES", 281, 289], ["white non-Hispanic", "TEST", 153, 171], ["Black non-Hispanic", "TEST", 182, 200], ["Hispanic adults", "TEST", 215, 230], ["infection", "PROBLEM", 266, 275], ["SARS", "TEST", 281, 285], ["CoV", "TEST", 286, 289], ["infection", "OBSERVATION", 266, 275]]], ["Compared to white non-Hispanic adults, racial/ethnic minority populations had disproportionately higher per population likelihoods of COVID-19 diagnosis (0.93% white non-Hispanic, 1.89% Black non-Hispanic, 1.85% Hispanic), hospitalization (0.11% white non-Hispanic, 0.50% Black non-Hispanic, 0.48% Hispanic) and death (0.03% white non-Hispanic, 0.18% Black non-Hispanic, 0.12% Hispanic).ResultsNext, the analyses indicate that among individuals with infection experience, diagnosis rates varied by race and ethnicity: 11.7% of infection-experienced white non-Hispanic adults were diagnosed, compared to 10.1% of Black non-Hispanic adults and 6.5% of Hispanic adults (Figure 1 ).", [["death", "DISEASE", 312, 317], ["infection", "DISEASE", 450, 459], ["infection", "DISEASE", 527, 536], ["adults", "ORGANISM", 568, 574], ["racial/ethnic minority populations", "PROBLEM", 39, 73], ["COVID", "TEST", 134, 139], ["death", "TEST", 312, 317], ["the analyses", "TEST", 400, 412], ["infection", "PROBLEM", 450, 459], ["diagnosis rates", "TEST", 472, 487], ["infection", "PROBLEM", 527, 536], ["white non-Hispanic adults", "PROBLEM", 549, 574], ["Black non-Hispanic adults", "TEST", 612, 637], ["disproportionately", "OBSERVATION_MODIFIER", 78, 96], ["higher", "OBSERVATION_MODIFIER", 97, 103], ["infection", "OBSERVATION", 450, 459], ["infection", "OBSERVATION", 527, 536]]], ["Levels of hospitalization among persons diagnosed were about two-fold higher Black non-Hispanic and Hispanic adults, compared to white non-Hispanic adults, with hospitalizations also relatively elevated among persons who were infected (Table 2) .ResultsFatality rates and rate ratios comparing racial and ethnic minorities to white adults are shown in Table 2 .", [["persons", "ORGANISM", 32, 39], ["persons", "ORGANISM", 209, 216], ["persons", "SPECIES", 32, 39], ["persons", "SPECIES", 209, 216], ["Fatality rates", "TEST", 253, 267], ["rate ratios", "TEST", 272, 283]]], ["The population fatality rate ratios illustrate that per population, Black non-Hispanic and Hispanic adults were respectively 5.38 and 3.48 times as likely to die of COVID-19 as were white non-Hispanic adults.", [["adults", "ORGANISM", 100, 106], ["The population fatality rate ratios", "TEST", 0, 35], ["COVID", "TEST", 165, 170]]], ["Conditioning among those who were infected, the IFR for Black non-Hispanic adults remained 2.30-fold that of white non-Hispanic, while no disparity remained for Hispanic vs. white non-Hispanic adults (IFR ratio = 0.98).", [["Black non-Hispanic adults", "TEST", 56, 81], ["white non-Hispanic", "PROBLEM", 109, 127], ["Hispanic", "PROBLEM", 161, 169], ["white non-Hispanic adults", "TEST", 174, 199], ["IFR ratio", "TEST", 201, 210]]], ["Among those diagnosed, the relative CFR was 2.65 for Black non-Hispanic vs. white non-Hispanic adults, and 1.75 for Hispanic vs. white non-Hispanic adults.ResultsThese divergent fatality disparities are explained by different trajectories along the continuum.ResultsAmong Black non-Hispanic adults, disparities are evident at all continuum steps; the 5.38 overall fatality ratio compared to white non-Hispanic adults is the product of risk-ratios of 2.35 for infection, 1.93 for severity (hospitalization given infection), and 1.19 for fatalities-to-hospitalizations.", [["infection", "DISEASE", 459, 468], ["infection", "DISEASE", 511, 520], ["fatalities", "DISEASE", 536, 546], ["the relative CFR", "TEST", 23, 39], ["Black non-Hispanic vs. white non-Hispanic adults", "PROBLEM", 53, 101], ["Hispanic vs. white non-Hispanic adults", "PROBLEM", 116, 154], ["ratios", "TEST", 440, 446], ["infection", "PROBLEM", 459, 468], ["severity", "PROBLEM", 479, 487], ["infection", "PROBLEM", 511, 520], ["divergent", "OBSERVATION_MODIFIER", 168, 177], ["fatality", "OBSERVATION", 178, 186]]], ["Among Hispanic adults, compared to white non-Hispanic adults, the risk ratio was 3.56 for infection, whereas the product of the latter two ratios of 1.24 for severity, and 0.79 for fatalities-to-hospitalizations, yields the estimated 0.98 relative risk for death given infection summarized by the IFR.DiscussionExamination of the racial and ethnic continua for SARS-CoV-2 in New York State shows that the disparities in fatalities in Hispanic communities relative to non-Hispanic white populations appear to be due in large part to differences earlier on in infections.", [["infection", "DISEASE", 90, 99], ["fatalities", "DISEASE", 181, 191], ["death", "DISEASE", 257, 262], ["infection", "DISEASE", 269, 278], ["continua", "DISEASE", 348, 356], ["SARS", "DISEASE", 361, 365], ["fatalities", "DISEASE", 420, 430], ["infections", "DISEASE", 558, 568], ["SARS-CoV", "SPECIES", 361, 369], ["the risk ratio", "TEST", 62, 76], ["infection", "PROBLEM", 90, 99], ["severity", "TEST", 158, 166], ["death", "PROBLEM", 257, 262], ["infection", "PROBLEM", 269, 278], ["SARS", "PROBLEM", 361, 365], ["non-Hispanic white populations", "PROBLEM", 467, 497], ["infection", "OBSERVATION", 269, 278], ["infections", "OBSERVATION", 558, 568]]], ["For non-Hispanic Black communities relative to white disparities in mortality appear to be due to both differences in infections and in hospitalization rates and equally so at approximately 2-fold disparity each.", [["infections", "DISEASE", 118, 128], ["white disparities in mortality", "PROBLEM", 47, 77], ["infections", "PROBLEM", 118, 128], ["infections", "OBSERVATION", 118, 128]]], ["This provides important signals about which stages on the continuum might be most useful to enhance service delivery and to focus policy interventions and further research.", [["delivery", "TREATMENT", 108, 116], ["policy interventions", "TREATMENT", 130, 150]]], ["For instance, to address racial and ethnic differences in cumulative infection in Hispanic and Black communities, one might consider addressing \"upstream\" factors that are directly related to exposure to SARS-CoV-2 such as housing and food insecurity, high housing density, more front line service occupations that made sheltering at home more difficult, and heightened reliance on public transportation, in addition to root causes of these conditions such as systemic income inequality, racism, and discrimination [7] [8] [9] 20] .", [["root", "ANATOMY", 420, 424], ["infection", "DISEASE", 69, 78], ["SARS", "DISEASE", 204, 208], ["food insecurity", "DISEASE", 235, 250], ["cumulative infection", "PROBLEM", 58, 78], ["these conditions", "PROBLEM", 435, 451], ["cumulative", "OBSERVATION_MODIFIER", 58, 68], ["infection", "OBSERVATION", 69, 78]]], ["To address differences in hospitalizations for Black communities, one might further consider disparities in underlying health conditions, such as diabetes, coronary disease and chronic lung disease, which appear to be predisposing to poor clinical outcomes in COVID-19 (the root societal causes of those underlying health conditions must also be addressed, of course) [7] [8] [9] 20] .DiscussionWe also provide the first State-level estimates of the percent of infections diagnosed by race and ethnicity, showing lower diagnosis levels among Black and particularly Hispanic adults, relative to white non-Hispanic adults.", [["coronary", "ANATOMY", 156, 164], ["lung", "ANATOMY", 185, 189], ["root", "ANATOMY", 274, 278], ["diabetes", "DISEASE", 146, 154], ["coronary disease", "DISEASE", 156, 172], ["chronic lung disease", "DISEASE", 177, 197], ["infections", "DISEASE", 461, 471], ["coronary", "MULTI-TISSUE_STRUCTURE", 156, 164], ["lung", "ORGAN", 185, 189], ["root", "ORGAN", 274, 278], ["[7] [8] [9] 20", "SIMPLE_CHEMICAL", 368, 382], ["Black communities", "PROBLEM", 47, 64], ["diabetes", "PROBLEM", 146, 154], ["coronary disease", "PROBLEM", 156, 172], ["chronic lung disease", "PROBLEM", 177, 197], ["poor clinical outcomes", "PROBLEM", 234, 256], ["COVID", "TEST", 260, 265], ["infections", "PROBLEM", 461, 471], ["lower diagnosis levels", "PROBLEM", 513, 535], ["coronary", "ANATOMY", 156, 164], ["disease", "OBSERVATION", 165, 172], ["chronic", "OBSERVATION_MODIFIER", 177, 184], ["lung", "ANATOMY", 185, 189], ["disease", "OBSERVATION", 190, 197], ["infections", "OBSERVATION", 461, 471]]], ["Lower levels of diagnosis may be related to diminished access to routine healthcare and/or specialized testing for SARS-CoV-2, due to a variety of factors including transportation, health insurance access, and other key social determinants of health.", [["SARS", "DISEASE", 115, 119], ["SARS-CoV", "SPECIES", 115, 123], ["specialized testing", "TEST", 91, 110], ["SARS", "PROBLEM", 115, 119]]], ["[7, 8, 9] We note that the lesser percent of infections diagnosed among Hispanic adults also serves to inflate apparent disparities in estimates of hospitalization among those diagnosed and the CFR relative to white adultsonce hospitalization and fatality are evaluated over a denominator of infection-experience, the disparities become more muted.", [["infections", "DISEASE", 45, 55], ["infection", "DISEASE", 292, 301], ["infections", "PROBLEM", 45, 55], ["infection", "PROBLEM", 292, 301], ["infections", "OBSERVATION", 45, 55], ["infection", "OBSERVATION", 292, 301]]], ["An important resulting epidemiologic lesson is that measures of hospitalization and fatality that condition on diagnosis may be ill-suited for understanding of disparities.DiscussionFurther, we note that the methodology used here to establish comparable measures across stages of the continuum and across racial and ethnic groups appears to triangulate well with other known data sources; for instance, the high per-population disparities in fatality by race and ethnicity closely track with what has been observed on the State and NYC fatality dashboards [10, 17] .DiscussionThere are several limitations in the current analysis, and they include the following.", [["the current analysis", "TEST", 609, 629]]], ["First, a number of the metrics measured or estimated here are subject to sources of random and systematic error.", [["random and systematic error", "PROBLEM", 84, 111]]], ["Given that there is no clear a priori estimate of the scope and direction of the latter bias since we are in the earlier days of the pandemic, we do not include further sensitivity analyses here in this first exposition of the continuum, but rather present the most detailed, empirically-based information for each stage.", [["further sensitivity analyses", "TEST", 161, 189], ["no", "UNCERTAINTY", 20, 22]]], ["However, we note that continued validation of the continuum parameter estimates will be important in the months and years ahead as further data are gathered relevant to each stage in the continua.", [["continua", "DISEASE", 187, 195]]], ["For instance, it is not yet clear whether there are differences by race and ethnicity in terms of percentage of persons living with SARS-CoV-2 who are asymptomatic or pre-symptomatic; as lessons are learned in the future in this regard, potential refinements to the continua can be made.DiscussionA second limitation is that our estimated continuum does not include as separate categories Asian, other Pacific Islander, Native American, Alaskan Native, and multi-racial, multi-ethnic communities, and this is a clear limitation of currently available data; given the population size of some of these racial and ethnic communities, it will be necessary to construct future applied studies and surveillance activities dedicated to the oversampling needed to make meaningful continua estimates by each population.DiscussionThird, while we estimate in detail the continuum for New York State, it will be useful to see the development of the continuum in other jurisdictions, and until that is accomplished we are careful not to generalize our findings beyond New York, although the methodology employed here could be productively used in other locales.", [["SARS", "DISEASE", 132, 136], ["persons", "ORGANISM", 112, 119], ["persons", "SPECIES", 112, 119], ["asymptomatic", "PROBLEM", 151, 163], ["pre-symptomatic", "PROBLEM", 167, 182], ["surveillance activities", "TEST", 692, 715], ["size", "OBSERVATION_MODIFIER", 578, 582]]], ["Fourth, while we have taken care to establish the continuum at a given, well-specified moment in time, the COVID-19 pandemic is evolving quickly, and it will be important to repeat this analysis at multiple, future time to better understand the dynamic trajectories of racial and ethnic disparities.DiscussionFifth, the continuum offered here provides a framework for further COVID-19 surveillance activities;Discussionindeed, a comprehensive, timely COVID-19 surveillance system could be crafted around this continuum, and the resultant data and analyses used as a dashboard to monitor progress in the pandemic both in terms of health outcomes, and social justice.DiscussionWe also note limitations to the construction of each step of the continuum from the currently available data sources, and maturation of the available data over time for each continuum step will be important.", [["the COVID", "TEST", 103, 112], ["this analysis", "TEST", 181, 194], ["the resultant data", "TEST", 524, 542]]], ["For example, our approach applied a general population cumulative incidence estimate to the entire population, including institutionalized persons, who are included in the diagnosis, hospital, and fatality outcomes.", [["persons", "ORGANISM", 139, 146], ["persons", "SPECIES", 139, 146]]], ["Given documented excess burden in institutional settings such as nursing homes, this likely underestimates our estimate of infection-experienced adults, but it is the only feasible option absent more comprehensive prevalence data on these populations, who make up 1.3% of the adult population [21] .DiscussionAnother limitation related to data availability is that current publicly-available data on the racial and ethnic composition of diagnoses are limited to partially-complete data on NYC, which contains about 43% of the State's population [16] .", [["infection", "DISEASE", 123, 132], ["adults", "ORGANISM", 145, 151], ["infection", "PROBLEM", 123, 132], ["excess", "OBSERVATION_MODIFIER", 17, 23], ["burden", "OBSERVATION", 24, 30], ["infection", "OBSERVATION", 123, 132]]], ["Enhancements for routine collection and reporting of race and ethnicity from diagnostic testing are needed.", [["routine collection", "TEST", 17, 35], ["diagnostic testing", "TEST", 77, 95]]], ["Indeed, the sparseness of racial and ethnic data for COVID-19 diagnoses has been a source of major discussion in the public domain, notably including a recent federal mandate that all jurisdictions must collect and report race and ethnicity for diagnoses by August 1, 2020 [22] .", [["racial", "OBSERVATION_MODIFIER", 26, 32]]], ["While data to characterize the distribution of this missingness, and assess the direction of potential bias, are currently not available, we have attempted to use the available information in the best way feasible; we have drawn on principles of risk factor redistribution from HIV surveillance by proportionally applying known information to those with unknown data in NYC and also to the rest of New York State, after first adjusting for the higher levels of diagnosis in the rest of the state.", [["HIV", "SPECIES", 278, 281], ["this missingness", "PROBLEM", 47, 63], ["HIV surveillance", "TEST", 278, 294]]], ["A major purpose of this paper is to lay out a framework for illuminating disparities using the best available data, and also for highlighting priority areas for future data refinement towards the end of increasing health equity; this is such a priority area.DiscussionA similar call can be made for more complete racial and ethnic information for hospitalizations.DiscussionHere we used a hospitalized sample reflecting 88% of NYS COVID-19 cases located in metropolitan NY, a region with proportionally more non-white persons than ROS.", [["ROS", "CHEMICAL", 531, 534], ["ROS", "SIMPLE_CHEMICAL", 531, 534], ["persons", "SPECIES", 518, 525], ["NYS COVID", "TEST", 427, 436]]], ["Were data on the racial/ethnic composition of the remaining 12% ROS hospitalizations available, they may more reflect white patient hospitalizations.", [["ROS", "SIMPLE_CHEMICAL", 64, 67], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131]]], ["Finally, in scaling in-hospital to all fatalities, we assumed nonhospital fatalities followed the same relative patterns as in-hospital fatalities by race and ethnicity.DiscussionWe note that our findings are not age-adjusted, thus providing an overall view of outcomes for and disparities between racial and ethnic groups, which may be further explained by differences in risk factors.", [["fatalities", "DISEASE", 136, 146]]], ["One such important factor is age, which is associated with COVID-19 severity [3, 18] .", [["COVID", "TEST", 59, 64]]], ["Although the lack of age distribution data within racial and ethnic groupings precludes control in this analysis, we note that per Census data 25%, 17%, and 13% of white non-Hispanic, Black non-Hispanic, and Hispanic adults in New York are above 65 years of age.", [["Census data", "TEST", 131, 142]]], ["Given that we observed racial and ethnic disparities in most continuum outcomes, despite the white non-Hispanic population being older, this suggests that the overall disparities documented might increase if we additionally controlled for age.DiscussionOur conceptualization of the continuum is not intended to be final, but rather illustrative of current key outcomes that are vital to describing the epidemic; stages may be added or modified as epidemiological and clinical understanding evolves.", [["racial and ethnic disparities", "PROBLEM", 23, 52], ["racial", "OBSERVATION_MODIFIER", 23, 29], ["ethnic", "OBSERVATION_MODIFIER", 34, 40], ["most continuum", "OBSERVATION_MODIFIER", 56, 70]]], ["We assert that this continuum should be a \"living document\" much as the HIV care continuum described above is continually updated with new clinical understanding, data, and analytic approaches.", [["HIV", "SPECIES", 72, 75]]], ["Indeed a series of such analyses should be performed over time so that the continua are better understood by the dynamic and evolving intersections of race and ethnicity with gender, age, geography, co-morbid conditions, and key social factors.DiscussionDespite these limitations, the COVID-19 continuum stratified by race and ethnicity, even in this early form, provides important insights as to what factors underlie the already widely recognized health disparities in COVID-19 deaths, and suggest possible points of intervention to begin to better build health equity in the era of the COVID-19 pandemic.", [["continua", "DISEASE", 75, 83], ["deaths", "DISEASE", 480, 486], ["such analyses", "TEST", 19, 32], ["the COVID", "TEST", 281, 290], ["intervention", "TREATMENT", 519, 531], ["the COVID", "TEST", 585, 594], ["pandemic", "PROBLEM", 598, 606]]]], "ae45a79ede6d3509cf36403e23896c1f3ac38ecc": [["IntroductionAmong the seven species of Eimeria infecting domestic chicken five species are of great economic importance due to their relatively high pathogenicity (Shirley et al. 1983 ).", [["Eimeria", "ORGANISM", 39, 46], ["chicken", "ORGANISM", 66, 73], ["chicken", "SPECIES", 66, 73], ["chicken", "SPECIES", 66, 73], ["IntroductionAmong", "TREATMENT", 0, 17], ["Eimeria infecting domestic chicken five species", "PROBLEM", 39, 86], ["Eimeria", "OBSERVATION_MODIFIER", 39, 46], ["infecting", "OBSERVATION_MODIFIER", 47, 56], ["high", "OBSERVATION_MODIFIER", 144, 148], ["pathogenicity", "OBSERVATION", 149, 162]]], ["Among the five species, E. tenella is the most pathogenic species and is localized within the caecum and causes fatal caecal coccidiosis (Soulsby 2012) .", [["caecum", "ANATOMY", 94, 100], ["caecal", "ANATOMY", 118, 124], ["caecal coccidiosis", "DISEASE", 118, 136], ["E. tenella", "ORGANISM", 24, 34], ["caecum", "ORGAN", 94, 100], ["caecal", "ORGANISM_SUBDIVISION", 118, 124], ["E. tenella", "SPECIES", 24, 34], ["E. tenella", "SPECIES", 24, 34], ["E. tenella", "PROBLEM", 24, 34], ["the most pathogenic species", "PROBLEM", 38, 65], ["fatal caecal coccidiosis", "PROBLEM", 112, 136], ["most pathogenic", "OBSERVATION_MODIFIER", 42, 57], ["species", "OBSERVATION", 58, 65], ["caecum", "ANATOMY", 94, 100], ["fatal", "OBSERVATION_MODIFIER", 112, 117], ["caecal", "ANATOMY", 118, 124], ["coccidiosis", "OBSERVATION", 125, 136]]], ["E. necatrix, E. acervulina and E. maxima cause intestinal coccidiosis.", [["intestinal", "ANATOMY", 47, 57], ["intestinal coccidiosis", "DISEASE", 47, 69], ["E. necatrix", "ORGANISM", 0, 11], ["E. acervulina", "ORGANISM", 13, 26], ["E. maxima", "ORGANISM", 31, 40], ["intestinal", "ORGAN", 47, 57], ["E. necatrix", "SPECIES", 0, 11], ["E. acervulina", "SPECIES", 13, 26], ["E. maxima", "SPECIES", 31, 40], ["E. necatrix", "SPECIES", 0, 11], ["E. acervulina", "SPECIES", 13, 26], ["E. maxima", "SPECIES", 31, 40], ["E. necatrix", "TREATMENT", 0, 11], ["E. acervulina", "TREATMENT", 13, 26], ["intestinal coccidiosis", "PROBLEM", 47, 69], ["necatrix", "OBSERVATION", 3, 11], ["E. acervulina", "OBSERVATION_MODIFIER", 13, 26], ["E. maxima", "OBSERVATION_MODIFIER", 31, 40], ["intestinal", "ANATOMY", 47, 57], ["coccidiosis", "OBSERVATION", 58, 69]]], ["E. necatrix is the second most pathogenic species after E. tenella and produces a more chronic form of the disease (Soulsby 2012 ).", [["E. necatrix", "ORGANISM", 0, 11], ["E. tenella", "ORGANISM", 56, 66], ["E. necatrix", "SPECIES", 0, 11], ["E. tenella", "SPECIES", 56, 66], ["E. necatrix", "SPECIES", 0, 11], ["E. tenella", "SPECIES", 56, 66], ["E. tenella", "PROBLEM", 56, 66], ["the disease", "PROBLEM", 103, 114], ["necatrix", "OBSERVATION", 3, 11], ["second most", "OBSERVATION_MODIFIER", 19, 30], ["E. tenella", "OBSERVATION_MODIFIER", 56, 66], ["more chronic", "OBSERVATION_MODIFIER", 82, 94], ["disease", "OBSERVATION", 107, 114]]], ["E. acervulina and E. maxima are moderately pathogenic species and hence cause high morbidity but low mortality.", [["E. acervulina", "ORGANISM", 0, 13], ["E. maxima", "ORGANISM", 18, 27], ["E. acervulina", "SPECIES", 0, 13], ["E. maxima", "SPECIES", 18, 27], ["E. acervulina", "SPECIES", 0, 13], ["E. maxima", "SPECIES", 18, 27], ["E. maxima", "PROBLEM", 18, 27], ["moderately pathogenic species", "PROBLEM", 32, 61], ["high morbidity", "PROBLEM", 78, 92], ["low mortality", "PROBLEM", 97, 110], ["acervulina", "OBSERVATION", 3, 13], ["E. maxima", "OBSERVATION_MODIFIER", 18, 27], ["moderately", "OBSERVATION_MODIFIER", 32, 42], ["pathogenic", "OBSERVATION", 43, 53]]], ["E. acervulina, E. necatrix and E. maxima are most common species of Eimeria responsible for intestinal coccidiosis prevalent in North India (Prakshbabu et al. 2017 ).", [["intestinal", "ANATOMY", 92, 102], ["Eimeria", "DISEASE", 68, 75], ["intestinal coccidiosis", "DISEASE", 92, 114], ["E. acervulina", "ORGANISM", 0, 13], ["E. necatrix", "ORGANISM", 15, 26], ["E. maxima", "ORGANISM", 31, 40], ["Eimeria", "ORGANISM", 68, 75], ["intestinal", "ORGAN", 92, 102], ["E. acervulina", "SPECIES", 0, 13], ["E. necatrix", "SPECIES", 15, 26], ["E. maxima", "SPECIES", 31, 40], ["E. acervulina", "SPECIES", 0, 13], ["E. necatrix", "SPECIES", 15, 26], ["E. maxima", "SPECIES", 31, 40], ["E. necatrix", "TREATMENT", 15, 26], ["E. maxima", "PROBLEM", 31, 40], ["intestinal coccidiosis", "PROBLEM", 92, 114], ["acervulina", "OBSERVATION", 3, 13], ["E. necatrix", "OBSERVATION_MODIFIER", 15, 26], ["E. maxima", "OBSERVATION_MODIFIER", 31, 40], ["most common", "OBSERVATION_MODIFIER", 45, 56], ["Eimeria", "OBSERVATION", 68, 75], ["intestinal", "ANATOMY", 92, 102], ["coccidiosis", "OBSERVATION", 103, 114]]], ["E. brunetti, the causative of rectal coccidiosis is highly pathogenic but has a low prevalence in India (Prakshbabu et al. 2017) .", [["rectal", "ANATOMY", 30, 36], ["rectal coccidiosis", "DISEASE", 30, 48], ["E. brunetti", "ORGANISM", 0, 11], ["rectal", "ORGAN", 30, 36], ["E. brunetti", "SPECIES", 0, 11], ["E. brunetti", "SPECIES", 0, 11], ["rectal coccidiosis", "PROBLEM", 30, 48], ["rectal", "ANATOMY", 30, 36], ["coccidiosis", "OBSERVATION", 37, 48], ["low prevalence", "OBSERVATION_MODIFIER", 80, 94]]], ["In farms of South India, highly pathogenic E. necatrix was more prevalent as compared to moderately pathogenic E. acervulina (Prakshbabu et al. 2017) .", [["E. necatrix", "ORGANISM", 43, 54], ["E. acervulina", "ORGANISM", 111, 124], ["E. necatrix", "SPECIES", 43, 54], ["E. acervulina", "SPECIES", 111, 124], ["E. necatrix", "SPECIES", 43, 54], ["E. acervulina", "SPECIES", 111, 124], ["highly pathogenic E. necatrix", "PROBLEM", 25, 54], ["necatrix", "OBSERVATION", 46, 54]]], ["The variation in population dynamics of high, moderate or low pathogenic species in farms of a geographical area will region do impact the farm economics in several ways.", [["population dynamics", "TEST", 17, 36], ["high, moderate or low pathogenic species", "PROBLEM", 40, 80], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["population", "OBSERVATION_MODIFIER", 17, 27], ["high", "OBSERVATION_MODIFIER", 40, 44], ["moderate", "OBSERVATION_MODIFIER", 46, 54], ["low", "OBSERVATION_MODIFIER", 58, 61], ["pathogenic", "OBSERVATION_MODIFIER", 62, 72], ["species", "OBSERVATION_MODIFIER", 73, 80], ["farm economics", "OBSERVATION", 139, 153]]], ["This epidemiological factor may determine the possibility of future coccidiosis outbreaks and prophylactic measures to be undertaken.", [["coccidiosis", "DISEASE", 68, 79], ["future coccidiosis outbreaks", "PROBLEM", 61, 89], ["prophylactic measures", "TREATMENT", 94, 115], ["may determine the possibility of", "UNCERTAINTY", 28, 60], ["coccidiosis", "OBSERVATION", 68, 79]]], ["Moreover, higher incidence of high or moderately pathogenic Eimeria species in different farming systems may be indicative development of resistance against anti-coccidial chemotherapy.", [["Eimeria", "ORGANISM", 60, 67], ["anti-coccidial", "SIMPLE_CHEMICAL", 157, 171], ["high or moderately pathogenic Eimeria species", "PROBLEM", 30, 75], ["anti-coccidial chemotherapy", "TREATMENT", 157, 184], ["higher", "OBSERVATION_MODIFIER", 10, 16], ["incidence", "OBSERVATION_MODIFIER", 17, 26], ["high", "OBSERVATION_MODIFIER", 30, 34], ["moderately", "OBSERVATION_MODIFIER", 38, 48], ["pathogenic", "OBSERVATION_MODIFIER", 49, 59], ["Eimeria species", "OBSERVATION", 60, 75], ["anti-coccidial chemotherapy", "OBSERVATION", 157, 184]]], ["Hence, quantification of each individual Eimeria species present in chicken faecal droppings is necessary for understanding disease outbreaks and risk factors associated with quantitative presence of virulent species.IntroductionIdentification of various Eimeria species of chicken in faecal droppings had been carried out based on traditional techniques like morphometry (based on shape and determination of size) and sporulation time based on compound microscope.", [["Eimeria species", "ORGANISM", 41, 56], ["chicken", "ORGANISM", 68, 75], ["faecal", "ORGANISM_SUBDIVISION", 76, 82], ["Eimeria", "ORGANISM", 255, 262], ["chicken", "ORGANISM", 274, 281], ["faecal droppings", "ORGANISM_SUBSTANCE", 285, 301], ["chicken", "SPECIES", 68, 75], ["chicken", "SPECIES", 274, 281], ["chicken", "SPECIES", 68, 75], ["chicken", "SPECIES", 274, 281], ["each individual Eimeria species", "PROBLEM", 25, 56], ["chicken faecal droppings", "PROBLEM", 68, 92], ["understanding disease outbreaks", "PROBLEM", 110, 141], ["risk factors", "PROBLEM", 146, 158], ["virulent species", "PROBLEM", 200, 216], ["IntroductionIdentification", "TREATMENT", 217, 243], ["various Eimeria species of chicken in faecal droppings", "PROBLEM", 247, 301], ["traditional techniques", "TEST", 332, 354], ["compound microscope", "TEST", 445, 464], ["Eimeria species", "OBSERVATION", 41, 56], ["virulent species", "OBSERVATION", 200, 216], ["various", "OBSERVATION_MODIFIER", 247, 254], ["Eimeria species", "OBSERVATION", 255, 270], ["size", "OBSERVATION_MODIFIER", 409, 413]]], ["An online morphometry database software based on size, morphology and texture/granularity of chicken Eimeria species named COCCIMORPH has been developed.", [["COCCIMORPH", "CHEMICAL", 123, 133], ["chicken", "ORGANISM", 93, 100], ["chicken", "SPECIES", 93, 100], ["chicken", "SPECIES", 93, 100], ["An online morphometry database software", "TEST", 0, 39], ["granularity of chicken Eimeria species", "PROBLEM", 78, 116], ["size", "OBSERVATION_MODIFIER", 49, 53], ["texture", "OBSERVATION_MODIFIER", 70, 77], ["granularity", "OBSERVATION_MODIFIER", 78, 89], ["chicken Eimeria species", "OBSERVATION", 93, 116]]], ["The microphotographs of oocysts can be uploaded onto this software and the software predicts the species of oocyst based on characteristics like size and granularity.", [["oocysts", "ANATOMY", 24, 31], ["oocysts", "PROBLEM", 24, 31], ["oocyst", "PROBLEM", 108, 114], ["oocysts", "OBSERVATION", 24, 31], ["oocyst", "OBSERVATION", 108, 114], ["size", "OBSERVATION_MODIFIER", 145, 149], ["granularity", "OBSERVATION", 154, 165]]], ["The software has been used for identification of Eimeria species in droppings of chicken collected from various farms of North India, but its efficiency in correctly identifying the species is low when compared to PCR based diagnostic methods (Kumar et al. 2014) .", [["Eimeria", "ORGANISM", 49, 56], ["chicken", "ORGANISM", 81, 88], ["chicken", "SPECIES", 81, 88], ["chicken", "SPECIES", 81, 88], ["Eimeria species", "PROBLEM", 49, 64], ["chicken", "TREATMENT", 81, 88], ["PCR", "TEST", 214, 217], ["Eimeria species", "OBSERVATION", 49, 64], ["low", "OBSERVATION_MODIFIER", 193, 196]]], ["Quantification of various Eimeria species from faecal droppings based on traditional morphometry or sporulation time would require more time and would be tedious for the technical person involved in diagnosis.", [["Eimeria", "ORGANISM", 26, 33], ["person", "SPECIES", 180, 186], ["various Eimeria species", "PROBLEM", 18, 41], ["faecal droppings", "PROBLEM", 47, 63], ["traditional morphometry", "TEST", 73, 96], ["various Eimeria species", "OBSERVATION", 18, 41], ["faecal droppings", "OBSERVATION", 47, 63]]], ["Moreover the traditional techniques would be less accurate in correct identification and quantification of species.IntroductionAs of today, quantitative PCR is the most useful technique since it can both identify and quantify Eimeria species in biological samples like faecal droppings or tissues (Blake et al. 2006; Kawahara et al. 2008; Morgan et al. 2009; Vrba et al. 2010; Kundu et al. 2017) .IntroductionThis study was performed to identify and enumerate the genome copies of E. necatrix, E. acervulina and E. maxima with quantitative realtime PCR in faecal droppings from different farming systems (broiler, layer and back yard rearing units) from four North India states of Uttarpradesh, Uttarakhand, Punjab and Haryana.Collection of poultry droppings and purification of oocystsPoultry droppings were collected from 31 commercial farms and backyard units from Uttar Pradesh, Uttarakhand, Punjab and Haryana.", [["samples", "ANATOMY", 256, 263], ["tissues", "ANATOMY", 289, 296], ["faecal droppings", "ORGANISM_SUBSTANCE", 269, 285], ["tissues", "TISSUE", 289, 296], ["E. necatrix", "ORGANISM", 481, 492], ["E. acervulina", "ORGANISM", 494, 507], ["E. maxima", "ORGANISM", 512, 521], ["E. necatrix", "SPECIES", 481, 492], ["E. acervulina", "SPECIES", 494, 507], ["E. maxima", "SPECIES", 512, 521], ["E. necatrix", "SPECIES", 481, 492], ["E. acervulina", "SPECIES", 494, 507], ["E. maxima", "SPECIES", 512, 521], ["species", "PROBLEM", 107, 114], ["quantitative PCR", "TEST", 140, 156], ["Eimeria species", "PROBLEM", 226, 241], ["biological samples", "TEST", 245, 263], ["faecal droppings", "PROBLEM", 269, 285], ["This study", "TEST", 409, 419], ["E. necatrix", "TREATMENT", 481, 492], ["E. acervulina", "TREATMENT", 494, 507], ["E. maxima", "TEST", 512, 521], ["quantitative realtime PCR", "TEST", 527, 552], ["faecal droppings", "PROBLEM", 556, 572], ["poultry droppings", "PROBLEM", 741, 758], ["oocysts", "PROBLEM", 779, 786], ["Poultry droppings", "PROBLEM", 786, 803], ["faecal droppings", "OBSERVATION", 269, 285], ["poultry droppings", "OBSERVATION", 741, 758], ["oocysts", "OBSERVATION", 779, 786]]], ["There were twenty one broiler farms, six layer farms and five back yard rearing units.", [["twenty", "OBSERVATION_MODIFIER", 11, 17], ["one", "OBSERVATION_MODIFIER", 18, 21], ["broiler farms", "OBSERVATION", 22, 35], ["layer", "OBSERVATION_MODIFIER", 41, 46], ["farms", "OBSERVATION_MODIFIER", 47, 52]]], ["Birds in each of these farms under study were in apparently good health and none of the farms had experienced coccidiosis outbreaks during collection.", [["coccidiosis", "DISEASE", 110, 121], ["coccidiosis outbreaks during collection", "PROBLEM", 110, 149], ["coccidiosis", "OBSERVATION", 110, 121]]], ["However, as per history collected from the owners, most of the broiler farms had suffered outbreaks of coccidiosis.", [["coccidiosis", "DISEASE", 103, 114], ["coccidiosis", "PROBLEM", 103, 114], ["coccidiosis", "OBSERVATION", 103, 114]]], ["None of the backyard units or layer farms had experienced outbreaks of coccidiosis in the past.", [["coccidiosis", "DISEASE", 71, 82], ["coccidiosis", "PROBLEM", 71, 82], ["coccidiosis", "OBSERVATION", 71, 82]]], ["Poultry droppings were collected, oocyst count per gram of droppings were estimated and further processed for separation of oocyts as described by Kumar et al. (2014) .Extraction of DNA from purified oocystsOocysts harvested from faecal droppings were allowed to sporulate in 2% potassium dichromate.", [["oocystsOocysts", "ANATOMY", 200, 214], ["potassium dichromate", "CHEMICAL", 279, 299], ["potassium dichromate", "CHEMICAL", 279, 299], ["Poultry", "ORGANISM", 0, 7], ["DNA", "CELLULAR_COMPONENT", 182, 185], ["faecal droppings", "ORGANISM_SUBSTANCE", 230, 246], ["potassium dichromate", "SIMPLE_CHEMICAL", 279, 299], ["Poultry droppings", "PROBLEM", 0, 17], ["oocyst count", "TEST", 34, 46], ["droppings", "PROBLEM", 59, 68], ["Extraction", "TREATMENT", 168, 178], ["DNA", "PROBLEM", 182, 185], ["purified oocystsOocysts harvested", "TREATMENT", 191, 224], ["faecal droppings", "PROBLEM", 230, 246], ["2% potassium dichromate", "TREATMENT", 276, 299], ["DNA", "OBSERVATION", 182, 185], ["oocystsOocysts harvested", "OBSERVATION", 200, 224], ["faecal droppings", "OBSERVATION", 230, 246]]], ["Sporulated oocysts were thoroughly washed, centrifuged in a 1.5 ml microcentrifuge tube at 5000 g for 5 min.", [["oocysts", "ANATOMY", 11, 18], ["oocysts", "CELL", 11, 18], ["Sporulated oocysts", "PROBLEM", 0, 18], ["a 1.5 ml microcentrifuge tube", "TREATMENT", 58, 87], ["oocysts", "OBSERVATION", 11, 18]]], ["Supernatant water was discarded and equal volume of autoclaved glass beads of approximately 0.5 mm diameter (Sigma-Aldrich, USA) were added to the oocyst pellet.", [["Supernatant", "ANATOMY", 0, 11], ["oocyst pellet", "ANATOMY", 147, 160], ["Supernatant water", "TREATMENT", 0, 17], ["water", "OBSERVATION_MODIFIER", 12, 17], ["equal", "OBSERVATION_MODIFIER", 36, 41], ["volume", "OBSERVATION_MODIFIER", 42, 48], ["autoclaved glass", "OBSERVATION", 52, 68], ["beads", "OBSERVATION_MODIFIER", 69, 74], ["0.5 mm", "OBSERVATION_MODIFIER", 92, 98], ["diameter", "OBSERVATION_MODIFIER", 99, 107]]], ["Lysis buffer (ASL buffer provided with QIAmp DNA stool mini kit, Qiagen, USA), 50 ll was added to the oocyst pellet and glass bead mixture and the mixure was vortexed on a Spinix vortexer (Tarsons, India) for 3 min to disrupt the oocysts..", [["pellet", "ANATOMY", 109, 115], ["Lysis buffer (ASL buffer", "TREATMENT", 0, 24], ["QIAmp DNA stool mini kit", "TREATMENT", 39, 63], ["the oocyst pellet and glass bead mixture", "TREATMENT", 98, 138], ["glass bead", "OBSERVATION_MODIFIER", 120, 130], ["oocysts", "OBSERVATION", 230, 237]]], ["The vortexing time was standardised by checking the presence of disrupted oocyts, sporocysts and sporozoites under 400X magnification of microscope.", [["oocyts", "ANATOMY", 74, 80], ["sporocysts", "ANATOMY", 82, 92], ["sporozoites", "ANATOMY", 97, 108], ["sporocysts", "CELL", 82, 92], ["sporozoites", "CELL", 97, 108], ["disrupted oocyts", "PROBLEM", 64, 80], ["sporocysts", "OBSERVATION", 82, 92]]], ["This method achieved in disrupting more than 90% of the oocysts.", [["This method", "TREATMENT", 0, 11], ["oocysts", "OBSERVATION", 56, 63]]], ["ASL buffer was further added to the disrupted oocyst pellet, vortexed thoroughly and incubated at 70\u00b0C for 5 min.", [["oocyst pellet", "ANATOMY", 46, 59], ["ASL", "SIMPLE_CHEMICAL", 0, 3], ["ASL buffer", "TREATMENT", 0, 10], ["the disrupted oocyst pellet", "TREATMENT", 32, 59], ["oocyst pellet", "OBSERVATION", 46, 59]]], ["Further steps for extraction of DNA were carried out as per the instructions provided in the manual provided with the Qiagen Stool DNA mini kit.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["extraction of DNA", "TREATMENT", 18, 35]]], ["DNA extracted from oocysts was stored at -20\u00b0C for further use.Extraction of DNA from purified oocystsQuantitative real time PCR (qPCR) for identification and quantification of E. necatrix, E. acervulina and E. maxima Primers used for identification and quantification of E. necatrix, E. acervulina and E. maxima were same as described earlier by Vrba et al. (2010) .", [["oocysts", "ANATOMY", 19, 26], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["oocysts", "ORGANISM_SUBSTANCE", 19, 26], ["DNA", "CELLULAR_COMPONENT", 77, 80], ["E. necatrix", "ORGANISM", 177, 188], ["E. acervulina", "ORGANISM", 190, 203], ["E. maxima", "ORGANISM", 208, 217], ["E. necatrix", "ORGANISM", 272, 283], ["E. acervulina", "ORGANISM", 285, 298], ["E. maxima", "ORGANISM", 303, 312], ["E. necatrix", "SPECIES", 177, 188], ["E. acervulina", "SPECIES", 190, 203], ["E. necatrix", "SPECIES", 272, 283], ["E. acervulina", "SPECIES", 285, 298], ["E. necatrix", "SPECIES", 177, 188], ["E. acervulina", "SPECIES", 190, 203], ["E. maxima", "SPECIES", 208, 217], ["E. necatrix", "SPECIES", 272, 283], ["E. acervulina", "SPECIES", 285, 298], ["DNA", "PROBLEM", 0, 3], ["oocysts", "PROBLEM", 19, 26], ["Extraction", "TREATMENT", 63, 73], ["DNA", "PROBLEM", 77, 80], ["purified oocysts", "PROBLEM", 86, 102], ["Quantitative real time PCR", "TEST", 102, 128], ["identification", "TEST", 140, 154], ["E. necatrix", "TREATMENT", 177, 188], ["E. acervulina", "TREATMENT", 190, 203], ["E. maxima Primers", "TREATMENT", 208, 225], ["identification", "TEST", 235, 249], ["E. necatrix", "TREATMENT", 272, 283], ["E. acervulina", "TREATMENT", 285, 298], ["oocysts", "OBSERVATION", 19, 26]]], ["The details of primers and annealing temperatures are provided in Table 1 .", [["annealing temperatures", "TREATMENT", 27, 49]]], ["Pure DNA of each Eimeria species provided by Prof. Damer P. Blake of Royal Veterinary College, London were used as template for initial PCR amplification and standardization of PCR.Extraction of DNA from purified oocystsIn brief, PCR reactions were performed in 25 ll reaction with 12.5 ll master mix (Takara GC Amp PCR master mix), 02 ll DNA, 01 ll each of forward and reverse primers (10 pmol ll -1 ) and 8.5 ll nuclease free water.", [["DNA", "CELLULAR_COMPONENT", 5, 8], ["DNA", "CELLULAR_COMPONENT", 195, 198], ["DNA", "CELLULAR_COMPONENT", 339, 342], ["02 ll DNA", "DNA", 333, 342], ["01 ll each of forward and reverse primers", "DNA", 344, 385], ["initial PCR amplification", "TREATMENT", 128, 153], ["standardization of PCR", "TREATMENT", 158, 180], ["Extraction", "TREATMENT", 181, 191], ["DNA", "PROBLEM", 195, 198], ["purified oocysts", "PROBLEM", 204, 220], ["PCR reactions", "TEST", 230, 243], ["Takara GC Amp PCR master mix", "TREATMENT", 302, 330], ["02 ll DNA", "TEST", 333, 342], ["reverse primers", "TREATMENT", 370, 385], ["pmol ll", "TEST", 390, 397], ["8.5 ll nuclease free water", "TREATMENT", 407, 433], ["Eimeria species", "OBSERVATION", 17, 32], ["DNA", "OBSERVATION", 195, 198], ["oocysts", "OBSERVATION", 213, 220]]], ["Thermal cycling condition were carried out with initial denaturation at 98\u00b0C for 10 s, 35 cycles of denaturation 98\u00b0C for 10 s, annealing along with extension at 60\u00b0C for 30 s.", [["Thermal cycling condition", "PROBLEM", 0, 25], ["initial denaturation", "PROBLEM", 48, 68], ["denaturation", "TEST", 100, 112], ["extension", "TEST", 149, 158]]], ["PCR products were used for ligation into TA vector.", [["PCR products", "DNA", 0, 12], ["TA vector", "DNA", 41, 50], ["PCR products", "TREATMENT", 0, 12], ["ligation into TA vector", "TREATMENT", 27, 50]]], ["Details of primer sequences have been provided in Table 1 .", [["primer sequences", "DNA", 11, 27], ["primer sequences", "TEST", 11, 27]]], ["The recombinant vector were coned into Escherichia coli and cultured.", [["Escherichia coli", "ORGANISM", 39, 55], ["Escherichia coli", "SPECIES", 39, 55], ["Escherichia coli", "SPECIES", 39, 55], ["The recombinant vector", "TREATMENT", 0, 22], ["Escherichia coli", "PROBLEM", 39, 55], ["Escherichia coli", "OBSERVATION", 39, 55]]], ["Recombinant plamids from the positive E. coli clones were extracted and used as standards.Extraction of DNA from purified oocystsRecombinant plasmids were quantified using Nanodrop spectrophotometer (ND-1000, Thermo Scientific).", [["plasmids", "ANATOMY", 141, 149], ["E. coli", "ORGANISM", 38, 45], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["positive E. coli clones", "CELL_LINE", 29, 52], ["Recombinant plasmids", "DNA", 129, 149], ["E. coli", "SPECIES", 38, 45], ["E. coli", "SPECIES", 38, 45], ["Recombinant plamids", "TREATMENT", 0, 19], ["the positive E. coli clones", "PROBLEM", 25, 52], ["Extraction", "TREATMENT", 90, 100], ["DNA", "PROBLEM", 104, 107], ["purified oocysts", "PROBLEM", 113, 129], ["Recombinant plasmids", "TREATMENT", 129, 149], ["Nanodrop spectrophotometer", "TREATMENT", 172, 198], ["coli clones", "OBSERVATION", 41, 52], ["DNA", "OBSERVATION", 104, 107], ["oocysts", "OBSERVATION", 122, 129]]], ["Copy numbers of recombinant plasmids were calculated from the concentration and size of the plasmids.", [["plasmids", "ANATOMY", 28, 36], ["plasmids", "ANATOMY", 92, 100], ["recombinant plasmids", "DNA", 16, 36], ["plasmids", "DNA", 92, 100], ["recombinant plasmids", "TREATMENT", 16, 36], ["the plasmids", "TREATMENT", 88, 100], ["recombinant plasmids", "OBSERVATION", 16, 36], ["size", "OBSERVATION_MODIFIER", 80, 84], ["plasmids", "OBSERVATION", 92, 100]]], ["Ten fold serial dilutions of recombinant plasmids in nuclease free water for all three species were prepared so as to obtain a range containing 10 6 plasmids per ll to 10 1 plasmids per ll.", [["plasmids", "ANATOMY", 41, 49], ["recombinant plasmids", "DNA", 29, 49], ["nuclease", "PROTEIN", 53, 61], ["Ten fold serial dilutions", "TREATMENT", 0, 25], ["recombinant plasmids", "TREATMENT", 29, 49], ["nuclease free water", "TREATMENT", 53, 72], ["a range containing 10 6 plasmids", "TREATMENT", 125, 157], ["ll", "ANATOMY", 186, 188]]], ["These were used as standards in qPCR for preparing the standard curves for absolute quantification during species specific qPCR studies.Extraction of DNA from purified oocystsFor amplification of DNA extracted from faecal samples each qPCR reaction mixture comprised of 10 ll of qPCR master mix with Eva Green dye (BioRad, USA), 03 ll of genomic DNA, 01 ll each of forward and reverse primers as per standardized concentration and nuclease free water to make the volume to 20 ll.", [["faecal samples", "ANATOMY", 215, 229], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["faecal samples", "ORGANISM_SUBSTANCE", 215, 229], ["DNA", "CELLULAR_COMPONENT", 346, 349], ["genomic DNA", "DNA", 338, 349], ["forward and reverse primers", "DNA", 365, 392], ["nuclease", "PROTEIN", 431, 439], ["the standard curves", "TEST", 51, 70], ["absolute quantification", "PROBLEM", 75, 98], ["specific qPCR studies", "TEST", 114, 135], ["Extraction", "TREATMENT", 136, 146], ["DNA", "PROBLEM", 150, 153], ["purified oocysts", "PROBLEM", 159, 175], ["DNA", "PROBLEM", 196, 199], ["faecal samples", "TEST", 215, 229], ["qPCR reaction mixture", "TEST", 235, 256], ["genomic DNA", "PROBLEM", 338, 349], ["reverse primers", "TREATMENT", 377, 392], ["nuclease free water", "TREATMENT", 431, 450], ["DNA", "OBSERVATION", 150, 153], ["oocysts", "OBSERVATION", 168, 175]]], ["Each concentration of plasmids in volume of 01 ll was used as template to prepare standard curve.", [["plasmids", "ANATOMY", 22, 30], ["plasmids", "DNA", 22, 30], ["plasmids in volume of 01 ll", "TREATMENT", 22, 49], ["plasmids", "OBSERVATION", 22, 30]]], ["Forward and reverse primers at concentration of 400 nM, 300 nM and 150 nM each were used for qPCR amplification of E. necatrix, E. maxima and E. acervulina respectively.", [["E. necatrix", "ORGANISM", 115, 126], ["E. maxima", "ORGANISM", 128, 137], ["E. acervulina", "ORGANISM", 142, 155], ["Forward and reverse primers", "DNA", 0, 27], ["E. necatrix", "SPECIES", 115, 126], ["E. maxima", "SPECIES", 128, 137], ["E. acervulina", "SPECIES", 142, 155], ["E. necatrix", "SPECIES", 115, 126], ["E. maxima", "SPECIES", 128, 137], ["E. acervulina", "SPECIES", 142, 155], ["qPCR amplification", "TEST", 93, 111], ["E. necatrix", "TREATMENT", 115, 126]]], ["Amplification for qPCR were initial denaturation at 95\u00b0C for 2 min, 40 cycles of denaturation at 95\u00b0C for 05 s and annealing with extension at 60\u00b0C for 10 s, followed by melt curve analysis step at temperature range of 65-95\u00b0C (0.5\u00b0C increment), 5 s per step.Calculation of genome copy numbers from standard curve of Ct valuesThe Ct values obtained from each plasmid concentration (logarithm of plasmid copy nymbers) in the qPCR system were plotted.", [["plasmid", "ANATOMY", 359, 366], ["qPCR", "TEST", 18, 22], ["initial denaturation", "PROBLEM", 28, 48], ["denaturation", "TREATMENT", 81, 93], ["extension", "TREATMENT", 130, 139], ["standard curve", "TEST", 299, 313], ["Ct values", "TEST", 317, 326], ["The Ct values", "TEST", 326, 339], ["plasmid copy nymbers", "TEST", 395, 415], ["the qPCR system", "TEST", 420, 435]]], ["Values of slope (m) of the linear regression curve and square of correlation co-efficient (r 2 ) was determined.", [["the linear regression curve", "TEST", 23, 50]]], ["The efficiency of the q-PCR was determined from the formula -1 ? 10 (-1/slope) .", [["the q-PCR", "TEST", 18, 27]]], ["The plot of Ct values against the logarithm (log) of plasmid copy numbers provided a standard curve for each Eimeria species.", [["plasmid", "ANATOMY", 53, 60], ["Ct values", "TEST", 12, 21], ["the logarithm", "TEST", 30, 43], ["a standard curve", "TEST", 83, 99], ["each Eimeria species", "PROBLEM", 104, 124]]], ["The linear regression equation for each Eimeria species was obtained as Y = mX ? c; where Y = Ct values (obtained from the real time data generated by the PCR machine), m = slope of the curve, c = y-intercept and X = log copy numbers (unknown).", [["The linear regression equation", "PROBLEM", 0, 30], ["each Eimeria species", "PROBLEM", 35, 55], ["Y = Ct values", "TEST", 90, 103], ["the curve", "TEST", 182, 191], ["linear", "OBSERVATION_MODIFIER", 4, 10]]], ["This equation was used to interpolate the Ct values obtained from DNA of field samples with unknown concentration of genomes of E. necatrix, E. maxima or E. acervulina.StatisticsAnalysis of variance (ANOVA) test supplemented with Tukey's post hoc was used for using evaluation of statistically significant difference between number of parasite genomes of each of the three species, E. tenella, E. necatrix, E. maxima and E. acervulina estimated by quantitative PCR between each farm types (broiler, layer and backyard units) (IBM SPSS Statistics 20.0, IBM Corp. 2011).Estimation of efficiency of quantitative real time PCRThe Ct values obtained during standardization of qPCR were plotted against the logarithm of plasmid copy numbers for each species.", [["samples", "ANATOMY", 79, 86], ["plasmid", "ANATOMY", 714, 721], ["DNA", "CELLULAR_COMPONENT", 66, 69], ["E. necatrix", "ORGANISM", 128, 139], ["E. maxima", "ORGANISM", 141, 150], ["E. acervulina", "ORGANISM", 154, 167], ["E. tenella", "ORGANISM", 382, 392], ["E. necatrix", "ORGANISM", 394, 405], ["E. maxima", "ORGANISM", 407, 416], ["E. acervulina", "ORGANISM", 421, 434], ["E. necatrix", "SPECIES", 128, 139], ["E. maxima", "SPECIES", 141, 150], ["E. acervulina", "SPECIES", 154, 167], ["E. tenella", "SPECIES", 382, 392], ["E. necatrix", "SPECIES", 394, 405], ["E. maxima", "SPECIES", 407, 416], ["E. acervulina", "SPECIES", 421, 434], ["E. necatrix", "SPECIES", 128, 139], ["E. maxima", "SPECIES", 141, 150], ["E. acervulina", "SPECIES", 154, 167], ["E. tenella", "SPECIES", 382, 392], ["E. necatrix", "SPECIES", 394, 405], ["E. maxima", "SPECIES", 407, 416], ["E. acervulina", "SPECIES", 421, 434], ["the Ct values", "TEST", 38, 51], ["DNA of field samples", "TEST", 66, 86], ["E. necatrix", "TREATMENT", 128, 139], ["E. acervulina", "TREATMENT", 154, 167], ["variance (ANOVA) test", "TEST", 190, 211], ["evaluation", "TEST", 266, 276], ["statistically significant difference", "PROBLEM", 280, 316], ["parasite genomes", "PROBLEM", 335, 351], ["E. necatrix", "TREATMENT", 394, 405], ["E. maxima", "TREATMENT", 407, 416], ["E. acervulina", "TREATMENT", 421, 434], ["quantitative PCR", "TEST", 448, 464], ["Ct values", "TEST", 626, 635], ["qPCR", "TEST", 671, 675], ["E. acervulina", "OBSERVATION", 154, 167], ["significant", "OBSERVATION_MODIFIER", 294, 305], ["difference", "OBSERVATION", 306, 316], ["parasite genomes", "OBSERVATION", 335, 351]]], ["These analyses provided the standard linear equation of Ct values and log copy number which was used for the quantification of genome copy numbers.", [["These analyses", "TEST", 0, 14], ["Ct values", "TEST", 56, 65]]], ["Efficiency and co-efficient of correlation (R 2 ) values of qPCR estimated for E. necatrix, E. maxima and E. No significant difference between the genome copy numbers of E. necatrix, E. acervulina and E. maxima in broiler farms, layer farms and back yard units was observed (Table 3) .", [["layer farms", "ANATOMY", 229, 240], ["E. necatrix", "ORGANISM", 79, 90], ["E. maxima", "ORGANISM", 92, 101], ["E. necatrix", "ORGANISM", 170, 181], ["E. acervulina", "ORGANISM", 183, 196], ["E. maxima", "ORGANISM", 201, 210], ["E. necatrix", "SPECIES", 79, 90], ["E. maxima", "SPECIES", 92, 101], ["E. necatrix", "SPECIES", 170, 181], ["E. acervulina", "SPECIES", 183, 196], ["E. maxima", "SPECIES", 201, 210], ["E. necatrix", "SPECIES", 79, 90], ["E. maxima", "SPECIES", 92, 101], ["E. necatrix", "SPECIES", 170, 181], ["E. acervulina", "SPECIES", 183, 196], ["E. maxima", "SPECIES", 201, 210], ["qPCR", "TEST", 60, 64], ["E. necatrix", "TREATMENT", 79, 90], ["significant difference", "PROBLEM", 112, 134], ["E. necatrix", "TREATMENT", 170, 181], ["E. acervulina", "TREATMENT", 183, 196], ["E. maxima in broiler farms", "TREATMENT", 201, 227], ["No", "UNCERTAINTY", 109, 111], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["layer", "OBSERVATION_MODIFIER", 229, 234], ["back", "ANATOMY", 245, 249]]], ["No significant difference in genome copy numbers of each Eimeria species between the different farm types was observed (Table 3 ).DiscussionEimeria species of domestic cannot be differentiated on the basis of morphology alone, with certainty.", [["significant difference", "PROBLEM", 3, 25], ["Eimeria species", "PROBLEM", 57, 72], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25], ["genome copy", "OBSERVATION", 29, 40], ["numbers", "OBSERVATION_MODIFIER", 41, 48], ["Eimeria species", "OBSERVATION", 57, 72], ["different", "OBSERVATION_MODIFIER", 85, 94], ["farm types", "OBSERVATION", 95, 105], ["domestic", "OBSERVATION", 159, 167]]], ["PCR based techniques targeting various genes or DNA fragments have been adopted for identification of different species existing in the poultry farms.", [["DNA", "CELLULAR_COMPONENT", 48, 51], ["DNA fragments", "DNA", 48, 61], ["PCR", "TEST", 0, 3], ["DNA fragments", "PROBLEM", 48, 61], ["different species", "PROBLEM", 102, 119], ["various genes", "OBSERVATION", 31, 44], ["DNA fragments", "OBSERVATION", 48, 61], ["different", "OBSERVATION_MODIFIER", 102, 111], ["species", "OBSERVATION", 112, 119], ["poultry farms", "OBSERVATION", 136, 149]]], ["Correct identification of Eimeria species in a mixed population of oocysts and their quantification in poultry litter or faecal droppings is important.", [["Eimeria", "ORGANISM", 26, 33], ["poultry", "ORGANISM_SUBDIVISION", 103, 110], ["litter", "ORGANISM_SUBDIVISION", 111, 117], ["poultry", "SPECIES", 103, 110], ["Eimeria species", "PROBLEM", 26, 41], ["oocysts", "PROBLEM", 67, 74], ["faecal droppings", "PROBLEM", 121, 137], ["Eimeria species", "OBSERVATION", 26, 41], ["mixed", "OBSERVATION_MODIFIER", 47, 52], ["population", "OBSERVATION_MODIFIER", 53, 63], ["oocysts", "OBSERVATION", 67, 74], ["poultry", "OBSERVATION_MODIFIER", 103, 110], ["litter", "OBSERVATION_MODIFIER", 111, 117], ["faecal droppings", "OBSERVATION", 121, 137]]], ["Thus, use of quantitative real time PCR for quantification of the parasite genome in the DNA from mixed oocyst population is the method of choice.", [["DNA", "CELLULAR_COMPONENT", 89, 92], ["parasite genome", "DNA", 66, 81], ["quantitative real time PCR", "TEST", 13, 39], ["the parasite genome", "PROBLEM", 62, 81], ["the DNA", "PROBLEM", 85, 92], ["mixed oocyst population", "PROBLEM", 98, 121], ["parasite genome", "OBSERVATION", 66, 81], ["mixed", "OBSERVATION_MODIFIER", 98, 103], ["oocyst", "OBSERVATION", 104, 110]]], ["An attempt was made to quantify genomes of E. acervulina, E. maxima and E. necatrix in DNA sample extracted from oocysts.", [["sample", "ANATOMY", 91, 97], ["oocysts", "ANATOMY", 113, 120], ["E. acervulina", "ORGANISM", 43, 56], ["E. maxima", "ORGANISM", 58, 67], ["E. necatrix", "ORGANISM", 72, 83], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["oocysts", "ORGANISM_SUBSTANCE", 113, 120], ["E. acervulina", "SPECIES", 43, 56], ["E. maxima", "SPECIES", 58, 67], ["E. necatrix", "SPECIES", 72, 83], ["E. acervulina", "SPECIES", 43, 56], ["E. maxima", "SPECIES", 58, 67], ["E. necatrix", "SPECIES", 72, 83], ["E. acervulina", "TREATMENT", 43, 56], ["E. maxima", "TREATMENT", 58, 67], ["E. necatrix", "TREATMENT", 72, 83], ["DNA sample", "PROBLEM", 87, 97], ["oocysts", "PROBLEM", 113, 120], ["oocysts", "OBSERVATION", 113, 120]]], ["Quantitative PCR has been used in chicken coccidiosis primarily to monitor the development of parasitic stages in the intestine of the host (Blake et al. 2008; Kundu et al. 2017; Nolan et al. 2015) .", [["intestine", "ANATOMY", 118, 127], ["coccidiosis", "DISEASE", 42, 53], ["chicken", "ORGANISM", 34, 41], ["intestine", "ORGAN", 118, 127], ["chicken", "SPECIES", 34, 41], ["chicken", "SPECIES", 34, 41], ["Quantitative PCR", "TEST", 0, 16], ["chicken coccidiosis", "PROBLEM", 34, 53], ["parasitic stages in the intestine", "PROBLEM", 94, 127], ["coccidiosis", "OBSERVATION", 42, 53], ["parasitic", "OBSERVATION", 94, 103], ["intestine", "ANATOMY", 118, 127]]], ["Kawahara et al. (2008) and Morgan et al. (2009) developed qPCR technique targeting ITS-1 and ITS-2 region of parasite DNA, as a tool to study molecular epidemiology.", [["ITS-1", "GENE_OR_GENE_PRODUCT", 83, 88], ["ITS-2", "GENE_OR_GENE_PRODUCT", 93, 98], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["ITS-1", "DNA", 83, 88], ["ITS-2 region", "DNA", 93, 105], ["parasite DNA", "DNA", 109, 121], ["qPCR technique", "TEST", 58, 72], ["parasite DNA", "PROBLEM", 109, 121], ["parasite DNA", "OBSERVATION", 109, 121]]], ["However ITS-1 and ITS-2 fragments are multiple nucleic acid regions and hence are not suitable for exact quantification of Eimeria genomes (Morgan et al. 2009 ).", [["ITS-1", "GENE_OR_GENE_PRODUCT", 8, 13], ["ITS-2", "GENE_OR_GENE_PRODUCT", 18, 23], ["Eimeria", "ORGANISM", 123, 130], ["ITS-1 and ITS-2 fragments", "DNA", 8, 33], ["multiple nucleic acid regions", "PROBLEM", 38, 67], ["Eimeria genomes", "PROBLEM", 123, 138], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["nucleic acid", "OBSERVATION", 47, 59], ["Eimeria genomes", "OBSERVATION", 123, 138]]], ["Vrba et al. (2010) used primers targeting sequence characterized amplified region (SCAR) and are single copy nucleic acid fragments.", [["amplified region", "DNA", 65, 81], ["SCAR", "DNA", 83, 87], ["single copy nucleic acid fragments", "DNA", 97, 131], ["primers targeting sequence", "TEST", 24, 50], ["SCAR", "PROBLEM", 83, 87], ["single copy nucleic acid fragments", "PROBLEM", 97, 131], ["SCAR", "OBSERVATION", 83, 87], ["acid fragments", "OBSERVATION", 117, 131]]], ["Hence, primers targeting SCARs are most suitable for quantification of species.", [["SCARs", "GENE_OR_GENE_PRODUCT", 25, 30], ["SCARs", "DNA", 25, 30], ["primers targeting SCARs", "PROBLEM", 7, 30], ["species", "PROBLEM", 71, 78], ["SCARs", "OBSERVATION", 25, 30], ["species", "OBSERVATION", 71, 78]]], ["The same primers were used in this study for quantification of genomes of E. necatrix, E. maxima and E. necatrix in faecal dropping from chicken farms.", [["E. necatrix", "ORGANISM", 74, 85], ["E. maxima", "ORGANISM", 87, 96], ["E. necatrix", "ORGANISM", 101, 112], ["faecal", "ORGANISM_SUBSTANCE", 116, 122], ["chicken", "ORGANISM", 137, 144], ["E. necatrix", "SPECIES", 74, 85], ["E. maxima", "SPECIES", 87, 96], ["E. necatrix", "SPECIES", 101, 112], ["chicken", "SPECIES", 137, 144], ["E. necatrix", "SPECIES", 74, 85], ["E. maxima", "SPECIES", 87, 96], ["E. necatrix", "SPECIES", 101, 112], ["chicken", "SPECIES", 137, 144], ["The same primers", "TREATMENT", 0, 16], ["this study", "TEST", 30, 40], ["E. necatrix", "TREATMENT", 74, 85], ["E. maxima", "TREATMENT", 87, 96], ["E. necatrix", "TREATMENT", 101, 112]]], ["Kumar et al. (2014) reported PCR based identification of various species of Eimeria is improved when DNA is extracted from concentrated oocysts rather than the faecal samples directly.", [["oocysts", "ANATOMY", 136, 143], ["faecal samples", "ANATOMY", 160, 174], ["Eimeria", "DISEASE", 76, 83], ["Eimeria", "ORGANISM", 76, 83], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["faecal samples", "ORGANISM_SUBSTANCE", 160, 174], ["PCR", "TEST", 29, 32], ["various species", "PROBLEM", 57, 72], ["Eimeria", "PROBLEM", 76, 83], ["DNA", "PROBLEM", 101, 104], ["concentrated oocysts", "PROBLEM", 123, 143], ["the faecal samples", "TEST", 156, 174], ["Eimeria", "OBSERVATION", 76, 83], ["improved", "OBSERVATION_MODIFIER", 87, 95], ["concentrated", "OBSERVATION_MODIFIER", 123, 135], ["oocysts", "OBSERVATION", 136, 143]]], ["Same protocol was used for extraction of DNA from purified oocysts and used for quantification of genomes of three Eimeria species.DiscussionParasite burden of E. necatrix was highest in broiler farms (71,577.818 \u00b1 42,619.99) followed by back yard units (56,669.6 \u00b1 44,564) and layer farms (18,506.5 \u00b1 13,369.9) .", [["DNA", "CELLULAR_COMPONENT", 41, 44], ["Eimeria", "ORGANISM", 115, 122], ["E. necatrix", "ORGANISM", 160, 171], ["E. necatrix", "SPECIES", 160, 171], ["E. necatrix", "SPECIES", 160, 171], ["Same protocol", "TREATMENT", 0, 13], ["extraction", "TREATMENT", 27, 37], ["DNA", "PROBLEM", 41, 44], ["purified oocysts", "PROBLEM", 50, 66], ["three Eimeria species", "PROBLEM", 109, 130], ["E. necatrix", "TREATMENT", 160, 171], ["layer farms", "TEST", 278, 289], ["oocysts", "OBSERVATION", 59, 66], ["Eimeria species", "OBSERVATION", 115, 130], ["necatrix", "OBSERVATION", 163, 171]]], ["Genome copies of E. acervulina in highest in broiler farms (23,689.076 \u00b1 8189.49) followed by backyard units (4535.66 \u00b1 2522) and layer units (1131.5 \u00b1 197.38) .", [["E. acervulina", "ORGANISM", 17, 30], ["E. acervulina", "SPECIES", 17, 30], ["E. acervulina", "SPECIES", 17, 30], ["E. acervulina", "PROBLEM", 17, 30], ["E. acervulina", "OBSERVATION_MODIFIER", 17, 30]]], ["Similarly, quantity of E. maxima oocysts were more in broiler farms (298.54 \u00b1 207.05) as compared to layer farms (27 \u00b1 8.72) and back yard units (26.66 \u00b1 11.68).", [["E. maxima oocysts", "ORGANISM", 23, 40], ["E. maxima", "SPECIES", 23, 32], ["E. maxima", "SPECIES", 23, 32], ["E. maxima oocysts", "PROBLEM", 23, 40], ["quantity", "OBSERVATION_MODIFIER", 11, 19], ["maxima oocysts", "OBSERVATION", 26, 40]]], ["The oocyst or parasite load of E. maxima in faecal droppings of layer and back yard units were similar.", [["oocyst", "ANATOMY", 4, 10], ["The oocyst", "PROBLEM", 0, 10], ["parasite load", "TEST", 14, 27], ["E. maxima", "TEST", 31, 40], ["oocyst", "OBSERVATION", 4, 10], ["parasite load", "OBSERVATION", 14, 27], ["maxima", "OBSERVATION_MODIFIER", 34, 40], ["faecal droppings", "OBSERVATION", 44, 60], ["layer", "OBSERVATION_MODIFIER", 64, 69], ["back", "ANATOMY", 74, 78]]], ["Though no statistically significant differences were observed between these quantities estimated in faecal droppings of three Eimeria species in the three different farm types (Table 3) , still it can be said that oocyst count of E. necatrix was highest in all the three types of farms compared to E. acervulina followed by E. maxima.", [["oocyst", "ANATOMY", 214, 220], ["faecal", "ORGANISM_SUBSTANCE", 100, 106], ["E. necatrix", "ORGANISM", 230, 241], ["E. acervulina", "ORGANISM", 298, 311], ["E. maxima", "ORGANISM", 324, 333], ["E. necatrix", "SPECIES", 230, 241], ["E. acervulina", "SPECIES", 298, 311], ["E. necatrix", "SPECIES", 230, 241], ["E. acervulina", "SPECIES", 298, 311], ["E. maxima", "SPECIES", 324, 333], ["these quantities", "TEST", 70, 86], ["faecal droppings", "PROBLEM", 100, 116], ["three Eimeria species", "PROBLEM", 120, 141], ["oocyst count", "TEST", 214, 226], ["E. necatrix", "TREATMENT", 230, 241], ["no", "UNCERTAINTY", 7, 9], ["statistically", "OBSERVATION_MODIFIER", 10, 23], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["differences", "OBSERVATION", 36, 47], ["faecal droppings", "OBSERVATION", 100, 116], ["Eimeria species", "OBSERVATION", 126, 141]]], ["Parasitic load of either E. necatrix or E. acervulina or E. maxima was highest in broiler farms as compared to backyard and layer farms.", [["E. necatrix", "ORGANISM", 25, 36], ["E. acervulina", "ORGANISM", 40, 53], ["E. maxima", "ORGANISM", 57, 66], ["E. necatrix", "SPECIES", 25, 36], ["E. acervulina", "SPECIES", 40, 53], ["E. maxima", "SPECIES", 57, 66], ["E. necatrix", "SPECIES", 25, 36], ["E. acervulina", "SPECIES", 40, 53], ["E. maxima", "SPECIES", 57, 66], ["Parasitic load", "TEST", 0, 14], ["E. necatrix", "TREATMENT", 25, 36], ["E. acervulina", "PROBLEM", 40, 53], ["E. maxima", "PROBLEM", 57, 66], ["maxima", "OBSERVATION_MODIFIER", 60, 66], ["highest", "OBSERVATION_MODIFIER", 71, 78], ["broiler farms", "OBSERVATION", 82, 95]]], ["In the Indian scenario, particularly in North India layer chickens are reared in cages and have less exposure to the oocyst infection.", [["oocyst infection", "DISEASE", 117, 133], ["chickens", "ORGANISM", 58, 66], ["chickens", "SPECIES", 58, 66], ["chickens", "SPECIES", 58, 66], ["the oocyst infection", "PROBLEM", 113, 133], ["oocyst", "OBSERVATION_MODIFIER", 117, 123], ["infection", "OBSERVATION", 124, 133]]], ["So it is not surprising that the oocyst burden is the least for any Eimeria species recorded in layer farms in this study.", [["oocyst", "ANATOMY", 33, 39], ["the oocyst burden", "PROBLEM", 29, 46], ["any Eimeria species", "PROBLEM", 64, 83], ["this study", "TEST", 111, 121], ["not surprising", "UNCERTAINTY", 9, 23], ["oocyst", "OBSERVATION", 33, 39]]], ["Broiler chickens are reared on deep litter system with more exposure to oocysts while feeding or drinking and hence the chance of picking up infection is more.", [["infection", "DISEASE", 141, 150], ["Broiler chickens", "ORGANISM", 0, 16], ["litter system", "ANATOMICAL_SYSTEM", 36, 49], ["chickens", "SPECIES", 8, 16], ["chickens", "SPECIES", 8, 16], ["Broiler chickens", "TREATMENT", 0, 16], ["picking up infection", "PROBLEM", 130, 150], ["chickens", "OBSERVATION", 8, 16], ["deep litter", "OBSERVATION_MODIFIER", 31, 42], ["oocysts", "OBSERVATION", 72, 79], ["infection", "OBSERVATION", 141, 150]]], ["More birds are infected by the circulating oocysts which sporulate in litter after being excreted by previously infected birds.", [["oocysts", "ANATOMY", 43, 50], ["birds", "ORGANISM", 5, 10], ["litter", "ORGANISM_SUBDIVISION", 70, 76], ["birds", "ORGANISM", 121, 126], ["the circulating oocysts", "PROBLEM", 27, 50], ["infected", "OBSERVATION_MODIFIER", 15, 23], ["circulating", "OBSERVATION_MODIFIER", 31, 42], ["oocysts", "OBSERVATION", 43, 50], ["litter", "OBSERVATION_MODIFIER", 70, 76], ["infected", "OBSERVATION", 112, 120]]], ["Backyard chickens are reared in a semi-intensive system, where they are on a partial free ranging system for a considerable part of the day and are housed only in the evening hours.", [["chickens", "ORGANISM", 9, 17], ["chickens", "SPECIES", 9, 17], ["chickens", "SPECIES", 9, 17]]], ["These birds pick up oocysts shed from the infected counterparts in the flock.", [["oocysts", "ANATOMY", 20, 27], ["birds", "ORGANISM", 6, 11], ["oocysts", "PROBLEM", 20, 27], ["oocysts", "OBSERVATION", 20, 27], ["infected", "OBSERVATION_MODIFIER", 42, 50]]], ["It may be assumed that the ground/ soil may not provide the suitable moisture and temperature conditions for oocyst sporulation compared to the litter bedding.", [["temperature conditions", "TREATMENT", 82, 104], ["oocyst sporulation", "PROBLEM", 109, 127]]], ["Moreover, free ranging habits of birds area helps spread of oocysts over a large area, hence minimizing concentrations of infective oocysts within a limited area as observed in the broiler house litter.", [["birds area", "PROBLEM", 33, 43], ["oocysts", "PROBLEM", 60, 67], ["infective oocysts", "PROBLEM", 122, 139], ["free", "OBSERVATION_MODIFIER", 10, 14], ["ranging", "OBSERVATION_MODIFIER", 15, 22], ["habits", "OBSERVATION_MODIFIER", 23, 29], ["birds", "OBSERVATION_MODIFIER", 33, 38], ["area", "OBSERVATION_MODIFIER", 39, 43], ["spread", "OBSERVATION_MODIFIER", 50, 56], ["oocysts", "OBSERVATION", 60, 67], ["large", "OBSERVATION_MODIFIER", 75, 80], ["area", "OBSERVATION_MODIFIER", 81, 85], ["minimizing concentrations", "OBSERVATION_MODIFIER", 93, 118], ["infective", "OBSERVATION_MODIFIER", 122, 131], ["oocysts", "OBSERVATION", 132, 139]]], ["The lesser number of birds in the free range system of backyard farms results in lower stocking density and hence lower environmental oocyst burden resulting in low oocyst shedding than intensively reared broiler chicken.DiscussionAdvantages of Q-PCR over the conventional and nPCR include single step amplification and quantification, no requirement of post amplification electrophoresis and visulisation of PCR product, thus saving on time and minimizing the chances of contamination during PCR (Kawahara et al. 2008 ).", [["birds", "ORGANISM", 21, 26], ["chicken", "ORGANISM", 213, 220], ["chicken", "SPECIES", 213, 220], ["broiler chicken", "SPECIES", 205, 220], ["lower stocking density", "PROBLEM", 81, 103], ["lower environmental oocyst burden", "PROBLEM", 114, 147], ["low oocyst shedding", "PROBLEM", 161, 180], ["Q-PCR", "TEST", 245, 250], ["single step amplification", "TEST", 290, 315], ["post amplification electrophoresis", "TEST", 354, 388], ["visulisation of PCR product", "TREATMENT", 393, 420], ["contamination during PCR", "PROBLEM", 472, 496], ["lesser", "OBSERVATION_MODIFIER", 4, 10], ["number", "OBSERVATION_MODIFIER", 11, 17], ["birds", "OBSERVATION_MODIFIER", 21, 26], ["lower stocking", "OBSERVATION_MODIFIER", 81, 95], ["density", "OBSERVATION", 96, 103], ["lower environmental", "OBSERVATION_MODIFIER", 114, 133], ["oocyst burden", "OBSERVATION", 134, 147], ["low oocyst", "OBSERVATION_MODIFIER", 161, 171]]], ["The only disadvantage being higher cost of reagents and the real time thermal cycler equipment.", [["reagents", "TREATMENT", 43, 51], ["thermal cycler equipment", "TREATMENT", 70, 94]]], ["Quantitative PCR in the recent past are limited only to species identification (Kawahara et al. 2008; Morgan et al. 2009; Luu et al. 2013) .", [["Quantitative PCR", "TEST", 0, 16]]], ["However, application of quantitative PCR would have been more meaningful if the relative abundance of each species could be estimated (Morgan et al. 2009 ).This may be of immense importance for designing vaccination strategy, identification and proportionate evaluation of circulating vaccine and wild strains in farms or help identify the species more prone to development of anti-coccidial resistance.", [["anti-coccidial", "CANCER", 377, 391], ["quantitative PCR", "TEST", 24, 40], ["each species", "PROBLEM", 102, 114], ["designing vaccination strategy", "TREATMENT", 194, 224], ["proportionate evaluation", "TEST", 245, 269], ["circulating vaccine", "TREATMENT", 273, 292], ["wild strains in farms", "PROBLEM", 297, 318], ["the species", "PROBLEM", 336, 347], ["anti-coccidial resistance", "PROBLEM", 377, 402], ["anti-coccidial resistance", "OBSERVATION", 377, 402]]]], "PMC7254909": [], "1689e039ad7f70aa4422580f1942dc1e47ba1e9a": [["These changes reflect growing diversity of the student body to include students from different racial and ethnic backgrounds, but also diversity in age, educational pathways, and academic preparedness, to cite just a few.", [["body", "ANATOMY", 55, 59], ["body", "ORGANISM_SUBDIVISION", 55, 59], ["growing", "OBSERVATION_MODIFIER", 22, 29], ["diversity", "OBSERVATION_MODIFIER", 30, 39], ["different", "OBSERVATION_MODIFIER", 85, 94], ["racial", "OBSERVATION_MODIFIER", 95, 101]]], ["Other changes include new pedagogies that explore active and problem-based learning, and, perhaps most significantly, instructional technology including courses delivered entirely online.", [["new pedagogies", "PROBLEM", 22, 36], ["active", "OBSERVATION_MODIFIER", 50, 56]]], ["Legislators, trustees, college administrators, parents, prospective and current students, and others call attention to the importance of student success, often using retention and graduation rates as indicators (Polatajko and Monaghan 2017) .IntroductionHere, we echo the concern for student success.", [["echo", "TEST", 263, 267]]], ["We use students majoring in Political Science and in International and Global Studies at the University of Central Florida, a large public university in the USA, as a case study.", [["a case study", "TEST", 165, 177], ["large", "OBSERVATION_MODIFIER", 126, 131]]], ["This relationship persists despite demographic and academic controls.", [["academic controls", "TREATMENT", 51, 68]]], ["On the other hand, at a time when an increasing number of students are completing online courses, we find that taking one online course, or even a few online courses, as part of their course load has a minimal effect on their academic success.", [["minimal", "OBSERVATION_MODIFIER", 202, 209]]], ["Although some differences between entirely online and entirely face-to-face students persist today (Kena et al. 2015) , a strict division of the student body into online-only and face-to-face-only categories no longer holds for a large segment of students.Online courses and student successMore students than ever are including both modalities into their course load (Jaggars 2014; Murphy and Stewart 2017) .", [["body", "ANATOMY", 153, 157], ["body", "ORGANISM_SUBDIVISION", 153, 157]]], ["As universities in the USA have moved away from a strictly in-person instructional model, students' learning environment has fundamentally changed, leading more students to take a mix of online and face-toface courses.Online courses and student successThe data indicate that this shift is foundational.", [["face-toface courses", "TREATMENT", 198, 217]]], ["A growing number of students, including both traditional and nontraditional college students, are taking online courses (Ortagus 2017; Seaman et al. 2018 ).", [["growing", "OBSERVATION_MODIFIER", 2, 9]]], ["These data suggest that online coursework is now part of the mainstream of higher education.", [["higher education", "TREATMENT", 75, 91]]], ["The vast majority (69.1%) of public university administrators see online course offerings as important to the future of their institutions (Allen and Seaman 2013: 4) , and over two-thirds (68.9%) of all students taking at least one online course are doing so at a public college or university (Seaman et al. 2018: 13) .Online courses and student successThus, as online courses become a more common part of the educational experience for a growing number of college students, the distinctions between online students and face-to-face students become less clear.", [["less", "OBSERVATION_MODIFIER", 549, 553], ["clear", "OBSERVATION", 554, 559]]], ["This is perhaps even more the case in the wake of COVID-19, when most colleges and universities in the USA and elsewhere quickly converted face-to-face instruction to remote pedagogies and even students in primary and secondary schools have switched to remote instruction.Online courses and student successThis new learning environment leads us as researchers to ask questions about whether the proportion of online courses students take affects their overall success.", [["COVID", "TEST", 50, 55]]], ["Whereas much of the previous literature has directly compared success rates in face-to-face only versus online only courses, we take individual students as the unit of analysis here and look at how the proportion of their course load that is online might impact their overall success.Online courses and student successWhat do we expect to find?", [["analysis", "TEST", 168, 176]]], ["Early concerns about online teaching and student learning centered on the issue of efficacy of the new modality as compared to traditional face-to-face teaching environments.", [["online teaching", "TREATMENT", 21, 36]]], ["That is, there is no significant difference in student learning outcomes across modalities (e.g. Lim et al. 2007; Means et al. 2010; Neuhauser 2010; Ni 2013; Stack 2015) .", [["no", "UNCERTAINTY", 18, 20], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["difference", "OBSERVATION_MODIFIER", 33, 43]]], ["Other studies (e.g. Nguyen 2015: 309) conclude that there is \"robust evidence to suggest online learning is generally at least as effective as the traditional format.\"", [["Other studies", "TEST", 0, 13]]], ["Thus, the studies suggest that those students who complete a course online generally are on par with students completing a course in the face-to-face modality, when considering learning outcomes.Online courses and student successAt the same time, other studies comparing online and face-to-face courses indicate that success in online courses is more difficult than in face-to-face settings.", [["the studies", "TEST", 6, 17], ["other studies", "TEST", 247, 260], ["success", "OBSERVATION", 317, 324]]], ["The same course taught online tends to have lower retention rates than its face-toface corollary (Glazier 2016; Murphy and Stewart 2017; Smart and Saxon 2016; Wladis et al. 2014) , even when it is taught by the same professor (Hart et al. 2018) , and even when the exact same lectures are used (Roberts 2015) .", [["lower retention rates", "PROBLEM", 44, 65]]], ["This literature leads us to expect lower retention rates as students take a higher proportion of courses online.", [["lower retention rates", "PROBLEM", 35, 56]]], ["However, one area of research that might be able to inform our expectations about online course load proportions in our analysis is hybrid courses, sometimes also referred to as \"blended\" or \"mixed-mode\" courses.", [["online course load proportions", "TREATMENT", 82, 112]]], ["Just as a college student's overall course load today might be made up of some online and some face-to-face courses, in a hybrid course, some face-to-face instruction is replaced by online instruction so that the learning environment includes some online and some face-toface elements.", [["face-toface elements", "DNA", 264, 284], ["a hybrid course", "TREATMENT", 120, 135]]], ["Hybrid courses are growing in popularity, with 79% of public institutions of higher education in the USA offering such courses (McGee and Reis 2012: 7).Online courses and student successWhat does this mean for student success?", [["growing", "OBSERVATION_MODIFIER", 19, 26], ["popularity", "OBSERVATION_MODIFIER", 30, 40]]], ["The literature on hybrid courses indicates that they have the potential to bring the best of both modalities together (Vaughan 2010; Verhoeven and Rudchenko 2013) .", [["hybrid courses", "TREATMENT", 18, 32]]], ["This may mean that students who take a mix of course modalities may be able to benefit from the particular advantage of each of these modalities.Online courses and student successHowever, although some research indicates that interest and learning may be higher in hybrid courses (Bolsen et al. 2016; Denhart 2010; Nowell 2011) , the overwhelming evidence indicates that completion rates are lower.", [["course modalities", "TREATMENT", 46, 63], ["completion rates", "TEST", 371, 387]]], ["Radunovich and Acharya (2018) conclude that students are less likely to engage with the online material in a hybrid course, and Sewell (2016) finds that withdrawal rates for both hybrid and online courses are higher than for the same courses taught through a face-to-face mode.", [["withdrawal rates", "PROBLEM", 153, 169], ["a face", "TREATMENT", 257, 263]]], ["In fact, even when only a small portion of a hybrid course takes place online, student completion rates decline (Murphy and Stewart 2017) .", [["a hybrid course", "TREATMENT", 43, 58], ["small", "OBSERVATION_MODIFIER", 26, 31]]], ["Baudewyns et al. (2018) look specifically at the uphill battle that MOOCs (Massive Online Only Courses) face in terms of retention, where course attrition can be as high as 85-90%.", [["Massive", "OBSERVATION_MODIFIER", 75, 82], ["retention", "OBSERVATION", 121, 130]]], ["While MOOCs are in many ways different from online courses that are offered as part of a regular degree program for degree-seeking students enrolled in an institution of higher learning, the study still suggests that perhaps there is something about the online environment that makes retention more difficult, especially as the distance from the instructor increases with class size.Online courses and student successThus, these findings regarding student success rates in online, hybrid, and faceto-face courses lead us to expect that student retention will be lower as the proportion of their course load that is taken online increases.", [["the study", "TEST", 187, 196], ["hybrid", "PROBLEM", 481, 487], ["student retention", "PROBLEM", 536, 553], ["size", "OBSERVATION_MODIFIER", 378, 382]]], ["Although hybrid courses may be preferred to online (Denhart 2010) , and the equivalent assumption that some face-to-face courses may be preferred to all online courses, it appears that the faceto-face instructional environment, where students see and connect directly with their instructor, makes retaining students easier, even if this direct connection occurs more sporadically compared to a fully face-to-face course.Online courses and student successAt the same time, the student population is increasingly heterogenous as students vary in age, gender, race and ethnic background, and academic preparedness.", [["increasingly heterogenous", "PROBLEM", 498, 523], ["increasingly", "OBSERVATION_MODIFIER", 498, 510], ["heterogenous", "OBSERVATION", 511, 523]]], ["Additional factors that possibly impact student retention and success may include students' socioeconomic background, where those students who take a larger share of courses online may have additional responsibilities (e.g. full-time employment, family) and fewer resources than students who select the majority, or all, their courses in person.", [["person", "SPECIES", 338, 344]]], ["Thus, we expect that the effect of the share of online courses on overall student success varies across different student demographics.The studyWe look at how the online proportion of a student's course load impacts their overall success by using data from a large university in the USA.", [["The study", "TEST", 135, 144], ["large", "OBSERVATION_MODIFIER", 259, 264]]], ["The key dependent variable we use to measure success is whether the student is retained (either re-enrolled or graduated).", [["dependent", "OBSERVATION_MODIFIER", 8, 17]]], ["The University of Central Florida is a large, public university that has offered online education as part of its regular curriculum for over two decades.", [["online education", "TREATMENT", 81, 97], ["Central Florida", "OBSERVATION", 18, 33], ["large", "OBSERVATION_MODIFIER", 39, 44]]], ["Our study focuses on the success of students enrolled in a major housed in the Political Science department, which offers undergraduate degrees in Political Science and in International and Global Studies.", [["Our study", "TEST", 0, 9], ["Global Studies", "TEST", 190, 204]]], ["Mirroring the university's recognized high quality in online education, the department's online degree in Political Science has also been ranked highest in the country by some college ranking organizations.Data and analysis: online learning and academic successOur data are based on course performance and demographic attributes for all UCF students majoring in either Political Science or International and Global Studies.", [["Our data", "TEST", 261, 269], ["Global Studies", "TEST", 408, 422]]], ["The students in the middle are not evenly distributed, so we divided them into three approximately equal categories: those taking between 1 and 28% of their hours online, those taking more than 28 but less than 50% of their hours online, and those taking more than 50% but less than 100% of their hours online.", [["middle", "ANATOMY_MODIFIER", 20, 26], ["not", "UNCERTAINTY", 31, 34], ["evenly", "OBSERVATION_MODIFIER", 35, 41], ["distributed", "OBSERVATION", 42, 53]]], ["Table 1 compares these five groups of students on several academic metrics: GPA (Fall 2016), percentage successful hours, percentage transfer students, and, most critically, percentage who re-enrolled (or graduated) in Fall 2017.Data and analysis: online learning and academic successEven a cursory examination of these data leads to one takeaway: Students whose course loads are exclusively online inhabit a world that is distinctly less successful than the world inhabited by all other students, regardless of modality mix.", [["a cursory examination", "TEST", 289, 310]]], ["What Fig. 1 instead dramatically illustrates is the Might these disappointing numbers be spurious artifacts of demographic factors, such as age, race, or gender?", [["spurious artifacts", "PROBLEM", 89, 107], ["demographic factors", "PROBLEM", 111, 130]]], ["Model 1 is merely a logit version of Table 1 's re-enrollment column, and it confirms that students taking at least some live hours with their online courses are as likely to reenroll as are students taking zero online hours.", [["Table 1 's re-enrollment column", "TREATMENT", 37, 68]]], ["At the same time, our data and findings suggest that students whose course load is entirely online are significantly less likely to be successful than those students who also, or exclusively, attend face-to-face courses, as measured in retention rates (re-enrollment in the next semester or graduation).", [["our data", "TEST", 18, 26]]], ["We have no systematic data about the student population in this study that would tell us why students are opting to take all their courses online.", [["this study", "TEST", 59, 69]]], ["Earlier studies suggest, for example, that online students tend to be slightly older, which may come with additional responsibilities.", [["Earlier studies", "TEST", 0, 15]]], ["While we do not have those data for the specific students in our study, we know that over one-third of all students that take all their course online in the state where the University of Central Florida is located live outside of the state.", [["our study", "TEST", 61, 70]]], ["It may be that the online student population is less motivated to re-enroll because they lack the direct, personal connection to their professor.", [["may be", "UNCERTAINTY", 3, 9]]], ["Willging and Johnson's (2009) study on dropout rates from an online graduate program identifies varied and individually unique reasons rather than demographic patterns or technology issues that account for students' dropout rate.", [["technology issues", "PROBLEM", 171, 188], ["dropout rate", "TEST", 216, 228]]], ["This makes it all the more pertinent that future studies explore the determinants of student success in online classes including student mastery of course contents and grades but also student retention.", [["future studies", "TEST", 42, 56]]]], "PMC7086732": [["IntroductionDengue is the most frequent human vector-borne viral disease [1].", [["viral disease", "DISEASE", 59, 72], ["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45]]], ["Dengue virus (DENV), a mosquito-borne virus belonging to the family Flaviviridae, is an enveloped, single-stranded positive-sense RNA virus.", [["Dengue virus (DENV)", "DISEASE", 0, 19], ["Dengue virus", "ORGANISM", 0, 12], ["DENV", "ORGANISM", 14, 18], ["mosquito-borne virus", "ORGANISM", 23, 43], ["Dengue virus", "SPECIES", 0, 12], ["mosquito-borne virus", "SPECIES", 23, 43], ["Dengue virus", "SPECIES", 0, 12], ["DENV", "SPECIES", 14, 18], ["mosquito-borne virus", "SPECIES", 23, 43], ["Dengue virus (DENV", "PROBLEM", 0, 18], ["a mosquito-borne virus", "PROBLEM", 21, 43], ["Flaviviridae", "TREATMENT", 68, 80], ["stranded positive-sense RNA virus", "PROBLEM", 106, 139]]], ["There are four genetically distinct DENV serotypes (DENV1 to 4) that cause disease in humans [2\u20134].", [["DENV", "ORGANISM", 36, 40], ["humans", "ORGANISM", 86, 92], ["humans", "SPECIES", 86, 92], ["humans", "SPECIES", 86, 92], ["four genetically distinct DENV serotypes", "PROBLEM", 10, 50], ["disease in humans", "PROBLEM", 75, 92], ["four", "OBSERVATION_MODIFIER", 10, 14], ["genetically", "OBSERVATION_MODIFIER", 15, 26], ["distinct", "OBSERVATION_MODIFIER", 27, 35], ["DENV serotypes", "OBSERVATION", 36, 50], ["disease", "OBSERVATION", 75, 82]]], ["During DENV infection, levels of several cytokines, cytokine receptors, and apoptosis have been found to be increased in humans and in experimental infections [5].", [["DENV infection", "DISEASE", 7, 21], ["infections", "DISEASE", 148, 158], ["DENV", "ORGANISM", 7, 11], ["humans", "ORGANISM", 121, 127], ["cytokines", "PROTEIN", 41, 50], ["cytokine receptors", "PROTEIN", 52, 70], ["humans", "SPECIES", 121, 127], ["DENV", "SPECIES", 7, 11], ["humans", "SPECIES", 121, 127], ["DENV infection", "PROBLEM", 7, 21], ["levels", "TEST", 23, 29], ["several cytokines", "TREATMENT", 33, 50], ["cytokine receptors", "TEST", 52, 70], ["apoptosis", "PROBLEM", 76, 85], ["experimental infections", "PROBLEM", 135, 158], ["DENV", "OBSERVATION_MODIFIER", 7, 11], ["infection", "OBSERVATION", 12, 21], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["infections", "OBSERVATION", 148, 158]]], ["Increased expression of IL-1 in infected DENV cells probably plays an important role in the pathogenesis of dengue [5, 6].", [["cells", "ANATOMY", 46, 51], ["dengue", "DISEASE", 108, 114], ["IL-1", "GENE_OR_GENE_PRODUCT", 24, 28], ["DENV cells", "CELL", 41, 51], ["IL-1", "PROTEIN", 24, 28], ["infected DENV cells", "CELL_TYPE", 32, 51], ["DENV", "SPECIES", 41, 45], ["dengue", "SPECIES", 108, 114], ["Increased expression of IL", "PROBLEM", 0, 26], ["infected DENV cells", "PROBLEM", 32, 51], ["IL", "OBSERVATION_MODIFIER", 24, 26], ["infected", "OBSERVATION_MODIFIER", 32, 40], ["DENV cells", "OBSERVATION", 41, 51]]], ["The renin\u2013angiotensin system is involved in the regulation of blood pressure, vasoconstriction, sodium intake, and potassium excretion.", [["blood", "ANATOMY", 62, 67], ["sodium", "CHEMICAL", 96, 102], ["potassium", "CHEMICAL", 115, 124], ["sodium", "CHEMICAL", 96, 102], ["potassium", "CHEMICAL", 115, 124], ["renin\u2013angiotensin", "GENE_OR_GENE_PRODUCT", 4, 21], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["sodium", "SIMPLE_CHEMICAL", 96, 102], ["potassium", "SIMPLE_CHEMICAL", 115, 124], ["blood pressure", "TEST", 62, 76], ["vasoconstriction", "PROBLEM", 78, 94], ["sodium intake", "TEST", 96, 109], ["potassium excretion", "TEST", 115, 134]]], ["Angiotensin II (Ang II) is one of the main effector molecules in this system, and its pro-inflammatory properties have reported recently.", [["Angiotensin II", "CHEMICAL", 0, 14], ["Ang II", "CHEMICAL", 16, 22], ["Angiotensin II", "GENE_OR_GENE_PRODUCT", 0, 14], ["Ang II", "GENE_OR_GENE_PRODUCT", 16, 22], ["Angiotensin II", "PROTEIN", 0, 14], ["Ang II", "PROTEIN", 16, 22], ["Angiotensin II (Ang II)", "TREATMENT", 0, 23], ["main", "OBSERVATION_MODIFIER", 38, 42], ["effector molecules", "OBSERVATION", 43, 61], ["pro-inflammatory", "OBSERVATION_MODIFIER", 86, 102]]], ["After binding of Ang II to its receptors, in particular AT1 (angiotensin II type 1 receptor: AT1 receptor), intracellular translocation of NF-kB to the nucleus occurs, inducing transcription of pro-inflammatory cytokines and production of oxygen-reactive species.", [["intracellular", "ANATOMY", 108, 121], ["nucleus", "ANATOMY", 152, 159], ["Ang II", "CHEMICAL", 17, 23], ["angiotensin II", "CHEMICAL", 61, 75], ["oxygen", "CHEMICAL", 239, 245], ["oxygen", "CHEMICAL", 239, 245], ["Ang II", "GENE_OR_GENE_PRODUCT", 17, 23], ["AT1", "GENE_OR_GENE_PRODUCT", 56, 59], ["angiotensin II type 1 receptor", "GENE_OR_GENE_PRODUCT", 61, 91], ["AT1 receptor", "GENE_OR_GENE_PRODUCT", 93, 105], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 121], ["NF-kB", "GENE_OR_GENE_PRODUCT", 139, 144], ["nucleus", "CELLULAR_COMPONENT", 152, 159], ["oxygen", "SIMPLE_CHEMICAL", 239, 245], ["Ang II", "PROTEIN", 17, 23], ["AT1", "PROTEIN", 56, 59], ["angiotensin II type 1 receptor", "PROTEIN", 61, 91], ["AT1 receptor", "PROTEIN", 93, 105], ["NF-kB", "PROTEIN", 139, 144], ["pro-inflammatory cytokines", "PROTEIN", 194, 220], ["Ang II to its receptors", "TREATMENT", 17, 40], ["AT1 receptor", "TREATMENT", 93, 105], ["intracellular translocation of NF", "PROBLEM", 108, 141], ["pro-inflammatory cytokines", "PROBLEM", 194, 220], ["reactive species", "PROBLEM", 246, 262], ["nucleus", "ANATOMY", 152, 159], ["pro-inflammatory cytokines", "OBSERVATION", 194, 220], ["oxygen", "OBSERVATION_MODIFIER", 239, 245], ["reactive species", "OBSERVATION", 246, 262]]], ["Ang II-mediated inflammatory events can be inhibited by using AT-1 receptor antagonists or by inhibition of angiotensin I converting enzyme (ACE) [7\u201311].", [["Ang II", "CHEMICAL", 0, 6], ["angiotensin", "CHEMICAL", 108, 119], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["AT-1 receptor antagonists", "GENE_OR_GENE_PRODUCT", 62, 87], ["angiotensin I converting enzyme", "GENE_OR_GENE_PRODUCT", 108, 139], ["ACE", "GENE_OR_GENE_PRODUCT", 141, 144], ["Ang II", "PROTEIN", 0, 6], ["angiotensin I converting enzyme", "PROTEIN", 108, 139], ["ACE", "PROTEIN", 141, 144], ["Ang II-mediated inflammatory events", "PROBLEM", 0, 35], ["AT-1 receptor antagonists", "TREATMENT", 62, 87], ["angiotensin I converting enzyme (ACE)", "TREATMENT", 108, 145], ["inflammatory", "OBSERVATION", 16, 28]]], ["Ang II is involved in the production of several cytokines, including interleukin-1 (IL-1) [12], and it is also involved in virus-induced respiratory pathogenesis [13\u201315].", [["respiratory", "ANATOMY", 137, 148], ["Ang II", "CHEMICAL", 0, 6], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 69, 82], ["IL-1) [12", "GENE_OR_GENE_PRODUCT", 84, 93], ["Ang II", "PROTEIN", 0, 6], ["cytokines", "PROTEIN", 48, 57], ["interleukin-1 (IL-1", "PROTEIN", 69, 88], ["several cytokines", "PROBLEM", 40, 57], ["interleukin-", "TEST", 69, 81], ["virus", "PROBLEM", 123, 128], ["respiratory pathogenesis", "PROBLEM", 137, 161], ["respiratory", "ANATOMY", 137, 148]]], ["This information suggests that Ang II is an important factor in inflammatory events during virus infection.", [["Ang II", "CHEMICAL", 31, 37], ["infection", "DISEASE", 97, 106], ["Ang II", "GENE_OR_GENE_PRODUCT", 31, 37], ["Ang II", "PROTEIN", 31, 37], ["Ang II", "PROBLEM", 31, 37], ["inflammatory events", "PROBLEM", 64, 83], ["virus infection", "PROBLEM", 91, 106], ["inflammatory", "OBSERVATION", 64, 76]]], ["There is no available information regarding the role of Ang II in DENV infection.", [["Ang II", "CHEMICAL", 56, 62], ["DENV infection", "DISEASE", 66, 80], ["Ang II", "GENE_OR_GENE_PRODUCT", 56, 62], ["DENV", "ORGANISM", 66, 70], ["Ang II", "PROTEIN", 56, 62], ["DENV", "SPECIES", 66, 70], ["DENV infection", "PROBLEM", 66, 80], ["no", "UNCERTAINTY", 9, 11], ["DENV", "OBSERVATION_MODIFIER", 66, 70], ["infection", "OBSERVATION", 71, 80]]], ["Therefore, the aim of this study was to determine the effect of losartan, an angiotensin II AT1 receptor antagonist, and enalapril, an inhibitor of ACE, on the cellular expression of viral antigens and on IL-1\u03b2 production by peritoneal macrophages infected by DENV2.Animals ::: Materials and methodsAdult male NMRI mice weighing 25-30 g (Central Animal Facility, Instituto de Investigaciones Cient\u00edficas, IVIC, Venezuela) were used.", [["cellular", "ANATOMY", 160, 168], ["peritoneal macrophages", "ANATOMY", 225, 247], ["losartan", "CHEMICAL", 64, 72], ["angiotensin II", "CHEMICAL", 77, 91], ["enalapril", "CHEMICAL", 121, 130], ["losartan", "CHEMICAL", 64, 72], ["enalapril", "CHEMICAL", 121, 130], ["losartan", "SIMPLE_CHEMICAL", 64, 72], ["angiotensin II AT1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 77, 115], ["enalapril", "SIMPLE_CHEMICAL", 121, 130], ["ACE", "GENE_OR_GENE_PRODUCT", 148, 151], ["cellular", "CELL", 160, 168], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 205, 210], ["peritoneal macrophages", "CELL", 225, 247], ["DENV2", "ORGANISM", 260, 265], ["NMRI mice", "ORGANISM", 310, 319], ["viral antigens", "PROTEIN", 183, 197], ["IL-1\u03b2", "PROTEIN", 205, 210], ["peritoneal macrophages", "CELL_TYPE", 225, 247], ["mice", "SPECIES", 315, 319], ["DENV2", "SPECIES", 260, 265], ["mice", "SPECIES", 315, 319], ["this study", "TEST", 22, 32], ["losartan", "TREATMENT", 64, 72], ["an angiotensin II AT1 receptor antagonist", "TREATMENT", 74, 115], ["enalapril", "TREATMENT", 121, 130], ["an inhibitor", "TREATMENT", 132, 144], ["ACE", "TREATMENT", 148, 151], ["viral antigens", "PROBLEM", 183, 197], ["IL", "TREATMENT", 205, 207], ["peritoneal macrophages", "PROBLEM", 225, 247], ["DENV2", "PROBLEM", 260, 265], ["Venezuela)", "TREATMENT", 411, 421], ["viral antigens", "OBSERVATION", 183, 197], ["peritoneal", "ANATOMY", 225, 235], ["macrophages", "OBSERVATION", 236, 247]]], ["Animals were housed at room temperature (24 \u00b0C) with water and food (Ratarina, Proteinal, Valencia, Venezuela) ad libitum and a natural day-night light cycle.Preparation of virus stock and virus titration ::: Materials and methodsDEN2 virus strain New Guinea C was propagated in C6/36HT mosquito cells that were cultured in Eagle\u2019s MEM medium containing 10 % FBS prior to infection of mice.", [["C6/36HT mosquito cells", "ANATOMY", 279, 301], ["FBS", "ANATOMY", 359, 362], ["infection", "DISEASE", 372, 381], ["Animals", "ORGANISM", 0, 7], ["methodsDEN2 virus", "ORGANISM", 223, 240], ["New Guinea C", "ORGANISM", 248, 260], ["C6/36HT mosquito cells", "CELL", 279, 301], ["FBS", "ORGANISM_SUBSTANCE", 359, 362], ["mice", "ORGANISM", 385, 389], ["C6/36HT mosquito cells", "CELL_LINE", 279, 301], ["mice", "SPECIES", 385, 389], ["mice", "SPECIES", 385, 389], ["virus stock", "TREATMENT", 173, 184], ["Materials", "TREATMENT", 209, 218], ["methodsDEN2 virus strain", "PROBLEM", 223, 247], ["New Guinea C", "PROBLEM", 248, 260], ["C6/36HT mosquito cells", "TREATMENT", 279, 301], ["infection of mice", "PROBLEM", 372, 389], ["virus stock", "OBSERVATION", 173, 184], ["C6", "ANATOMY", 279, 281]]], ["The virus-containing culture medium was harvested after 5 days of incubation, and after removal of cell debris by centrifugation, the supernatant was aliquoted and stored at -70 \u00b0C until used.", [["cell", "ANATOMY", 99, 103], ["supernatant", "ANATOMY", 134, 145], ["cell", "CELL", 99, 103], ["The virus", "PROBLEM", 0, 9], ["culture medium", "TREATMENT", 21, 35], ["incubation", "TREATMENT", 66, 76], ["removal", "TREATMENT", 88, 95], ["cell debris", "PROBLEM", 99, 110], ["the supernatant", "TREATMENT", 130, 145], ["virus", "OBSERVATION", 4, 9], ["cell debris", "OBSERVATION", 99, 110]]], ["Virus was titrated by plaque formation assays on Vero cells.", [["plaque", "ANATOMY", 22, 28], ["Vero cells", "ANATOMY", 49, 59], ["Virus", "ORGANISM", 0, 5], ["plaque", "PATHOLOGICAL_FORMATION", 22, 28], ["Vero cells", "CELL", 49, 59], ["Vero cells", "CELL_LINE", 49, 59], ["Virus", "PROBLEM", 0, 5], ["Vero cells", "TREATMENT", 49, 59], ["plaque", "OBSERVATION", 22, 28], ["Vero cells", "OBSERVATION", 49, 59]]], ["Cells were seeded at 1 \u00d7 106 cells/well in 24-well plates, and subsequently, serial dilutions of virus were added and the mixtures were incubated at 37 \u00b0C for 7 days.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 29, 34], ["Cells", "CELL", 0, 5], ["cells", "CELL", 29, 34], ["Cells", "TEST", 0, 5], ["serial dilutions of virus", "TREATMENT", 77, 102]]], ["Afterwards, the plaques were visualized by staining with a dye solution containing 1 % crystal violet.", [["plaques", "ANATOMY", 16, 23], ["plaques", "PATHOLOGICAL_FORMATION", 16, 23], ["crystal violet", "SIMPLE_CHEMICAL", 87, 101], ["the plaques", "PROBLEM", 12, 23], ["a dye solution", "TREATMENT", 57, 71], ["1 % crystal violet", "TREATMENT", 83, 101], ["plaques", "OBSERVATION", 16, 23]]], ["Virus concentrations are given as plaque-forming units (PFU)/ml.Experimental design ::: Materials and methodsMice were left untreated or treated with losartan or enalapril (Merck & Co., Whitehouse Station, NJ, USA) by gavage at 25 mg/kg/day during the entire experimental period.", [["plaque", "ANATOMY", 34, 40], ["losartan", "CHEMICAL", 150, 158], ["enalapril", "CHEMICAL", 162, 171], ["losartan", "CHEMICAL", 150, 158], ["enalapril", "CHEMICAL", 162, 171], ["Virus", "ORGANISM", 0, 5], ["Mice", "ORGANISM", 109, 113], ["losartan", "SIMPLE_CHEMICAL", 150, 158], ["enalapril", "SIMPLE_CHEMICAL", 162, 171], ["Mice", "SPECIES", 109, 113], ["Virus concentrations", "PROBLEM", 0, 20], ["losartan", "TREATMENT", 150, 158], ["enalapril", "TREATMENT", 162, 171]]], ["After one week of treatment, untreated and treated mice were injected intraperitoneally (ip) with 2 mL of 3 % thioglycollate solution (Difco Laboratories,Detroit, MI, USA) to elicit inflammatory macrophages.", [["intraperitoneally", "ANATOMY", 70, 87], ["macrophages", "ANATOMY", 195, 206], ["mice", "ORGANISM", 51, 55], ["thioglycollate", "SIMPLE_CHEMICAL", 110, 124], ["macrophages", "CELL", 195, 206], ["inflammatory macrophages", "CELL_TYPE", 182, 206], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["treatment", "TREATMENT", 18, 27], ["3 % thioglycollate solution", "TREATMENT", 106, 133], ["MI", "PROBLEM", 163, 165], ["inflammatory macrophages", "PROBLEM", 182, 206], ["inflammatory macrophages", "OBSERVATION", 182, 206]]], ["Four days later, mice were infected ip with a suspension of DENV2 (50 \u03bcl) at an MOI of 1.", [["mice", "ORGANISM", 17, 21], ["DENV2", "ORGANISM", 60, 65], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["DENV2", "SPECIES", 60, 65], ["a suspension of DENV2", "TREATMENT", 44, 65]]], ["This was based on the assumption that, under these conditions, approximately 1 \u00d7 107 peritoneal cells/ mL are usually obtained.", [["peritoneal cells", "ANATOMY", 85, 101], ["peritoneal cells", "CELL", 85, 101], ["peritoneal cells/ mL", "TEST", 85, 105], ["peritoneal", "ANATOMY", 85, 95]]], ["Six groups of animals were studied (10 per group): losartan-treated, enalapril-treated, and untreated infected animals and losartan-treated, enalapril-treated and untreated uninfected animals.", [["losartan", "CHEMICAL", 51, 59], ["enalapril", "CHEMICAL", 69, 78], ["losartan", "CHEMICAL", 123, 131], ["enalapril", "CHEMICAL", 141, 150], ["losartan", "CHEMICAL", 51, 59], ["enalapril", "CHEMICAL", 69, 78], ["losartan", "CHEMICAL", 123, 131], ["enalapril", "CHEMICAL", 141, 150], ["animals", "ORGANISM", 14, 21], ["losartan", "SIMPLE_CHEMICAL", 51, 59], ["enalapril", "SIMPLE_CHEMICAL", 69, 78], ["losartan", "SIMPLE_CHEMICAL", 123, 131], ["enalapril", "SIMPLE_CHEMICAL", 141, 150], ["losartan", "TREATMENT", 51, 59], ["enalapril", "TREATMENT", 69, 78], ["losartan", "TREATMENT", 123, 131], ["enalapril", "TREATMENT", 141, 150]]], ["After 12 hours of intraperitoneal incubation, 5 mL of cold sterile PBS was injected ip, and macrophages and peritoneal fluid were obtained after centrifugation (1500 rpm \u00d7 10 min) from all of the animals.", [["intraperitoneal", "ANATOMY", 18, 33], ["macrophages", "ANATOMY", 92, 103], ["peritoneal fluid", "ANATOMY", 108, 124], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 33], ["macrophages", "CELL", 92, 103], ["peritoneal fluid", "ORGANISM_SUBSTANCE", 108, 124], ["macrophages", "CELL_TYPE", 92, 103], ["intraperitoneal incubation", "TREATMENT", 18, 44], ["cold sterile PBS", "TREATMENT", 54, 70], ["macrophages", "ANATOMY", 92, 103], ["peritoneal", "ANATOMY", 108, 118], ["fluid", "OBSERVATION", 119, 124]]], ["A portion of macrophage samples was homogenized, and supernatants (peritoneal fluid) and homogenates were kept at -20 \u00b0C until needed for IL-1\u03b2 determination.", [["macrophage samples", "ANATOMY", 13, 31], ["supernatants", "ANATOMY", 53, 65], ["peritoneal fluid", "ANATOMY", 67, 83], ["homogenates", "ANATOMY", 89, 100], ["macrophage samples", "CELL", 13, 31], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 67, 83], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 138, 143], ["IL", "PROTEIN", 138, 140], ["macrophage samples", "TEST", 13, 31], ["supernatants (peritoneal fluid)", "TEST", 53, 84], ["homogenates", "TEST", 89, 100], ["IL", "TREATMENT", 138, 140], ["macrophage", "OBSERVATION", 13, 23], ["peritoneal", "ANATOMY", 67, 77]]], ["Another portion of the macrophage preparation (0.5 \u00d7 106 cells/mL) was cytocentrifuged to measure cellular DENV2 expression and identify CD14-positive cells.DENV2, IL-1\u03b2, CD14 and protein determinations ::: Materials and methodsMacrophages were fixed for 5 minutes with cold acetone or with 2 % of paraformaldehyde to determine viral antigen or macrophage antigen (CD14), respectively.", [["macrophage", "ANATOMY", 23, 33], ["cells", "ANATOMY", 57, 62], ["cellular", "ANATOMY", 98, 106], ["CD14-positive cells", "ANATOMY", 137, 156], ["Macrophages", "ANATOMY", 228, 239], ["acetone", "CHEMICAL", 275, 282], ["acetone", "CHEMICAL", 275, 282], ["paraformaldehyde", "CHEMICAL", 298, 314], ["macrophage", "CELL", 23, 33], ["cells", "CELL", 57, 62], ["cellular", "CELL", 98, 106], ["CD14", "GENE_OR_GENE_PRODUCT", 137, 141], ["DENV2", "ORGANISM", 157, 162], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 164, 169], ["CD14", "GENE_OR_GENE_PRODUCT", 171, 175], ["Macrophages", "CELL", 228, 239], ["acetone", "SIMPLE_CHEMICAL", 275, 282], ["paraformaldehyde", "SIMPLE_CHEMICAL", 298, 314], ["macrophage antigen", "GENE_OR_GENE_PRODUCT", 345, 363], ["CD14", "GENE_OR_GENE_PRODUCT", 365, 369], ["CD14", "PROTEIN", 137, 141], ["DENV2, IL-1\u03b2", "PROTEIN", 157, 169], ["CD14", "PROTEIN", 171, 175], ["Macrophages", "CELL_TYPE", 228, 239], ["viral antigen", "PROTEIN", 328, 341], ["macrophage antigen", "PROTEIN", 345, 363], ["CD14", "PROTEIN", 365, 369], ["DENV2", "SPECIES", 107, 112], ["DENV2", "SPECIES", 157, 162], ["the macrophage preparation", "TREATMENT", 19, 45], ["cellular DENV2 expression", "TEST", 98, 123], ["CD14", "TEST", 137, 141], ["DENV2", "TEST", 157, 162], ["IL", "TEST", 164, 166], ["protein determinations", "TEST", 180, 202], ["methodsMacrophages", "TREATMENT", 221, 239], ["cold acetone", "TREATMENT", 270, 282], ["paraformaldehyde", "TREATMENT", 298, 314], ["viral antigen", "TEST", 328, 341], ["macrophage antigen", "TEST", 345, 363], ["macrophage", "OBSERVATION_MODIFIER", 23, 33], ["DENV2 expression", "OBSERVATION", 107, 123], ["positive cells", "OBSERVATION", 142, 156]]], ["Intracellular viral antigens were detected in cytocentrifuged macrophages by a direct immunofluorescence assay using a fluorescein-conjugated anti-DENV2-specific monoclonal antibody (Chemicon International Inc. MA, USA).", [["Intracellular", "ANATOMY", 0, 13], ["macrophages", "ANATOMY", 62, 73], ["fluorescein", "CHEMICAL", 119, 130], ["fluorescein", "CHEMICAL", 119, 130], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["macrophages", "CELL", 62, 73], ["fluorescein", "SIMPLE_CHEMICAL", 119, 130], ["anti-DENV2", "SIMPLE_CHEMICAL", 142, 152], ["Intracellular viral antigens", "PROTEIN", 0, 28], ["cytocentrifuged macrophages", "CELL_TYPE", 46, 73], ["anti-DENV2", "PROTEIN", 142, 152], ["monoclonal antibody", "PROTEIN", 162, 181], ["Intracellular viral antigens", "TEST", 0, 28], ["a direct immunofluorescence assay", "TEST", 77, 110], ["a fluorescein", "TEST", 117, 130], ["viral", "OBSERVATION", 14, 19]]], ["Macrophages were also identified in separate samples using a fluorescein-conjugated monoclonal anti-murine CD14 antibody (eBioscience, Inc. San Diego, CA.", [["Macrophages", "ANATOMY", 0, 11], ["samples", "ANATOMY", 45, 52], ["fluorescein", "CHEMICAL", 61, 72], ["fluorescein", "CHEMICAL", 61, 72], ["Macrophages", "CELL", 0, 11], ["fluorescein", "SIMPLE_CHEMICAL", 61, 72], ["CD14", "GENE_OR_GENE_PRODUCT", 107, 111], ["Macrophages", "CELL_TYPE", 0, 11], ["fluorescein-conjugated monoclonal anti-murine CD14 antibody", "PROTEIN", 61, 120], ["eBioscience, Inc. San Diego, CA", "PROTEIN", 122, 153], ["Macrophages", "PROBLEM", 0, 11], ["a fluorescein", "TEST", 59, 72]]], ["Two hundred cells were counted, and the percentage of positive cells for each monoclonal antibody was determined.", [["cells", "ANATOMY", 12, 17], ["cells", "ANATOMY", 63, 68], ["cells", "CELL", 12, 17], ["cells", "CELL", 63, 68], ["positive cells", "CELL_TYPE", 54, 68], ["monoclonal antibody", "PROTEIN", 78, 97], ["Two hundred cells", "TEST", 0, 17], ["positive cells", "PROBLEM", 54, 68], ["each monoclonal antibody", "TEST", 73, 97], ["hundred cells", "OBSERVATION", 4, 17], ["positive cells", "OBSERVATION", 54, 68]]], ["The IL-1\u03b2 content was determined by ELISA (Biotra Amersham, Int.", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 4, 9], ["IL-1\u03b2", "PROTEIN", 4, 9], ["The IL", "TREATMENT", 0, 6]]], ["England) and expressed as pg/mgs of cellular protein or as pg/mL of peritoneal fluid.", [["cellular", "ANATOMY", 36, 44], ["peritoneal fluid", "ANATOMY", 68, 84], ["cellular", "CELL", 36, 44], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 68, 84], ["cellular protein", "PROTEIN", 36, 52], ["cellular protein", "TREATMENT", 36, 52], ["peritoneal fluid", "PROBLEM", 68, 84], ["peritoneal", "ANATOMY", 68, 78], ["fluid", "OBSERVATION", 79, 84]]], ["The total protein content in the macrophage homogenates was measured using the bicinchoninic acid assay [16].Statistical analysis ::: Materials and methodsData were expressed as mean \u00b1 standard deviation and analyzed by ANOVA followed by Bonferroni\u2019s test.", [["macrophage homogenates", "ANATOMY", 33, 55], ["bicinchoninic acid", "CHEMICAL", 79, 97], ["bicinchoninic acid", "CHEMICAL", 79, 97], ["macrophage homogenates", "TISSUE", 33, 55], ["The total protein content", "TEST", 0, 25], ["the macrophage homogenates", "TREATMENT", 29, 55], ["the bicinchoninic acid assay", "TEST", 75, 103], ["methodsData", "TEST", 148, 159], ["Bonferroni\u2019s test", "TEST", 238, 255]]], ["P-values less than 0.05 were considered statistically significant.ResultsPeritoneal macrophages were obtained from the peritoneal cavity after 12 hours of viral interaction to determine the presence of viral antigen in the cells.", [["Peritoneal macrophages", "ANATOMY", 73, 95], ["peritoneal cavity", "ANATOMY", 119, 136], ["cells", "ANATOMY", 223, 228], ["Peritoneal macrophages", "CELL", 73, 95], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 119, 136], ["cells", "CELL", 223, 228], ["Peritoneal macrophages", "CELL_TYPE", 73, 95], ["viral antigen", "PROTEIN", 202, 215], ["P-values", "TEST", 0, 8], ["Peritoneal macrophages", "TEST", 73, 95], ["viral interaction", "PROBLEM", 155, 172], ["viral antigen in the cells", "PROBLEM", 202, 228], ["Peritoneal", "ANATOMY", 73, 83], ["macrophages", "OBSERVATION", 84, 95], ["peritoneal cavity", "ANATOMY", 119, 136], ["viral", "OBSERVATION", 202, 207], ["cells", "ANATOMY", 223, 228]]], ["At this time, a high percentage of peritoneal macrophages from untreated infected mice were positive for DENV2, as revealed by immunofluorescence assay with an anti-DENV monoclonal antibody, indicating that penetration of the cells had occurred.", [["peritoneal macrophages", "ANATOMY", 35, 57], ["cells", "ANATOMY", 226, 231], ["peritoneal macrophages", "CELL", 35, 57], ["mice", "ORGANISM", 82, 86], ["DENV2", "ORGANISM", 105, 110], ["cells", "CELL", 226, 231], ["peritoneal macrophages", "CELL_TYPE", 35, 57], ["anti-DENV monoclonal antibody", "PROTEIN", 160, 189], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["DENV2", "SPECIES", 105, 110], ["anti-DENV", "SPECIES", 160, 169], ["a high percentage of peritoneal macrophages", "PROBLEM", 14, 57], ["untreated infected mice", "PROBLEM", 63, 86], ["DENV2", "PROBLEM", 105, 110], ["immunofluorescence assay", "TEST", 127, 151], ["an anti-DENV monoclonal antibody", "TEST", 157, 189], ["penetration of the cells", "PROBLEM", 207, 231], ["peritoneal", "ANATOMY", 35, 45], ["macrophages", "OBSERVATION", 46, 57], ["monoclonal antibody", "OBSERVATION", 170, 189]]], ["Infected cells that had been treated with losartan or enalapril showed reduced expression of viral antigens (Fig. 1).", [["cells", "ANATOMY", 9, 14], ["losartan", "CHEMICAL", 42, 50], ["enalapril", "CHEMICAL", 54, 63], ["losartan", "CHEMICAL", 42, 50], ["enalapril", "CHEMICAL", 54, 63], ["cells", "CELL", 9, 14], ["losartan", "SIMPLE_CHEMICAL", 42, 50], ["enalapril", "SIMPLE_CHEMICAL", 54, 63], ["viral antigens", "PROTEIN", 93, 107], ["Infected cells", "PROBLEM", 0, 14], ["losartan", "TREATMENT", 42, 50], ["enalapril", "TREATMENT", 54, 63], ["reduced expression of viral antigens", "PROBLEM", 71, 107], ["viral antigens", "OBSERVATION", 93, 107]]], ["In addition, the peritoneal fluid and macrophage contents (homogenates) were tested for the presence of IL-1\u03b2, a cytokine related to viral infection.", [["peritoneal fluid", "ANATOMY", 17, 33], ["macrophage", "ANATOMY", 38, 48], ["homogenates", "ANATOMY", 59, 70], ["viral infection", "DISEASE", 133, 148], ["peritoneal fluid", "ORGANISM_SUBSTANCE", 17, 33], ["macrophage", "CELL", 38, 48], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 104, 109], ["IL-1\u03b2", "PROTEIN", 104, 109], ["cytokine", "PROTEIN", 113, 121], ["the peritoneal fluid and macrophage contents", "TEST", 13, 57], ["IL", "TREATMENT", 104, 106], ["a cytokine", "PROBLEM", 111, 121], ["viral infection", "PROBLEM", 133, 148], ["peritoneal", "ANATOMY", 17, 27], ["fluid", "OBSERVATION", 28, 33], ["macrophage contents", "OBSERVATION", 38, 57], ["viral", "OBSERVATION_MODIFIER", 133, 138], ["infection", "OBSERVATION", 139, 148]]], ["Viral expression was accompanied by increased of IL-1 \u03b2 levels in the peritoneal fluid and in peritoneal macrophages, suggesting that macrophages were involved in the increased production of this cytokine.", [["peritoneal fluid", "ANATOMY", 70, 86], ["peritoneal macrophages", "ANATOMY", 94, 116], ["macrophages", "ANATOMY", 134, 145], ["Viral", "ORGANISM", 0, 5], ["IL-1 \u03b2", "GENE_OR_GENE_PRODUCT", 49, 55], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 70, 86], ["peritoneal macrophages", "CELL", 94, 116], ["macrophages", "CELL", 134, 145], ["IL-1 \u03b2", "PROTEIN", 49, 55], ["peritoneal macrophages", "CELL_TYPE", 94, 116], ["macrophages", "CELL_TYPE", 134, 145], ["cytokine", "PROTEIN", 196, 204], ["IL", "TEST", 49, 51], ["peritoneal macrophages", "PROBLEM", 94, 116], ["macrophages", "PROBLEM", 134, 145], ["this cytokine", "PROBLEM", 191, 204], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["peritoneal", "ANATOMY", 70, 80], ["fluid", "OBSERVATION", 81, 86], ["peritoneal", "ANATOMY", 94, 104], ["macrophages", "OBSERVATION", 105, 116], ["macrophages", "OBSERVATION", 134, 145], ["increased", "OBSERVATION_MODIFIER", 167, 176], ["production", "OBSERVATION_MODIFIER", 177, 187]]], ["Losartan treatment resulted in decreased IL-1 production in dengue-virus-infected cells, but enalapril did not affect IL-1 production (Fig. 2).", [["cells", "ANATOMY", 82, 87], ["Losartan", "CHEMICAL", 0, 8], ["dengue-virus-infected", "DISEASE", 60, 81], ["enalapril", "CHEMICAL", 93, 102], ["Losartan", "CHEMICAL", 0, 8], ["enalapril", "CHEMICAL", 93, 102], ["Losartan", "SIMPLE_CHEMICAL", 0, 8], ["IL-1", "GENE_OR_GENE_PRODUCT", 41, 45], ["dengue-virus", "ORGANISM", 60, 72], ["cells", "CELL", 82, 87], ["enalapril", "SIMPLE_CHEMICAL", 93, 102], ["IL-1", "GENE_OR_GENE_PRODUCT", 118, 122], ["IL", "PROTEIN", 41, 43], ["IL", "PROTEIN", 118, 120], ["dengue-virus", "SPECIES", 60, 72], ["dengue-virus", "SPECIES", 60, 72], ["Losartan treatment", "TREATMENT", 0, 18], ["decreased IL", "PROBLEM", 31, 43], ["dengue-virus", "PROBLEM", 60, 72], ["infected cells", "PROBLEM", 73, 87], ["enalapril", "TREATMENT", 93, 102], ["decreased", "OBSERVATION_MODIFIER", 31, 40], ["infected cells", "OBSERVATION", 73, 87]]], ["Resident macrophages had lower IL-1\u03b2 levels (81 \u00b1 23 pg/mg of protein and 72 \u00b1 13 pg/ml; cellular and peritoneal fluid contents, respectively) than that observed in macrophages elicited by thioglycollate treatment.", [["macrophages", "ANATOMY", 9, 20], ["cellular", "ANATOMY", 89, 97], ["peritoneal fluid", "ANATOMY", 102, 118], ["macrophages", "ANATOMY", 165, 176], ["thioglycollate", "CHEMICAL", 189, 203], ["macrophages", "CELL", 9, 20], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 31, 36], ["cellular", "CELL", 89, 97], ["peritoneal fluid", "MULTI-TISSUE_STRUCTURE", 102, 118], ["macrophages", "CELL", 165, 176], ["thioglycollate", "SIMPLE_CHEMICAL", 189, 203], ["Resident macrophages", "CELL_TYPE", 0, 20], ["IL-1\u03b2", "PROTEIN", 31, 36], ["macrophages", "CELL_TYPE", 165, 176], ["lower IL", "TEST", 25, 33], ["protein", "TEST", 62, 69], ["cellular and peritoneal fluid contents", "TEST", 89, 127], ["macrophages", "PROBLEM", 165, 176], ["thioglycollate treatment", "TREATMENT", 189, 213], ["peritoneal", "ANATOMY", 102, 112], ["fluid contents", "OBSERVATION", 113, 127], ["macrophages", "OBSERVATION", 165, 176]]], ["A high percentage (92 % \u00b1 7 %) of CD14 cells was observed, suggesting that macrophages were the main cell type analyzed in this study.", [["CD14 cells", "ANATOMY", 34, 44], ["macrophages", "ANATOMY", 75, 86], ["cell", "ANATOMY", 101, 105], ["CD14", "GENE_OR_GENE_PRODUCT", 34, 38], ["macrophages", "CELL", 75, 86], ["cell type", "CELL", 101, 110], ["CD14 cells", "CELL_LINE", 34, 44], ["macrophages", "CELL_TYPE", 75, 86], ["A high percentage", "TEST", 0, 17], ["CD14 cells", "PROBLEM", 34, 44], ["macrophages", "PROBLEM", 75, 86], ["this study", "TEST", 123, 133], ["high", "OBSERVATION_MODIFIER", 2, 6], ["percentage", "OBSERVATION_MODIFIER", 7, 17], ["CD14 cells", "OBSERVATION", 34, 44], ["macrophages", "OBSERVATION", 75, 86], ["main cell type", "OBSERVATION", 96, 110]]]], "PMC7224347": [["From government officials to mainstream media and even celebrities, coronavirus disease 2019 (COVID-19) has been touted as \u201cthe great equalizer.\u201d", [["coronavirus disease", "DISEASE", 68, 87], ["COVID-19", "CHEMICAL", 94, 102], ["mainstream media", "TREATMENT", 29, 45], ["coronavirus disease", "PROBLEM", 68, 87], ["COVID", "TEST", 94, 99], ["coronavirus disease", "OBSERVATION", 68, 87]]], ["It is a disease that transcends wealth, fame, prestige, or age.", [["a disease", "PROBLEM", 6, 15], ["disease", "OBSERVATION", 8, 15]]], ["The statement highlights our vulnerability as part of a society that lacks any immunity to the novel virus.", [["the novel virus", "PROBLEM", 91, 106]]]], "PMC5876289": [["Relevance to the Research Topic: Single Cell Approaches to Study the Immune SystemThe selection and study of single antigen-specific B cells and the identification of their expressed antibodies can help shed light on the nature and functions of the human humoral immune response.", [["Cell", "ANATOMY", 40, 44], ["B cells", "ANATOMY", 133, 140], ["B cells", "CELL", 133, 140], ["human", "ORGANISM", 249, 254], ["B cells", "CELL_TYPE", 133, 140], ["antibodies", "PROTEIN", 183, 193], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["Single Cell Approaches", "TREATMENT", 33, 55], ["study", "TEST", 100, 105], ["single antigen", "TEST", 109, 123], ["their expressed antibodies", "TREATMENT", 167, 193]]], ["In our study, we present an antigen-conjugated fluorescent bead methodology designed to identify and isolate single antibody-expressing cells and to derive and clone matched heavy and light chain antibody variable regions into full length antibodies.", [["cells", "ANATOMY", 136, 141], ["cells", "CELL", 136, 141], ["single antibody-expressing cells", "CELL_TYPE", 109, 141], ["heavy and light chain antibody variable regions", "PROTEIN", 174, 221], ["full length antibodies", "PROTEIN", 227, 249], ["our study", "TEST", 3, 12], ["single antibody", "TEST", 109, 124], ["expressing cells", "PROBLEM", 125, 141], ["clone matched heavy and light chain antibody variable regions", "PROBLEM", 160, 221]]], ["We believe that our single cell-to-functional antibody strategy falls within the scope of this research topic, as it opens the way for opportunities to analyze B cells and their antibody profiles at the single cell level and may be potentially applied to help unravel diverse humoral immune repertoires in different health and disease states.IntroductionThe study of humoral immunity may be key to understand human health, aging, and disease, as well as to predict or monitor host immune responses to pathogen challenge and disease progression (1).", [["cell", "ANATOMY", 27, 31], ["B cells", "ANATOMY", 160, 167], ["cell", "ANATOMY", 210, 214], ["cell", "CELL", 27, 31], ["B cells", "CELL", 160, 167], ["single cell", "CELL", 203, 214], ["human", "ORGANISM", 409, 414], ["B cells", "CELL_TYPE", 160, 167], ["human", "SPECIES", 409, 414], ["human", "SPECIES", 409, 414], ["functional antibody strategy falls", "PROBLEM", 35, 69], ["their antibody profiles", "TEST", 172, 195], ["disease progression", "PROBLEM", 524, 543]]], ["Moreover, dissecting B cell responses could help inform medical interventions such as preventative vaccines or therapeutic treatments (2, 3).", [["B cell", "ANATOMY", 21, 27], ["B cell", "CELL", 21, 27], ["dissecting B cell responses", "PROBLEM", 10, 37], ["medical interventions", "TREATMENT", 56, 77], ["preventative vaccines", "TREATMENT", 86, 107], ["therapeutic treatments", "TREATMENT", 111, 133]]], ["Currently, therapeutic monoclonal antibodies are part of the standard care of treatment for various conditions including diabetes, autoimmune and allergic diseases, and various types of cancer.", [["cancer", "ANATOMY", 186, 192], ["diabetes", "DISEASE", 121, 129], ["autoimmune and allergic diseases", "DISEASE", 131, 163], ["cancer", "DISEASE", 186, 192], ["cancer", "CANCER", 186, 192], ["therapeutic monoclonal antibodies", "PROTEIN", 11, 44], ["therapeutic monoclonal antibodies", "TREATMENT", 11, 44], ["treatment", "TREATMENT", 78, 87], ["various conditions", "PROBLEM", 92, 110], ["diabetes", "PROBLEM", 121, 129], ["autoimmune", "PROBLEM", 131, 141], ["allergic diseases", "PROBLEM", 146, 163], ["cancer", "PROBLEM", 186, 192], ["monoclonal antibodies", "OBSERVATION", 23, 44], ["diabetes", "OBSERVATION", 121, 129], ["allergic diseases", "OBSERVATION", 146, 163], ["cancer", "OBSERVATION", 186, 192]]], ["A big proportion of these antibodies are fully mouse or mouse\u2013human chimeras (4).", [["mouse", "ORGANISM", 47, 52], ["antibodies", "PROTEIN", 26, 36], ["mouse", "SPECIES", 47, 52], ["mouse", "SPECIES", 47, 52], ["antibodies", "OBSERVATION", 26, 36]]], ["Therefore, identification of fully human, heavy (H), and light (L) variable region-matched antibodies may be of interest for clinical applications, as administration of fully human antibodies is considered less likely to induce antidrug antibody responses compared with chimeric or humanized antibodies (5).", [["human", "ORGANISM", 35, 40], ["human", "ORGANISM", 175, 180], ["antibodies", "PROTEIN", 91, 101], ["human antibodies", "PROTEIN", 175, 191], ["antidrug antibody", "PROTEIN", 228, 245], ["chimeric or humanized antibodies", "PROTEIN", 270, 302], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 175, 180], ["light (L) variable region", "PROBLEM", 57, 82], ["clinical applications", "TREATMENT", 125, 146], ["fully human antibodies", "PROBLEM", 169, 191], ["antidrug antibody responses", "TEST", 228, 255]]], ["Immune monitoring of human B cells recognizing specific antigens, alongside identification, cloning, and production of their cognate monoclonal antibodies, may, therefore, be of substantial value to help evaluate reactivity and immunological response to these antigens.IntroductionAnalyses of the antibody repertoires of B cells have been reported in the human setting and in animal models, with the most common applications in the study of autoimmune diseases (6), viral infections, and B cell malignancies (7\u20139).", [["B cells", "ANATOMY", 27, 34], ["B cells", "ANATOMY", 321, 328], ["B cell malignancies", "ANATOMY", 488, 507], ["autoimmune diseases", "DISEASE", 441, 460], ["viral infections", "DISEASE", 466, 482], ["B cell malignancies", "DISEASE", 488, 507], ["human", "ORGANISM", 21, 26], ["B cells", "CELL", 27, 34], ["B cells", "CELL", 321, 328], ["human", "ORGANISM", 355, 360], ["B cell malignancies", "CANCER", 488, 507], ["human B cells", "CELL_TYPE", 21, 34], ["cognate monoclonal antibodies", "PROTEIN", 125, 154], ["antigens", "PROTEIN", 260, 268], ["B cells", "CELL_TYPE", 321, 328], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 355, 360], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 355, 360], ["Immune monitoring", "TEST", 0, 17], ["human B cells", "TEST", 21, 34], ["their cognate monoclonal antibodies", "TEST", 119, 154], ["the antibody repertoires", "TEST", 293, 317], ["B cells", "PROBLEM", 321, 328], ["the study", "TEST", 428, 437], ["autoimmune diseases", "PROBLEM", 441, 460], ["viral infections", "PROBLEM", 466, 482], ["B cell malignancies", "PROBLEM", 488, 507], ["B cells", "OBSERVATION", 321, 328], ["autoimmune", "OBSERVATION", 441, 451], ["viral infections", "OBSERVATION", 466, 482], ["B cell malignancies", "OBSERVATION", 488, 507]]], ["Some studies have employed high-throughput sequencing of heavy chain variable regions or of paired H and L variable region sequences (10, 11).", [["heavy chain variable regions", "DNA", 57, 85], ["paired H and L variable region sequences", "DNA", 92, 132], ["Some studies", "TEST", 0, 12], ["heavy chain variable regions", "PROBLEM", 57, 85], ["paired H and L variable region sequences", "PROBLEM", 92, 132], ["L", "ANATOMY_MODIFIER", 105, 106]]], ["Ultra-high-throughput sequencing techniques have also been developed, capable of analyzing repertoires of thousands of B cells from small human blood samples, with some allowing the mapping of paired H and L variable regions, in a few hours (12\u201314).IntroductionB cells may also be a source of antigen-specific antibodies for clinical diagnostics or for therapeutic applications.", [["B cells", "ANATOMY", 119, 126], ["blood samples", "ANATOMY", 144, 157], ["cells", "ANATOMY", 263, 268], ["B cells", "CELL", 119, 126], ["human", "ORGANISM", 138, 143], ["blood samples", "ORGANISM_SUBSTANCE", 144, 157], ["cells", "CELL", 263, 268], ["B cells", "CELL_TYPE", 119, 126], ["antigen-specific antibodies", "PROTEIN", 293, 320], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["Ultra", "TEST", 0, 5], ["sequencing techniques", "TEST", 22, 43], ["B cells", "PROBLEM", 119, 126], ["small human blood samples", "PROBLEM", 132, 157], ["the mapping", "TEST", 178, 189], ["IntroductionB cells", "PROBLEM", 249, 268], ["antigen", "PROBLEM", 293, 300], ["clinical diagnostics", "TEST", 325, 345], ["therapeutic applications", "TREATMENT", 353, 377], ["B cells", "OBSERVATION", 119, 126], ["small", "OBSERVATION_MODIFIER", 132, 137], ["L", "ANATOMY_MODIFIER", 206, 207]]], ["Existing methods to identify antigen-specific B cells and generate monoclonal antibodies include ex vivo B cell culture approaches, which could promote the survival and expansion of certain B cell subsets, screening of the culture supernatants to identify B cell reactivity and fluorescent-activated cell sorting (15\u201320).", [["B cells", "ANATOMY", 46, 53], ["B cell", "ANATOMY", 105, 111], ["B cell", "ANATOMY", 190, 196], ["supernatants", "ANATOMY", 231, 243], ["B cell", "ANATOMY", 256, 262], ["cell", "ANATOMY", 300, 304], ["antigen", "GENE_OR_GENE_PRODUCT", 29, 36], ["B cells", "CELL", 46, 53], ["B cell", "CELL", 105, 111], ["B cell subsets", "CELL", 190, 204], ["B cell", "CELL", 256, 262], ["cell", "CELL", 300, 304], ["B cells", "CELL_TYPE", 46, 53], ["monoclonal antibodies", "PROTEIN", 67, 88], ["B cell subsets", "CELL_TYPE", 190, 204], ["Existing methods", "TEST", 0, 16], ["antigen", "TEST", 29, 36], ["specific B cells", "PROBLEM", 37, 53], ["monoclonal antibodies", "TEST", 67, 88], ["ex vivo B cell culture approaches", "TEST", 97, 130], ["certain B cell subsets", "PROBLEM", 182, 204], ["the culture supernatants", "TEST", 219, 243], ["B cell reactivity", "TEST", 256, 273], ["fluorescent", "TEST", 278, 289], ["activated cell sorting", "TEST", 290, 312], ["cell subsets", "OBSERVATION", 192, 204]]], ["An essential element in the process of selecting antigen-specific B cells is detection of antibodies with a certain degree of specificity.", [["B cells", "ANATOMY", 66, 73], ["antigen", "GENE_OR_GENE_PRODUCT", 49, 56], ["B cells", "CELL", 66, 73], ["B cells", "CELL_TYPE", 66, 73], ["antibodies", "PROTEIN", 90, 100], ["selecting antigen", "TEST", 39, 56], ["antibodies", "PROBLEM", 90, 100], ["essential element", "OBSERVATION", 3, 20]]], ["This could be achieved by screening cell culture supernatants through ELISPOT assays or ELISA-based methods using immobilized recombinant antigens or cells (16, 20).", [["cell", "ANATOMY", 36, 40], ["supernatants", "ANATOMY", 49, 61], ["cells", "ANATOMY", 150, 155], ["cell", "CELL", 36, 40], ["cells", "CELL", 150, 155], ["recombinant antigens", "PROTEIN", 126, 146], ["screening cell culture supernatants", "TEST", 26, 61], ["ELISPOT assays", "TEST", 70, 84], ["ELISA", "TEST", 88, 93], ["immobilized recombinant antigens", "TREATMENT", 114, 146]]], ["Screening cell culture supernatants by ELISA, although highly sensitive, represents only a surrogate parameter and antigen reactivity should ultimately be confirmed only after sequencing and expression of the selected clone.", [["cell", "ANATOMY", 10, 14], ["supernatants", "ANATOMY", 23, 35], ["cell", "CELL", 10, 14], ["clone", "CELL", 218, 223], ["Screening cell culture supernatants", "TEST", 0, 35], ["ELISA", "TEST", 39, 44], ["a surrogate parameter", "TEST", 89, 110], ["the selected clone", "PROBLEM", 205, 223]]], ["For all these applications, the gold standard of identifying antigen-specific antibodies remains the expression of the recombinant antibody and further evaluation of its antigen recognition properties.", [["antigen", "GENE_OR_GENE_PRODUCT", 61, 68], ["antigen-specific antibodies", "PROTEIN", 61, 88], ["recombinant antibody", "PROTEIN", 119, 139], ["specific antibodies", "TEST", 69, 88], ["the recombinant antibody", "TEST", 115, 139], ["further evaluation", "TEST", 144, 162]]], ["Workflows to facilitate selection of single human B cells without ex vivo growth, stimulation, and clone expansion, and which do not require sampling of cell culture supernatants could offer additional tools for the study of human B cell immunity.", [["B cells", "ANATOMY", 50, 57], ["clone", "ANATOMY", 99, 104], ["cell", "ANATOMY", 153, 157], ["supernatants", "ANATOMY", 166, 178], ["B cell", "ANATOMY", 231, 237], ["human", "ORGANISM", 44, 49], ["B cells", "CELL", 50, 57], ["clone", "CELL", 99, 104], ["cell", "CELL", 153, 157], ["human", "ORGANISM", 225, 230], ["B cell", "CELL", 231, 237], ["single human B cells", "CELL_TYPE", 37, 57], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 225, 230], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 225, 230], ["single human B cells", "TREATMENT", 37, 57], ["clone expansion", "TEST", 99, 114], ["cell culture supernatants", "TEST", 153, 178], ["the study", "TEST", 212, 221]]], ["Novel approaches to address these requirements involve the use of modified fluorescent tetramers for direct B cell screening by fluorescent-activated cell sorting (21, 22).IntroductionIn this study, we describe the design of a bead-based methodology to identify single antibody-expressing B cells, and to clone and produce antigen-specific antibodies.", [["B cell", "ANATOMY", 108, 114], ["cell", "ANATOMY", 150, 154], ["B cells", "ANATOMY", 289, 296], ["B cell", "CELL", 108, 114], ["cell", "CELL", 150, 154], ["B cells", "CELL", 289, 296], ["clone", "CELL", 305, 310], ["single antibody-expressing B cells", "CELL_TYPE", 262, 296], ["antigen-specific antibodies", "PROTEIN", 323, 350], ["modified fluorescent tetramers", "TREATMENT", 66, 96], ["direct B cell screening", "TEST", 101, 124], ["activated cell sorting", "TEST", 140, 162], ["this study", "TEST", 187, 197], ["single antibody", "TEST", 262, 277], ["expressing B cells", "PROBLEM", 278, 296], ["antigen", "TEST", 323, 330]]], ["The workflow features bead-based identification and isolation of specific B cells using direct fluorescent-activated cell sorting, sequencing, and cloning of matched heavy and light chain variable regions in a single full sequence antibody expression vector system, and expression and testing the antigenic reactivity of the antibody clone.", [["B cells", "ANATOMY", 74, 81], ["cell", "ANATOMY", 117, 121], ["B cells", "CELL", 74, 81], ["cell", "CELL", 117, 121], ["B cells", "CELL_TYPE", 74, 81], ["heavy and light chain variable regions", "DNA", 166, 204], ["antibody clone", "CELL_LINE", 325, 339], ["specific B cells", "PROBLEM", 65, 81], ["direct fluorescent", "TEST", 88, 106], ["activated cell sorting", "TEST", 107, 129], ["sequencing", "TEST", 131, 141], ["matched heavy and light chain variable regions", "PROBLEM", 158, 204], ["the antibody clone", "PROBLEM", 321, 339], ["bead", "OBSERVATION_MODIFIER", 22, 26], ["antibody clone", "OBSERVATION", 325, 339]]], ["The workflow is designed to avoid ex vivo B cell expansion and secondary clone selection and to facilitate antibody generation and downstream evaluation.Human Samples ::: Materials and MethodsHuman immune cells were isolated from venous blood of healthy volunteers and patients with malignant melanoma.", [["B cell", "ANATOMY", 42, 48], ["clone", "ANATOMY", 73, 78], ["MethodsHuman immune cells", "ANATOMY", 185, 210], ["venous blood", "ANATOMY", 230, 242], ["malignant melanoma", "ANATOMY", 283, 301], ["malignant melanoma", "DISEASE", 283, 301], ["B cell", "CELL", 42, 48], ["clone", "CELL", 73, 78], ["Human", "ORGANISM", 153, 158], ["MethodsHuman immune cells", "CELL", 185, 210], ["venous blood", "ORGANISM_SUBSTANCE", 230, 242], ["volunteers", "ORGANISM", 254, 264], ["patients", "ORGANISM", 269, 277], ["malignant melanoma", "CANCER", 283, 301], ["MethodsHuman immune cells", "CELL_LINE", 185, 210], ["Human", "SPECIES", 153, 158], ["patients", "SPECIES", 269, 277], ["Human", "SPECIES", 153, 158], ["ex vivo B cell expansion", "TREATMENT", 34, 58], ["secondary clone selection", "TREATMENT", 63, 88], ["antibody generation", "TREATMENT", 107, 126], ["downstream evaluation", "TEST", 131, 152], ["Materials", "TREATMENT", 171, 180], ["MethodsHuman immune cells", "TREATMENT", 185, 210], ["malignant melanoma", "PROBLEM", 283, 301], ["cell expansion", "OBSERVATION", 44, 58], ["secondary clone selection", "OBSERVATION", 63, 88], ["venous", "ANATOMY", 230, 236], ["malignant", "OBSERVATION_MODIFIER", 283, 292], ["melanoma", "OBSERVATION", 293, 301]]], ["Specimens were collected with informed written consent in accordance with the Declaration of Helsinki.", [["Specimens", "ANATOMY", 0, 9]]], ["The study was conducted at King\u2019s College London, King\u2019s College London, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust (08/H0804/139 approved by London Bridge NRES committee; 16/LO/0366 approved by London-Central NRES Committee).", [["The study", "TEST", 0, 9]]], ["Human peripheral blood mononuclear cells (PBMC) were isolated from 40 ml blood using Ficoll\u00ae Paque Plus density centrifugation (GE Healthcare).Cell Culture ::: Materials and MethodsCell culture was performed using aseptic technique at 37\u00b0C in a humidified atmosphere in 5% CO2, unless otherwise specified.", [["peripheral blood mononuclear cells", "ANATOMY", 6, 40], ["PBMC", "ANATOMY", 42, 46], ["blood", "ANATOMY", 73, 78], ["Cell", "ANATOMY", 143, 147], ["Cell", "ANATOMY", 181, 185], ["CO2", "CHEMICAL", 273, 276], ["CO2", "CHEMICAL", 273, 276], ["Human", "ORGANISM", 0, 5], ["peripheral blood mononuclear cells", "CELL", 6, 40], ["PBMC", "CELL", 42, 46], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["Cell", "CELL", 143, 147], ["Cell", "CELL", 181, 185], ["C", "SIMPLE_CHEMICAL", 238, 239], ["CO2", "SIMPLE_CHEMICAL", 273, 276], ["Human peripheral blood mononuclear cells", "CELL_TYPE", 0, 40], ["PBMC", "CELL_TYPE", 42, 46], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human peripheral blood mononuclear cells", "TEST", 0, 40], ["PBMC", "TEST", 42, 46], ["Ficoll\u00ae Paque Plus density centrifugation (GE Healthcare", "TREATMENT", 85, 141], ["Cell Culture", "TEST", 143, 155], ["MethodsCell culture", "TEST", 174, 193], ["aseptic technique", "TEST", 214, 231], ["a humidified atmosphere", "TREATMENT", 243, 266], ["5% CO2", "TREATMENT", 270, 276], ["peripheral", "ANATOMY_MODIFIER", 6, 16], ["blood", "ANATOMY", 17, 22], ["mononuclear cells", "OBSERVATION", 23, 40], ["density centrifugation", "OBSERVATION", 104, 126]]], ["The human ovarian carcinoma cell line IGROV1 naturally over-expressing folate receptor alpha (FR\u03b1) was grown in RPMI 1640 GlutaMAX\u2122 medium (Thermo Scientific) supplemented with 10% fetal calf serum (FCS).", [["ovarian carcinoma cell line IGROV1", "ANATOMY", 10, 44], ["fetal calf serum", "ANATOMY", 181, 197], ["ovarian carcinoma", "DISEASE", 10, 27], ["folate", "CHEMICAL", 71, 77], ["folate", "CHEMICAL", 71, 77], ["human", "ORGANISM", 4, 9], ["ovarian carcinoma cell line IGROV1", "CELL", 10, 44], ["folate receptor alpha", "GENE_OR_GENE_PRODUCT", 71, 92], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 94, 97], ["fetal calf", "ORGANISM_SUBSTANCE", 181, 191], ["serum", "ORGANISM_SUBSTANCE", 192, 197], ["FCS", "ORGANISM_SUBSTANCE", 199, 202], ["human ovarian carcinoma cell line IGROV1", "CELL_LINE", 4, 44], ["folate receptor alpha", "PROTEIN", 71, 92], ["FR\u03b1", "PROTEIN", 94, 97], ["human", "SPECIES", 4, 9], ["calf", "SPECIES", 187, 191], ["human", "SPECIES", 4, 9], ["The human ovarian carcinoma", "PROBLEM", 0, 27], ["folate receptor alpha", "TEST", 71, 92], ["ovarian", "ANATOMY", 10, 17], ["carcinoma cell line", "OBSERVATION", 18, 37]]], ["The human breast cancer cell line MDA-MB-231 was grown in DMEM GlutaMAX\u2122 medium (Thermo Scientific) supplemented with 10% FCS.", [["breast cancer cell line MDA-MB-231", "ANATOMY", 10, 44], ["breast cancer", "DISEASE", 10, 23], ["MDA-MB-231", "CHEMICAL", 34, 44], ["human", "ORGANISM", 4, 9], ["breast cancer cell line MDA-MB-231", "CELL", 10, 44], ["human breast cancer cell line MDA-MB-231", "CELL_LINE", 4, 44], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human breast cancer", "PROBLEM", 0, 23], ["MDA", "TEST", 34, 37], ["MB", "TEST", 38, 40], ["10% FCS", "TREATMENT", 118, 125], ["breast", "ANATOMY", 10, 16], ["cancer", "OBSERVATION", 17, 23], ["cell line", "OBSERVATION", 24, 33]]], ["The permanently transfected murine myeloma cell lines SP2/0-MOv18 specific for FR\u03b1 and SP2/0-SF25, recognizing a colon carcinoma antigen (23), were cultured in Dulbecco\u2019s Modified Eagle\u2019s Medium plus 10% FCS as previously described (24).", [["myeloma cell lines", "ANATOMY", 35, 53], ["colon carcinoma", "ANATOMY", 113, 128], ["colon carcinoma", "DISEASE", 113, 128], ["murine", "ORGANISM", 28, 34], ["myeloma cell lines SP2", "CELL", 35, 57], ["MOv18", "GENE_OR_GENE_PRODUCT", 60, 65], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 79, 82], ["SF25", "GENE_OR_GENE_PRODUCT", 93, 97], ["colon carcinoma", "CANCER", 113, 128], ["murine myeloma cell lines", "CELL_LINE", 28, 53], ["SP2/0-MOv18", "DNA", 54, 65], ["FR\u03b1", "PROTEIN", 79, 82], ["SP2/0-SF25", "DNA", 87, 97], ["murine", "SPECIES", 28, 34], ["The permanently transfected murine myeloma", "PROBLEM", 0, 42], ["SP2", "TEST", 54, 57], ["FR\u03b1", "TEST", 79, 82], ["SP2", "TEST", 87, 90], ["a colon carcinoma antigen", "PROBLEM", 111, 136], ["transfected murine", "OBSERVATION", 16, 34], ["myeloma cell lines", "OBSERVATION", 35, 53], ["colon", "ANATOMY", 113, 118], ["carcinoma", "OBSERVATION", 119, 128]]], ["The human embryonic kidney cell lines, Expi293F cells, were cultured in serum-free Expi293 expression medium (Thermo Scientific) on a Stuart orbital shaker at 125 rpm at 8% CO2.Transient Expression of Human Monoclonal Antibodies in Expi293F Cells ::: Materials and MethodsExpi293F cells were transfected with pVitro1-hygro-mcs antibody constructs using the ExpiFectamine293 Transfection kit (Thermo Scientific) as per manufacturer\u2019s instructions.", [["embryonic kidney cell lines", "ANATOMY", 10, 37], ["Expi293F cells", "ANATOMY", 39, 53], ["serum", "ANATOMY", 72, 77], ["Cells", "ANATOMY", 241, 246], ["MethodsExpi293F cells", "ANATOMY", 265, 286], ["CO2", "CHEMICAL", 173, 176], ["ExpiFectamine293", "CHEMICAL", 357, 373], ["CO2", "CHEMICAL", 173, 176], ["human", "ORGANISM", 4, 9], ["embryonic kidney cell lines", "CELL", 10, 37], ["Expi293F cells", "CELL", 39, 53], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["CO2", "SIMPLE_CHEMICAL", 173, 176], ["Human", "ORGANISM", 201, 206], ["Expi293F Cells", "CELL", 232, 246], ["MethodsExpi293F cells", "CELL", 265, 286], ["pVitro1", "GENE_OR_GENE_PRODUCT", 309, 316], ["human embryonic kidney cell lines", "CELL_LINE", 4, 37], ["Expi293F cells", "CELL_LINE", 39, 53], ["Human Monoclonal Antibodies", "PROTEIN", 201, 228], ["Expi293F Cells", "CELL_LINE", 232, 246], ["MethodsExpi293F cells", "CELL_LINE", 265, 286], ["pVitro1-hygro-mcs antibody constructs", "DNA", 309, 346], ["human", "SPECIES", 4, 9], ["Human", "SPECIES", 201, 206], ["human", "SPECIES", 4, 9], ["Human", "SPECIES", 201, 206], ["The human embryonic kidney cell lines", "TEST", 0, 37], ["Expi293F cells", "TEST", 39, 53], ["serum", "TEST", 72, 77], ["Human Monoclonal Antibodies", "TEST", 201, 228], ["MethodsExpi293F cells", "TREATMENT", 265, 286], ["pVitro1", "TEST", 309, 316], ["the ExpiFectamine", "TREATMENT", 353, 370], ["kidney", "ANATOMY", 20, 26], ["cell lines", "OBSERVATION", 27, 37], ["orbital", "ANATOMY", 141, 148], ["Monoclonal Antibodies", "OBSERVATION", 207, 228]]], ["The anti-human epidermal growth factor receptor 2 (HER2) and the melanoma-associated antigen-specific chondroitin sulfate proteoglycan (CSPG4) antibody constructs were previously described (25, 26).Fluorescent Beads ::: Materials and MethodsDifferent avidin- or streptavidin-coated fluorescent beads of different sizes were used (Table S1 in Supplementary Material): XMAP LumAvidin Microspheres (LumAvidin 5.6 \u00b5m) (L100-L150-01) with a size of 5.6 \u00b5m and fluorescent in the APC channel (from Luminex); Sphero Coated-fluorescent particles (Spherotec Inc.) as follows: Sphero Streptavidin-coated fluorescent particles, Nile Red 0.4\u20130.6 \u00b5m (SA-Red 0.5 \u00b5m) (Cat No SVFP-0556-5), Sphero Avidin-coated fluorescent particles Nile Red, 0.7\u20130.9 \u00b5m (A-Red 0.8 \u00b5m) (Cat No VFP-0856-5), and Sphero Streptavidin-Coated fluorescent particles, Blue, 1.0\u20131.9 \u00b5m (SA-Blue 1.1 \u00b5m) (Cat No SVFP-1068-5).Generation of Melanoma Cell Line Protein Extracts ::: Materials and MethodsTo biotinylate proteins of melanoma cell lines, confluent cell monolayers were washed with PBS and borate buffer pH 9.", [["melanoma", "ANATOMY", 65, 73], ["Cell", "ANATOMY", 907, 911], ["melanoma cell lines", "ANATOMY", 986, 1005], ["cell monolayers", "ANATOMY", 1017, 1032], ["melanoma", "DISEASE", 65, 73], ["chondroitin sulfate", "CHEMICAL", 102, 121], ["SVFP-0556-5", "CHEMICAL", 661, 672], ["VFP-0856-5", "CHEMICAL", 762, 772], ["SVFP-1068-5", "CHEMICAL", 871, 882], ["Melanoma", "DISEASE", 898, 906], ["melanoma", "DISEASE", 986, 994], ["Nile Red", "CHEMICAL", 617, 625], ["Nile Red", "CHEMICAL", 718, 726], ["borate", "CHEMICAL", 1058, 1064], ["anti-human epidermal growth factor receptor 2", "GENE_OR_GENE_PRODUCT", 4, 49], ["HER2", "GENE_OR_GENE_PRODUCT", 51, 55], ["melanoma", "CANCER", 65, 73], ["chondroitin sulfate proteoglycan", "GENE_OR_GENE_PRODUCT", 102, 134], ["CSPG4", "GENE_OR_GENE_PRODUCT", 136, 141], ["avidin", "GENE_OR_GENE_PRODUCT", 251, 257], ["streptavidin", "SIMPLE_CHEMICAL", 262, 274], ["XMAP LumAvidin Microspheres", "SIMPLE_CHEMICAL", 367, 394], ["APC", "GENE_OR_GENE_PRODUCT", 474, 477], ["Sphero Streptavidin-coated fluorescent particles", "SIMPLE_CHEMICAL", 567, 615], ["Sphero", "SIMPLE_CHEMICAL", 675, 681], ["Avidin", "SIMPLE_CHEMICAL", 682, 688], ["Sphero Streptavidin-Coated fluorescent particles", "SIMPLE_CHEMICAL", 779, 827], ["Blue", "SIMPLE_CHEMICAL", 829, 833], ["Melanoma Cell", "CELL", 898, 911], ["melanoma cell lines", "CELL", 986, 1005], ["cell monolayers", "CELL", 1017, 1032], ["anti-human epidermal growth factor receptor 2", "PROTEIN", 4, 49], ["HER2", "PROTEIN", 51, 55], ["melanoma-associated antigen-specific chondroitin sulfate proteoglycan (CSPG4) antibody constructs", "DNA", 65, 162], ["streptavidin", "PROTEIN", 262, 274], ["APC channel", "PROTEIN", 474, 485], ["MethodsTo biotinylate proteins", "PROTEIN", 952, 982], ["melanoma cell lines", "CELL_LINE", 986, 1005], ["confluent cell monolayers", "CELL_LINE", 1007, 1032], ["The anti-human epidermal growth factor receptor", "TEST", 0, 47], ["HER2", "TEST", 51, 55], ["the melanoma", "PROBLEM", 61, 73], ["antigen", "TEST", 85, 92], ["specific chondroitin sulfate proteoglycan (CSPG4) antibody constructs", "TREATMENT", 93, 162], ["Materials", "TEST", 220, 229], ["MethodsDifferent avidin", "TREATMENT", 234, 257], ["streptavidin-coated fluorescent beads of different sizes", "TREATMENT", 262, 318], ["Table S1 in Supplementary Material", "TREATMENT", 330, 364], ["XMAP LumAvidin Microspheres (LumAvidin", "TREATMENT", 367, 405], ["fluorescent in the APC channel (from Luminex)", "TREATMENT", 455, 500], ["Sphero Coated-fluorescent particles (Spherotec Inc.)", "TREATMENT", 502, 554], ["Sphero Streptavidin", "TREATMENT", 567, 586], ["Nile Red", "TEST", 617, 625], ["SVFP", "TEST", 661, 665], ["Sphero Avidin", "TEST", 675, 688], ["Nile Red", "TEST", 718, 726], ["Cat", "TEST", 755, 758], ["VFP", "TEST", 762, 765], ["Sphero Streptavidin", "TREATMENT", 779, 798], ["Blue", "TEST", 829, 833], ["SVFP", "TEST", 871, 875], ["Materials", "TREATMENT", 938, 947], ["MethodsTo biotinylate proteins", "TREATMENT", 952, 982], ["melanoma cell lines", "TREATMENT", 986, 1005], ["confluent cell monolayers", "PROBLEM", 1007, 1032], ["PBS and borate buffer pH", "TREATMENT", 1050, 1074], ["melanoma", "OBSERVATION", 65, 73], ["Beads", "OBSERVATION_MODIFIER", 210, 215], ["Melanoma Cell Line", "OBSERVATION", 898, 916], ["melanoma cell lines", "OBSERVATION", 986, 1005], ["confluent", "OBSERVATION_MODIFIER", 1007, 1016], ["cell monolayers", "OBSERVATION", 1017, 1032]]], ["Then, sulfo-NHS-LC-biotin at 1 mg/ml in PBS was added and incubated for 20 min on ice.", [["sulfo-NHS-LC-biotin", "CHEMICAL", 6, 25], ["biotin", "CHEMICAL", 19, 25], ["sulfo-NHS-LC-biotin", "SIMPLE_CHEMICAL", 6, 25], ["sulfo-NHS", "TREATMENT", 6, 15], ["biotin", "TREATMENT", 19, 25], ["PBS", "TREATMENT", 40, 43]]], ["The reaction was quenched with 200 mM Tris, 120 mM NaCl pH 7.4, and the cells were subsequently extensively washed with PBS.", [["cells", "ANATOMY", 72, 77], ["NaCl", "CHEMICAL", 51, 55], ["Tris", "CHEMICAL", 38, 42], ["NaCl", "CHEMICAL", 51, 55], ["cells", "CELL", 72, 77], ["The reaction", "PROBLEM", 0, 12], ["mM NaCl pH", "TEST", 48, 58], ["the cells", "PROBLEM", 68, 77], ["PBS", "TREATMENT", 120, 123]]], ["Cell lysis buffer (Cell Signaling Technology) containing 0.1% Triton and supplemented with 2 mM PMSF was added to the monolayer and the cells were harvested by scrapping.", [["Cell", "ANATOMY", 0, 4], ["Cell", "ANATOMY", 19, 23], ["monolayer", "ANATOMY", 118, 127], ["cells", "ANATOMY", 136, 141], ["Triton", "CHEMICAL", 62, 68], ["PMSF", "CHEMICAL", 96, 100], ["Cell", "CELL", 0, 4], ["Cell", "CELL", 19, 23], ["Triton", "SIMPLE_CHEMICAL", 62, 68], ["PMSF", "SIMPLE_CHEMICAL", 96, 100], ["monolayer", "CELL", 118, 127], ["cells", "CELL", 136, 141], ["Cell lysis buffer (Cell Signaling Technology)", "TREATMENT", 0, 45], ["0.1% Triton", "TREATMENT", 57, 68], ["2 mM PMSF", "TREATMENT", 91, 100]]], ["Lysates were briefly sonicated and incubated on an orbital rocker for 30 min at 4 C. The lysates were cleared by centrifugation at 900 \u00d7 g for 15 min, followed by a second centrifugation at 12,000 \u00d7 g for 30 min.", [["Lysates", "ANATOMY", 0, 7], ["lysates", "ANATOMY", 89, 96], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["lysates", "ORGANISM_SUBSTANCE", 89, 96], ["Lysates", "TREATMENT", 0, 7], ["an orbital rocker", "TREATMENT", 48, 65], ["The lysates", "TREATMENT", 85, 96], ["a second centrifugation", "TREATMENT", 163, 186], ["orbital rocker", "ANATOMY", 51, 65]]], ["Supernatants were either used immediately or stored at \u221280\u00b0C.Coupling of Recombinant Proteins to Fluorescent Beads ::: Materials and MethodsRecombinant Folate Receptor \u03b1 (FR\u03b1) (R&D Systems, Cat no 5646-FR) and human epidermal growth factor receptor 2 (ErbB2/HER2) Fc chimera (R&D Systems, Cat no 1129-ER) were reconstituted in PBS at 0.1 mg/ml as recommended by the manufacturer.", [["Supernatants", "ANATOMY", 0, 12], ["Folate", "CHEMICAL", 152, 158], ["Folate", "CHEMICAL", 152, 158], ["Supernatants", "CELL", 0, 12], ["MethodsRecombinant Folate Receptor \u03b1", "GENE_OR_GENE_PRODUCT", 133, 169], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 171, 174], ["human", "ORGANISM", 210, 215], ["epidermal growth factor receptor 2", "GENE_OR_GENE_PRODUCT", 216, 250], ["ErbB2", "GENE_OR_GENE_PRODUCT", 252, 257], ["HER2", "GENE_OR_GENE_PRODUCT", 258, 262], ["1129-ER", "GENE_OR_GENE_PRODUCT", 296, 303], ["Recombinant Proteins", "PROTEIN", 73, 93], ["MethodsRecombinant Folate Receptor \u03b1", "PROTEIN", 133, 169], ["FR\u03b1", "PROTEIN", 171, 174], ["R&D", "PROTEIN", 177, 180], ["Cat", "PROTEIN", 190, 193], ["5646", "PROTEIN", 197, 201], ["FR", "PROTEIN", 202, 204], ["human epidermal growth factor receptor 2 (ErbB2/HER2) Fc chimera", "PROTEIN", 210, 274], ["R&D", "PROTEIN", 276, 279], ["Cat", "PROTEIN", 289, 292], ["1129", "PROTEIN", 296, 300], ["ER", "PROTEIN", 301, 303], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 210, 215], ["Materials", "TEST", 119, 128], ["MethodsRecombinant Folate Receptor \u03b1 (FR\u03b1)", "TREATMENT", 133, 175], ["Cat", "TEST", 190, 193], ["human epidermal growth factor receptor", "TREATMENT", 210, 248], ["ErbB2/HER2)", "TREATMENT", 252, 263]]], ["Biotins with three different arms were used: (i) sulfo-NHS-LC-biotin with a spacer arm of 22.4 \u00c5; (ii) sulfo-NHS-LC-LC-biotin with a spacer arm of 30.5 \u00c5, and (iii) NHS-PEG12-biotin with a spacer arm of 56 \u00c5 (all from Pierce-Thermo Fisher Scientific).", [["sulfo-NHS-LC-biotin", "CHEMICAL", 49, 68], ["sulfo-NHS-LC-LC-biotin", "CHEMICAL", 103, 125], ["NHS-PEG12-biotin", "CHEMICAL", 165, 181], ["Biotins", "CHEMICAL", 0, 7], ["biotin", "CHEMICAL", 62, 68], ["biotin", "CHEMICAL", 119, 125], ["biotin", "CHEMICAL", 175, 181], ["Biotins", "SIMPLE_CHEMICAL", 0, 7], ["sulfo-NHS-LC-biotin", "SIMPLE_CHEMICAL", 49, 68], ["sulfo-NHS", "SIMPLE_CHEMICAL", 103, 112], ["biotin", "SIMPLE_CHEMICAL", 119, 125], ["NHS-PEG12-biotin", "SIMPLE_CHEMICAL", 165, 181], ["PEG12", "PROTEIN", 169, 174], ["Biotins", "TREATMENT", 0, 7], ["sulfo", "TEST", 49, 54], ["biotin", "TREATMENT", 62, 68], ["a spacer arm", "TREATMENT", 74, 86], ["sulfo", "TEST", 103, 108], ["LC", "TEST", 113, 115], ["a spacer arm", "TREATMENT", 131, 143], ["NHS", "TEST", 165, 168], ["PEG12-biotin", "TREATMENT", 169, 181], ["a spacer arm", "TREATMENT", 187, 199], ["LC", "ANATOMY", 113, 115], ["LC", "ANATOMY", 116, 118]]], ["The three forms of biotin were reconstituted following the manufacturer\u2019s instructions and mixed with the recombinant proteins in PBS at a 20:1 (biotin:recombinant protein) molar ratio and incubated for 90 min at room temperature (RT).", [["biotin", "CHEMICAL", 19, 25], ["biotin", "CHEMICAL", 19, 25], ["biotin", "CHEMICAL", 145, 151], ["biotin", "SIMPLE_CHEMICAL", 19, 25], ["biotin", "SIMPLE_CHEMICAL", 145, 151], ["recombinant proteins", "PROTEIN", 106, 126], ["recombinant protein", "PROTEIN", 152, 171], ["biotin", "TREATMENT", 19, 25], ["the recombinant proteins in PBS", "TREATMENT", 102, 133], ["molar ratio", "TEST", 173, 184]]], ["Free biotin was removed by dialysis in PBS.Coupling of Recombinant Proteins to Fluorescent Beads ::: Materials and MethodsFor binding of biotin-conjugated FR\u03b1 to LumAvidin 5.6 \u00b5m microspheres, 100 \u00b5l of microsphere solution was washed with 1 ml of 1% BSA\u2013PBS\u20130.05% sodium azide, spun at 8,000 \u00d7 g for 2 min, and pellets were resuspended in 100 \u00b5l of 1% BSA\u2013PBS\u20130.05% sodium azide.", [["biotin", "CHEMICAL", 5, 11], ["biotin", "CHEMICAL", 137, 143], ["BSA", "CHEMICAL", 251, 254], ["sodium azide", "CHEMICAL", 265, 277], ["BSA", "CHEMICAL", 353, 356], ["sodium azide", "CHEMICAL", 367, 379], ["biotin", "CHEMICAL", 5, 11], ["biotin", "CHEMICAL", 137, 143], ["sodium azide", "CHEMICAL", 265, 277], ["sodium azide", "CHEMICAL", 367, 379], ["biotin", "SIMPLE_CHEMICAL", 5, 11], ["biotin-conjugated FR\u03b1", "SIMPLE_CHEMICAL", 137, 158], ["LumAvidin", "SIMPLE_CHEMICAL", 162, 171], ["BSA", "SIMPLE_CHEMICAL", 251, 254], ["sodium azide", "SIMPLE_CHEMICAL", 265, 277], ["BSA", "SIMPLE_CHEMICAL", 353, 356], ["sodium azide", "SIMPLE_CHEMICAL", 367, 379], ["Recombinant Proteins", "PROTEIN", 55, 75], ["Free biotin", "TREATMENT", 0, 11], ["dialysis in PBS", "TREATMENT", 27, 42], ["Methods", "TREATMENT", 115, 122], ["biotin-conjugated FR\u03b1", "TREATMENT", 137, 158], ["LumAvidin", "TREATMENT", 162, 171], ["microsphere solution", "TREATMENT", 203, 223], ["0.05% sodium azide", "TREATMENT", 259, 277], ["biotin", "OBSERVATION", 5, 11]]], ["Then, 37.5 \u00b5g of biotin-conjugated recombinant protein (in 300 \u00b5l of PBS-1% BSA) was added to the beads and mixed, by rotation, for up to 16 h at RT.", [["beads", "ANATOMY", 98, 103], ["biotin", "CHEMICAL", 17, 23], ["biotin", "CHEMICAL", 17, 23], ["biotin", "SIMPLE_CHEMICAL", 17, 23], ["BSA", "SIMPLE_CHEMICAL", 76, 79], ["biotin-conjugated recombinant protein", "PROTEIN", 17, 54], ["biotin-conjugated recombinant protein", "TREATMENT", 17, 54], ["PBS", "TEST", 69, 72]]], ["Beads were then washed three times with 1 ml of 1% BSA\u2013PBS\u20130.05% sodium azide and resuspended in 100 \u00b5l of 1% BSA\u2013PBS\u20130.05% sodium azide.Coupling of Recombinant Proteins to Fluorescent Beads ::: Materials and MethodsFor binding of biotin-conjugated FR\u03b1 to all Sphero fluorescent particles, 100 \u00b5l of beads were washed with 1 ml of 1% BSA\u2013PBS\u20130.05% sodium azide, spun at 13,000 \u00d7 g for 20 min at RT, and the pellet was resuspended in the original volume of beads with 1% BSA\u2013PBS\u20130.05% sodium azide.", [["beads", "ANATOMY", 300, 305], ["BSA", "CHEMICAL", 51, 54], ["sodium azide", "CHEMICAL", 65, 77], ["BSA", "CHEMICAL", 110, 113], ["sodium azide", "CHEMICAL", 124, 136], ["biotin", "CHEMICAL", 231, 237], ["BSA", "CHEMICAL", 334, 337], ["sodium azide", "CHEMICAL", 348, 360], ["BSA", "CHEMICAL", 470, 473], ["sodium azide", "CHEMICAL", 484, 496], ["sodium azide", "CHEMICAL", 65, 77], ["sodium azide", "CHEMICAL", 124, 136], ["biotin", "CHEMICAL", 231, 237], ["sodium azide", "CHEMICAL", 348, 360], ["sodium azide", "CHEMICAL", 484, 496], ["Beads", "CELL", 0, 5], ["BSA", "SIMPLE_CHEMICAL", 51, 54], ["sodium azide", "SIMPLE_CHEMICAL", 65, 77], ["BSA", "SIMPLE_CHEMICAL", 110, 113], ["sodium azide", "SIMPLE_CHEMICAL", 124, 136], ["biotin", "SIMPLE_CHEMICAL", 231, 237], ["conjugated FR\u03b1", "SIMPLE_CHEMICAL", 238, 252], ["Sphero fluorescent particles", "SIMPLE_CHEMICAL", 260, 288], ["BSA", "SIMPLE_CHEMICAL", 334, 337], ["sodium azide", "SIMPLE_CHEMICAL", 348, 360], ["BSA", "SIMPLE_CHEMICAL", 470, 473], ["sodium azide", "SIMPLE_CHEMICAL", 484, 496], ["Recombinant Proteins", "PROTEIN", 149, 169], ["FR\u03b1", "PROTEIN", 249, 252], ["sodium azide", "TREATMENT", 65, 77], ["PBS", "TEST", 114, 117], ["Methods", "TREATMENT", 209, 216], ["biotin-conjugated FR\u03b1", "TREATMENT", 231, 252], ["all Sphero fluorescent particles", "TREATMENT", 256, 288], ["0.05% sodium azide", "TREATMENT", 342, 360], ["the pellet", "TREATMENT", 403, 413], ["% sodium azide", "TREATMENT", 482, 496]]], ["Then, 25 \u00b5g of biotin-conjugated recombinant protein was added and mixed, by rotation, for 2\u201316 h at RT.", [["biotin", "CHEMICAL", 15, 21], ["biotin", "CHEMICAL", 15, 21], ["biotin", "SIMPLE_CHEMICAL", 15, 21], ["biotin-conjugated recombinant protein", "PROTEIN", 15, 52], ["biotin-conjugated recombinant protein", "TREATMENT", 15, 52]]], ["After binding, beads were washed three times with 1 ml 1% BSA\u2013PBS\u20130.05% sodium azide and resuspended in 100 \u00b5l of 1% BSA\u2013PBS\u20130.05% sodium azide.Coupling of Recombinant Proteins to Fluorescent Beads ::: Materials and MethodsFor binding of biotin-conjugated cell extracts to LumAvidin 5.6 \u00b5m microspheres, 200 \u00b5l of microsphere solution were washed with 1 ml of 1% BSA\u2013PBS\u20130.05% sodium azide, spun at 8,000 \u00d7 g for 2 min, and pellets were resuspended in 200 \u00b5l of 1% BSA\u2013PBS\u20130.05% sodium azide.", [["cell extracts", "ANATOMY", 256, 269], ["BSA", "CHEMICAL", 58, 61], ["sodium azide", "CHEMICAL", 72, 84], ["BSA", "CHEMICAL", 117, 120], ["sodium azide", "CHEMICAL", 131, 143], ["biotin", "CHEMICAL", 238, 244], ["LumAvidin", "CHEMICAL", 273, 282], ["BSA", "CHEMICAL", 363, 366], ["sodium azide", "CHEMICAL", 377, 389], ["BSA", "CHEMICAL", 465, 468], ["sodium azide", "CHEMICAL", 479, 491], ["sodium azide", "CHEMICAL", 72, 84], ["sodium azide", "CHEMICAL", 131, 143], ["biotin", "CHEMICAL", 238, 244], ["sodium azide", "CHEMICAL", 377, 389], ["sodium azide", "CHEMICAL", 479, 491], ["BSA", "SIMPLE_CHEMICAL", 58, 61], ["sodium azide", "SIMPLE_CHEMICAL", 72, 84], ["BSA", "SIMPLE_CHEMICAL", 117, 120], ["sodium azide", "SIMPLE_CHEMICAL", 131, 143], ["biotin", "SIMPLE_CHEMICAL", 238, 244], ["cell extracts", "ORGANISM_SUBSTANCE", 256, 269], ["LumAvidin", "SIMPLE_CHEMICAL", 273, 282], ["BSA", "SIMPLE_CHEMICAL", 363, 366], ["sodium azide", "SIMPLE_CHEMICAL", 377, 389], ["BSA", "SIMPLE_CHEMICAL", 465, 468], ["sodium azide", "SIMPLE_CHEMICAL", 479, 491], ["Recombinant Proteins", "PROTEIN", 156, 176], ["beads", "TREATMENT", 15, 20], ["sodium azide", "TREATMENT", 72, 84], ["PBS", "TEST", 121, 124], ["Methods", "TREATMENT", 216, 223], ["biotin-conjugated cell extracts", "TREATMENT", 238, 269], ["LumAvidin", "TREATMENT", 273, 282], ["microsphere solution", "TREATMENT", 314, 334], ["0.05% sodium azide", "TREATMENT", 371, 389]]], ["Then, 300 \u00b5l of biotin-conjugated cell extracts were added to the beads and mixed, by rotation, for up to 16 h at RT.", [["cell extracts", "ANATOMY", 34, 47], ["beads", "ANATOMY", 66, 71], ["biotin", "CHEMICAL", 16, 22], ["biotin", "CHEMICAL", 16, 22], ["biotin", "SIMPLE_CHEMICAL", 16, 22], ["cell extracts", "ORGANISM_SUBSTANCE", 34, 47], ["biotin-conjugated cell extracts", "TREATMENT", 16, 47], ["mixed", "OBSERVATION_MODIFIER", 76, 81]]], ["After binding, beads were washed three times with 1 ml of 1% BSA\u2013PBS\u20130.05% sodium azide and resuspended in 200 \u00b5l of 1% BSA\u2013PBS\u20130.05% sodium azide.", [["BSA", "CHEMICAL", 61, 64], ["sodium azide", "CHEMICAL", 75, 87], ["BSA", "CHEMICAL", 120, 123], ["sodium azide", "CHEMICAL", 134, 146], ["sodium azide", "CHEMICAL", 75, 87], ["sodium azide", "CHEMICAL", 134, 146], ["BSA", "SIMPLE_CHEMICAL", 61, 64], ["sodium azide", "SIMPLE_CHEMICAL", 75, 87], ["BSA", "SIMPLE_CHEMICAL", 120, 123], ["sodium azide", "SIMPLE_CHEMICAL", 134, 146], ["beads", "TREATMENT", 15, 20], ["sodium azide", "TREATMENT", 75, 87], ["PBS", "TEST", 124, 127]]], ["For each test, 15 \u00b5l beads were used.Fluorescent Labeling of Conjugated Beads ::: Materials and MethodsTo check that FR\u03b1/HER2 proteins were attached on the bead surface, conjugated beads were stained with specific antibodies for FR\u03b1/HER2.", [["bead surface", "ANATOMY", 156, 168], ["beads", "ANATOMY", 181, 186], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 117, 120], ["HER2", "GENE_OR_GENE_PRODUCT", 121, 125], ["bead surface", "CELLULAR_COMPONENT", 156, 168], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 229, 232], ["HER2", "GENE_OR_GENE_PRODUCT", 233, 237], ["FR\u03b1", "PROTEIN", 117, 120], ["HER2 proteins", "PROTEIN", 121, 134], ["specific antibodies", "PROTEIN", 205, 224], ["FR\u03b1", "PROTEIN", 229, 232], ["HER2", "PROTEIN", 233, 237], ["each test", "TEST", 4, 13], ["15 \u00b5l beads", "TREATMENT", 15, 26], ["FR\u03b1/HER2 proteins", "TREATMENT", 117, 134], ["the bead surface", "TREATMENT", 152, 168], ["conjugated beads", "TREATMENT", 170, 186], ["Conjugated Beads", "OBSERVATION", 61, 77]]], ["Conjugated beads (10 \u00b5l) were incubated in 200 \u00b5l of FACS buffer (5% FCS\u2013PBS) for 20 min at RT, then, 1 \u00b5g of the monoclonal antibody MOv18 (anti-FR\u03b1), anti-HER2 [previously described in Ref.", [["MOv18", "GENE_OR_GENE_PRODUCT", 134, 139], ["anti-FR\u03b1", "GENE_OR_GENE_PRODUCT", 141, 149], ["anti-HER2", "GENE_OR_GENE_PRODUCT", 152, 161], ["monoclonal antibody", "PROTEIN", 114, 133], ["MOv18", "PROTEIN", 134, 139], ["FR\u03b1", "PROTEIN", 146, 149], ["anti-HER2", "PROTEIN", 152, 161], ["Conjugated beads", "TREATMENT", 0, 16], ["FACS buffer", "TREATMENT", 53, 64], ["5% FCS\u2013PBS", "TREATMENT", 66, 76], ["the monoclonal antibody MOv18", "TREATMENT", 110, 139], ["anti-HER2", "TREATMENT", 152, 161]]], ["(27)] or isotype control antibodies were added.", [["isotype control antibodies", "PROTEIN", 9, 35], ["isotype control antibodies", "TREATMENT", 9, 35]]], ["In all described experiments, the hapten-specific in-house produced monoclonal antibody anti-NIP IgG was used as an isotype control.", [["monoclonal antibody", "PROTEIN", 68, 87], ["anti-NIP IgG", "PROTEIN", 88, 100], ["anti-NIP", "SPECIES", 88, 96], ["the hapten", "TREATMENT", 30, 40], ["monoclonal antibody anti-NIP IgG", "TREATMENT", 68, 100], ["an isotype control", "TREATMENT", 113, 131]]], ["The beads were incubated for 30 min at 4\u00b0C, washed with 2 ml of FACS buffer, and incubated with anti-human immunoglobulin (Ig) antibody conjugated to FITC (Vector Laboratories) for another 30 min at 4\u00b0C. After a final wash with FACS buffer, stained beads were analyzed on a FACSCanto\u2122 flow cytometer (BD Biosciences).", [["beads", "ANATOMY", 4, 9], ["FITC", "CHEMICAL", 150, 154], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 107, 121], ["FITC", "SIMPLE_CHEMICAL", 150, 154], ["anti-human immunoglobulin (Ig) antibody", "PROTEIN", 96, 135], ["FITC", "PROTEIN", 150, 154], ["The beads", "TREATMENT", 0, 9], ["FACS buffer", "TREATMENT", 64, 75], ["anti-human immunoglobulin (Ig) antibody", "TREATMENT", 96, 135], ["FACS buffer", "TREATMENT", 228, 239], ["stained beads", "TREATMENT", 241, 254], ["a FACSCanto\u2122 flow cytometer", "TREATMENT", 272, 299]]], ["Beads coated with melanoma cell line extracts were tested by staining with a monoclonal IgG antibody recognizing the melanoma-associated antigen CSPG4.Binding of Conjugated Beads to Cells Expressing MOv18 or Anti-HER2 Antibodies ::: Materials and MethodsSp2/0 B cells transfected with MOv18 IgG1 antibody or Expi293F cells transfected to transiently express anti-HER2 antibodies (105 cells in 100 \u00b5l of FACS buffer) were incubated with 2\u201330 \u00b5l of conjugated beads for 30\u201345 min at RT, washed with 2 ml of FACS buffer, and left on ice until analyzed on a FACSCanto\u2122 flow cytometer (BD Biosciences).Spiking of PBMC with Antibody-Expressing Cells ::: Materials and MethodsSp2/0 cells expressing MOv18 IgG or the control antibody SF25 were prestained with anti-mouse MHC Class I-PE antibody to be used with Streptavidin SA-Blue 1.1 \u00b5m or LumAvidin 5.6 \u00b5m beads (Table S1 in Supplementary Material) or anti-mouse CD45 APC antibody (BD Biosciences)/Far-red cell tracking dye (Thermo Fisher Scientific) to be used with Avidin fluorescent A-Red 0.8 \u00b5m beads.", [["melanoma cell line extracts", "ANATOMY", 18, 45], ["melanoma", "ANATOMY", 117, 125], ["Cells", "ANATOMY", 182, 187], ["Sp2/0 B cells", "ANATOMY", 254, 267], ["Expi293F cells", "ANATOMY", 308, 322], ["cells", "ANATOMY", 384, 389], ["PBMC", "ANATOMY", 608, 612], ["Cells", "ANATOMY", 638, 643], ["MethodsSp2/0 cells", "ANATOMY", 662, 680], ["cell", "ANATOMY", 951, 955], ["melanoma", "DISEASE", 18, 26], ["melanoma", "DISEASE", 117, 125], ["melanoma cell line extracts", "ORGANISM_SUBSTANCE", 18, 45], ["melanoma", "CANCER", 117, 125], ["CSPG4", "GENE_OR_GENE_PRODUCT", 145, 150], ["Cells", "CELL", 182, 187], ["MOv18", "GENE_OR_GENE_PRODUCT", 199, 204], ["Anti-HER2", "GENE_OR_GENE_PRODUCT", 208, 217], ["Sp2/0 B cells", "CELL", 254, 267], ["MOv18 IgG1 antibody", "GENE_OR_GENE_PRODUCT", 285, 304], ["Expi293F cells", "CELL", 308, 322], ["anti-HER2", "GENE_OR_GENE_PRODUCT", 358, 367], ["cells", "CELL", 384, 389], ["PBMC", "CELL", 608, 612], ["Cells", "CELL", 638, 643], ["MethodsSp2/0 cells", "CELL", 662, 680], ["MOv18 IgG", "GENE_OR_GENE_PRODUCT", 692, 701], ["SF25", "GENE_OR_GENE_PRODUCT", 726, 730], ["Streptavidin SA-Blue 1.1 \u00b5m", "SIMPLE_CHEMICAL", 803, 830], ["LumAvidin", "SIMPLE_CHEMICAL", 834, 843], ["CD45", "GENE_OR_GENE_PRODUCT", 908, 912], ["Avidin", "SIMPLE_CHEMICAL", 1012, 1018], ["melanoma cell line", "CELL_LINE", 18, 36], ["monoclonal IgG antibody", "PROTEIN", 77, 100], ["melanoma-associated antigen", "PROTEIN", 117, 144], ["CSPG4", "PROTEIN", 145, 150], ["MOv18", "PROTEIN", 199, 204], ["Anti-HER2 Antibodies", "PROTEIN", 208, 228], ["Sp2/0 B cells", "CELL_LINE", 254, 267], ["MOv18 IgG1 antibody", "PROTEIN", 285, 304], ["Expi293F cells", "CELL_LINE", 308, 322], ["anti-HER2 antibodies", "PROTEIN", 358, 378], ["PBMC", "CELL_TYPE", 608, 612], ["Antibody", "PROTEIN", 618, 626], ["MethodsSp2/0 cells", "CELL_LINE", 662, 680], ["MOv18 IgG", "PROTEIN", 692, 701], ["SF25", "PROTEIN", 726, 730], ["anti-mouse MHC Class I-PE antibody", "PROTEIN", 752, 786], ["anti-mouse CD45 APC antibody", "PROTEIN", 897, 925], ["BD Biosciences", "PROTEIN", 927, 941], ["MOv18", "SPECIES", 285, 290], ["melanoma cell line extracts", "TREATMENT", 18, 45], ["a monoclonal IgG antibody", "TEST", 75, 100], ["the melanoma", "PROBLEM", 113, 125], ["Materials", "TEST", 233, 242], ["MethodsSp2/0 B cells", "TEST", 247, 267], ["MOv18 IgG1 antibody", "TEST", 285, 304], ["Expi293F cells", "PROBLEM", 308, 322], ["anti-HER2 antibodies", "TEST", 358, 378], ["conjugated beads", "TREATMENT", 447, 463], ["FACS buffer", "TREATMENT", 505, 516], ["ice", "TREATMENT", 530, 533], ["a FACSCanto\u2122 flow cytometer", "TREATMENT", 552, 579], ["Materials", "TEST", 648, 657], ["MethodsSp2/0 cells", "TREATMENT", 662, 680], ["IgG", "TEST", 698, 701], ["the control antibody SF25", "TEST", 705, 730], ["PE antibody", "TREATMENT", 775, 786], ["Streptavidin SA-Blue", "TREATMENT", 803, 823], ["LumAvidin", "TREATMENT", 834, 843], ["Supplementary Material", "TREATMENT", 870, 892], ["anti-mouse CD45 APC antibody", "TEST", 897, 925], ["BD Biosciences", "TEST", 927, 941], ["Far-red cell tracking dye", "TREATMENT", 943, 968], ["Red 0.8 \u00b5m beads", "TREATMENT", 1033, 1049], ["melanoma cell line", "OBSERVATION", 18, 36], ["melanoma", "OBSERVATION", 117, 125], ["left", "ANATOMY_MODIFIER", 522, 526]]], ["Expi293F cells expressing anti-HER2 or the control anti-CSPG4 antibody (3\u20134 days post transfection) were labeled with Far-red cell tracking dye (Thermo Fisher Scientific).", [["Expi293F cells", "ANATOMY", 0, 14], ["cell", "ANATOMY", 126, 130], ["Expi293F cells", "CELL", 0, 14], ["anti-HER2", "GENE_OR_GENE_PRODUCT", 26, 35], ["anti-CSPG4", "GENE_OR_GENE_PRODUCT", 51, 61], ["Expi293F cells", "CELL_LINE", 0, 14], ["anti-HER2", "PROTEIN", 26, 35], ["anti-CSPG4 antibody", "PROTEIN", 51, 70], ["anti-HER2", "TREATMENT", 26, 35], ["the control anti-CSPG4 antibody", "TEST", 39, 70]]], ["Beads coated with recombinant antigens were incubated with 100 \u00b5l of blocking buffer (10% FCS\u2013PBS, unless stated) for 30 min at RT.", [["recombinant antigens", "PROTEIN", 18, 38], ["recombinant antigens", "TREATMENT", 18, 38], ["blocking buffer", "TREATMENT", 69, 84], ["PBS", "TREATMENT", 94, 97]]], ["Then, 106 PBMCs were added in 100 \u00b5l of blocking buffer and spiking was conducted with pre-labeled Sp2/0-or Expi293F cells at different PBMC:pre-labeled cell ratios in another 50 \u00b5l.", [["PBMCs", "ANATOMY", 10, 15], ["Expi293F cells", "ANATOMY", 108, 122], ["PBMC", "ANATOMY", 136, 140], ["cell", "ANATOMY", 153, 157], ["PBMCs", "CELL", 10, 15], ["Expi293F cells", "CELL", 108, 122], ["PBMC", "CELL", 136, 140], ["pre-labeled cell", "CELL", 141, 157], ["PBMCs", "CELL_TYPE", 10, 15], ["pre-labeled Sp2/0-or Expi293F cells", "CELL_LINE", 87, 122], ["PBMC", "CELL_TYPE", 136, 140], ["PBMCs", "TEST", 10, 15], ["blocking buffer", "TREATMENT", 40, 55], ["pre-labeled Sp2", "TEST", 87, 102], ["Expi293F cells", "PROBLEM", 108, 122], ["PBMC", "TEST", 136, 140], ["pre-labeled cell ratios", "TEST", 141, 164]]], ["Cells and beads were incubated for 30 min at 4\u00b0C, washed with 2 ml of FACS buffer, and stained with DAPI before samples were analyzed on a FACSCanto\u2122 flow cytometer (BD Biosciences).", [["Cells", "ANATOMY", 0, 5], ["beads", "ANATOMY", 10, 15], ["samples", "ANATOMY", 112, 119], ["DAPI", "CHEMICAL", 100, 104], ["Cells", "CELL", 0, 5], ["beads", "CELL", 10, 15], ["DAPI", "SIMPLE_CHEMICAL", 100, 104], ["Cells and beads", "TREATMENT", 0, 15], ["FACS buffer", "TREATMENT", 70, 81], ["DAPI", "TREATMENT", 100, 104], ["a FACSCanto\u2122 flow cytometer", "TREATMENT", 137, 164]]], ["The data were analyzed using the FlowJo\u00ae software version 10.4.1.", [["The data", "TEST", 0, 8], ["the FlowJo\u00ae software version", "TEST", 29, 57]]], ["The actual dilution was calculated by dividing the number of live Far-red positive events (antigen-specific cells) by the number of live Far-red negative events (PBMC).Cell Sorting ::: Materials and MethodsSp2/0 cells transfected with MOv18 IgG and stained with FR\u03b1-conjugated fluorescent beads were sorted on 96-well plates at 1, 5, and 10 cells/well directly into 10 \u00b5l of lysis buffer (Single cell lysis kit, Ambion-Thermo Fisher Scientific), using an BD FACSAria\u2122 II Cell Sorter (BD Biosciences) with an 85 \u00b5m nozzle.", [["cells", "ANATOMY", 108, 113], ["PBMC", "ANATOMY", 162, 166], ["Cell", "ANATOMY", 168, 172], ["MethodsSp2/0 cells", "ANATOMY", 199, 217], ["cells", "ANATOMY", 341, 346], ["cell", "ANATOMY", 396, 400], ["antigen", "GENE_OR_GENE_PRODUCT", 91, 98], ["cells", "CELL", 108, 113], ["PBMC", "CELL", 162, 166], ["Cell", "CELL", 168, 172], ["MethodsSp2/0 cells", "CELL", 199, 217], ["MOv18 IgG", "GENE_OR_GENE_PRODUCT", 235, 244], ["cells", "CELL", 341, 346], ["antigen-specific cells", "CELL_TYPE", 91, 113], ["PBMC", "CELL_TYPE", 162, 166], ["MethodsSp2/0 cells", "CELL_LINE", 199, 217], ["MOv18 IgG", "PROTEIN", 235, 244], ["FR\u03b1", "PROTEIN", 262, 265], ["MOv18", "SPECIES", 235, 240], ["The actual dilution", "TEST", 0, 19], ["Far-red positive events", "PROBLEM", 66, 89], ["MethodsSp2/0 cells", "TREATMENT", 199, 217], ["MOv18 IgG", "TEST", 235, 244], ["FR\u03b1", "TEST", 262, 265], ["conjugated fluorescent beads", "TREATMENT", 266, 294], ["lysis buffer", "TREATMENT", 375, 387], ["Single cell lysis kit", "TREATMENT", 389, 410], ["an BD FACSAria\u2122 II Cell Sorter (BD Biosciences", "TREATMENT", 452, 498], ["an 85 \u00b5m nozzle", "TREATMENT", 505, 520]]], ["Samples were transferred to 0.2 ml PCR tubes and stored at \u221280\u00b0C until further processing.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["PCR tubes", "TREATMENT", 35, 44]]], ["Enriched B cells were obtained from 40 ml peripheral blood of two patients with melanoma using RosetteSep human B cell enrichment cocktail (StemCell Technologies) following the manufacturer\u2019s instructions.", [["B cells", "ANATOMY", 9, 16], ["peripheral blood", "ANATOMY", 42, 58], ["melanoma", "ANATOMY", 80, 88], ["B cell", "ANATOMY", 112, 118], ["melanoma", "DISEASE", 80, 88], ["B cells", "CELL", 9, 16], ["peripheral blood", "ORGANISM_SUBSTANCE", 42, 58], ["patients", "ORGANISM", 66, 74], ["melanoma", "CANCER", 80, 88], ["human", "ORGANISM", 106, 111], ["B cell", "CELL", 112, 118], ["B cells", "CELL_TYPE", 9, 16], ["patients", "SPECIES", 66, 74], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["Enriched B cells", "TEST", 0, 16], ["melanoma", "PROBLEM", 80, 88], ["RosetteSep human B cell enrichment cocktail", "TREATMENT", 95, 138], ["StemCell Technologies", "TREATMENT", 140, 161], ["B cells", "OBSERVATION", 9, 16], ["melanoma", "OBSERVATION", 80, 88]]], ["B cells were incubated with Fc Blocking Reagent (Miltenyi Biotec) for 10 min at RT and stained with anti-CD19 FITC, anti-CD22 FITC, anti CD45 PE (all antibodies from BD Biosciences) and simultaneously incubated with 15 \u00b5l of 5.6 \u00b5m LumiAvidin beads coated with SK-MEL-28 melanoma cell extracts for 30 min on ice in sort buffer (PBS, 2% BSA, 2 mM EDTA).", [["B cells", "ANATOMY", 0, 7], ["SK-MEL-28 melanoma cell extracts", "ANATOMY", 261, 293], ["SK-MEL-28", "CHEMICAL", 261, 270], ["FITC", "CHEMICAL", 110, 114], ["FITC", "CHEMICAL", 126, 130], ["EDTA", "CHEMICAL", 346, 350], ["B cells", "CELL", 0, 7], ["anti-CD19 FITC", "SIMPLE_CHEMICAL", 100, 114], ["anti-CD22 FITC", "GENE_OR_GENE_PRODUCT", 116, 130], ["CD45", "GENE_OR_GENE_PRODUCT", 137, 141], ["PE", "SIMPLE_CHEMICAL", 142, 144], ["SK-MEL-28 melanoma cell extracts", "CELL", 261, 293], ["BSA", "SIMPLE_CHEMICAL", 336, 339], ["EDTA", "SIMPLE_CHEMICAL", 346, 350], ["B cells", "CELL_TYPE", 0, 7], ["Fc", "PROTEIN", 28, 30], ["Miltenyi Biotec", "PROTEIN", 49, 64], ["anti-CD19 FITC", "PROTEIN", 100, 114], ["CD22 FITC", "PROTEIN", 121, 130], ["anti CD45 PE", "PROTEIN", 132, 144], ["antibodies", "PROTEIN", 150, 160], ["BD Biosciences", "PROTEIN", 166, 180], ["B cells", "PROBLEM", 0, 7], ["Fc Blocking Reagent (Miltenyi Biotec)", "TREATMENT", 28, 65], ["anti-CD19 FITC", "TEST", 100, 114], ["anti-CD22 FITC", "TEST", 116, 130], ["anti CD45 PE", "PROBLEM", 132, 144], ["all antibodies", "TEST", 146, 160], ["BD Biosciences", "TEST", 166, 180], ["LumiAvidin beads", "TREATMENT", 232, 248], ["SK", "TEST", 261, 263], ["melanoma cell extracts", "TREATMENT", 271, 293], ["PBS", "TEST", 328, 331], ["melanoma cell", "OBSERVATION", 271, 284]]], ["Immediately before acquisition, DAPI live/dead dye was added.", [["DAPI", "CHEMICAL", 32, 36], ["DAPI", "SIMPLE_CHEMICAL", 32, 36], ["dead dye", "SIMPLE_CHEMICAL", 42, 50], ["DAPI live/dead dye", "TREATMENT", 32, 50]]], ["The cells binding fluorescent beads were sorted into 72-well plates at 1 cell/well into 10 \u00b5l of lysis buffer as above.", [["cells", "ANATOMY", 4, 9], ["cell", "ANATOMY", 73, 77], ["cells", "CELL", 4, 9], ["cell", "CELL", 73, 77], ["The cells binding fluorescent beads", "TREATMENT", 0, 35], ["lysis buffer", "TREATMENT", 97, 109], ["lysis", "OBSERVATION", 97, 102]]], ["For B cells, a 70 \u00b5m nozzle was used.Ig Variable Region Cloning ::: Materials and MethodsPCR tubes containing sorted cells in lysis buffer were thawed and reverse transcription was performed in a thermal cycler using the SuperScript VILO cDNA Synthesis kit (Thermo Fisher Scientific) following the manufacturer\u2019s recommendations.", [["B cells", "ANATOMY", 4, 11], ["cells", "ANATOMY", 117, 122], ["B cells", "CELL", 4, 11], ["cells", "CELL", 117, 122], ["B cells", "CELL_TYPE", 4, 11], ["sorted cells", "CELL_TYPE", 110, 122], ["B cells", "TREATMENT", 4, 11], ["a 70 \u00b5m nozzle", "TREATMENT", 13, 27], ["Materials", "TREATMENT", 68, 77], ["MethodsPCR tubes", "TREATMENT", 82, 98], ["lysis buffer", "TREATMENT", 126, 138], ["a thermal cycler", "TREATMENT", 194, 210]]], ["Variable regions of Ig heavy and light chains were amplified by two rounds of PCR amplification in 20 \u00b5l mix, using 10 \u00b5l of Phusion Flash polymerase mix per reaction (Finnzymes), each primer at 0.5 \u00b5M, 2 \u00b5l of the reverse transcriptase reaction as template for the first PCR and 2 \u00b5l of the first PCR as template in the second PCR.", [["Ig heavy and light chains", "GENE_OR_GENE_PRODUCT", 20, 45], ["Ig heavy and light chains", "PROTEIN", 20, 45], ["reverse transcriptase", "PROTEIN", 215, 236], ["Ig heavy and light chains", "PROBLEM", 20, 45], ["PCR amplification", "TREATMENT", 78, 95], ["Phusion Flash polymerase", "TREATMENT", 125, 149], ["the reverse transcriptase reaction", "TREATMENT", 211, 245], ["the first PCR", "TEST", 262, 275], ["the first PCR", "TEST", 288, 301], ["the second PCR", "TEST", 317, 331], ["Ig heavy", "OBSERVATION_MODIFIER", 20, 28], ["light chains", "OBSERVATION_MODIFIER", 33, 45]]], ["For the variable regions in the MOv18 heavy chain, the cycles for amplification were: 1 min at 98\u00b0C, 36 cycles of 10 s at 98\u00b0C, 15 s at 60\u00b0C, and 15 s at 72\u00b0C, followed by a final step at 72\u00b0C for 1 min.", [["MOv18 heavy chain", "PROTEIN", 32, 49]]], ["In the first PCR, the reverse primer was IgGRev in the constant region of the IgG, and in the second PCR, the reverse primer was MOv18VH_R.", [["IgGRev", "GENE_OR_GENE_PRODUCT", 41, 47], ["IgG", "GENE_OR_GENE_PRODUCT", 78, 81], ["reverse primer", "DNA", 22, 36], ["IgGRev", "DNA", 41, 47], ["IgG", "PROTEIN", 78, 81], ["reverse primer", "DNA", 110, 124], ["MOv18VH_R", "DNA", 129, 138], ["the first PCR", "TEST", 3, 16], ["the IgG", "TEST", 74, 81], ["the second PCR", "TEST", 90, 104], ["IgG", "OBSERVATION", 78, 81]]], ["For the variable regions in the MOv18 light chain, the cycles for amplification were: 1 min at 98\u00b0C, 36 cycles of 10 s at 98\u00b0C, 15 s at 57\u00b0C, and 15 s at 72\u00b0C, followed by a final step at 72\u00b0C for 1 min.", [["MOv18 light chain", "PROTEIN", 32, 49]]], ["In the first PCR, the reverse primer was Kappa_R in the constant region of the kappa chain, and in the second PCR, the reverse primer was MOv18K_R.", [["reverse primer", "DNA", 22, 36], ["Kappa_R", "DNA", 41, 48], ["kappa chain", "DNA", 79, 90], ["reverse primer", "DNA", 119, 133], ["MOv18K_R", "DNA", 138, 146], ["the first PCR", "TEST", 3, 16], ["the second PCR", "TEST", 99, 113], ["kappa chain", "OBSERVATION", 79, 90]]], ["Primers: MOv18VH_F: CAGGTTCAACTGCAGCAGTCTGGA; MOv18VH_R: TGAGGAGACGGTGACTGAGGTTCC; MOv18VK_F: GATATCCAGATGACACAGACTACA; MOv18VK_R: TTTCCAGCTTGGTGCCTCC; IgGRev: CCAACTCTCTTGTCCACCTTGG; Kappa_R: GTTTCTCGTAGTCTGCTTTGCTCA.", [["MO", "PROTEIN", 120, 122], ["IgGRev", "PROTEIN", 152, 158], ["Kappa_R", "PROTEIN", 184, 191]]], ["Forward and reverse primers used for the amplification of unknown Ig light and heavy chain fragments (Table 1), and the nested PCR protocol were previously described (28).", [["Ig light", "GENE_OR_GENE_PRODUCT", 66, 74], ["Forward and reverse primers", "DNA", 0, 27], ["Ig light and heavy chain fragments", "PROTEIN", 66, 100], ["Forward and reverse primers", "TREATMENT", 0, 27], ["the amplification", "TEST", 37, 54], ["Ig light and heavy chain fragments", "TREATMENT", 66, 100], ["the nested PCR protocol", "TEST", 116, 139], ["heavy", "OBSERVATION_MODIFIER", 79, 84], ["chain fragments", "OBSERVATION_MODIFIER", 85, 100]]], ["PCR products were separated on agarose gels, purified using the QIAquick gel extraction kit (Qiagen), and cloned using the ZeroBlunt PCR cloning kit (Life Technologies).", [["PCR products", "TREATMENT", 0, 12], ["agarose gels", "TREATMENT", 31, 43], ["the QIAquick gel extraction kit", "TREATMENT", 60, 91], ["the ZeroBlunt PCR", "TREATMENT", 119, 136]]], ["Six colonies were grown for each PCR band, plasmid DNA purified using QIAprep spin miniprep kit (Qiagen) and sequenced by Source Bioscience using the M13 forward primer.", [["colonies", "ANATOMY", 4, 12], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["PCR band", "DNA", 33, 41], ["plasmid DNA", "DNA", 43, 54], ["M13 forward primer", "DNA", 150, 168], ["Six colonies", "TEST", 0, 12], ["each PCR band", "TREATMENT", 28, 41], ["plasmid DNA", "TREATMENT", 43, 54], ["QIAprep spin miniprep kit", "TREATMENT", 70, 95], ["the M13 forward primer", "TREATMENT", 146, 168]]], ["Sequences were analyzed using IMGT/V-QUEST (29).Recombinant Antibody Cloning and Expression ::: Materials and MethodsHeavy and light chain variable regions were cloned in pVitro-hygro-1 (Invivogen) using polymerase incomplete primer extension (PIPE) cloning as previously described (25).", [["pVitro-hygro-1", "GENE_OR_GENE_PRODUCT", 171, 185], ["pVitro-hygro-1", "DNA", 171, 185], ["Invivogen", "DNA", 187, 196], ["Sequences", "TEST", 0, 9], ["IMGT", "TEST", 30, 34], ["MethodsHeavy and light chain variable regions", "TREATMENT", 110, 155], ["polymerase incomplete primer extension (PIPE) cloning", "TREATMENT", 204, 257], ["Antibody Cloning", "OBSERVATION", 60, 76]]], ["In brief, pVitro-hygro-1, containing pre-cloned human antibody heavy and light constant region cassettes (gamma 1/kappa) was used as a template in two separate PIPE PCR reactions to amplify two linear plasmid fragments with partially single-stranded 5\u2033 ends.", [["fragments", "ANATOMY", 209, 218], ["human", "ORGANISM", 48, 53], ["gamma 1", "GENE_OR_GENE_PRODUCT", 106, 113], ["kappa", "GENE_OR_GENE_PRODUCT", 114, 119], ["pVitro-hygro-1", "DNA", 10, 24], ["pre-cloned human antibody heavy and light constant region cassettes", "DNA", 37, 104], ["gamma 1/kappa", "DNA", 106, 119], ["linear plasmid fragments", "DNA", 194, 218], ["single-stranded 5\u2033 ends", "DNA", 234, 257], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["pVitro", "TEST", 10, 16], ["light constant region cassettes", "TREATMENT", 73, 104], ["a template", "TREATMENT", 133, 143], ["two separate PIPE PCR reactions", "TREATMENT", 147, 178], ["two linear plasmid fragments", "TREATMENT", 190, 218], ["linear", "OBSERVATION_MODIFIER", 194, 200], ["plasmid fragments", "OBSERVATION", 201, 218]]], ["Similarly, the Ig heavy and light chain variable regions were PIPE PCR-amplified, using the pCR-Blunt constructs, generated previously, as PCR templates.", [["Ig heavy", "GENE_OR_GENE_PRODUCT", 15, 23], ["Ig heavy and light chain variable regions", "DNA", 15, 56], ["PIPE PCR", "DNA", 62, 70], ["pCR-Blunt constructs", "DNA", 92, 112], ["PCR templates", "DNA", 139, 152], ["the Ig heavy and light chain variable regions", "PROBLEM", 11, 56], ["PIPE PCR", "TEST", 62, 70], ["the pCR", "TEST", 88, 95], ["PCR templates", "TEST", 139, 152], ["heavy", "OBSERVATION_MODIFIER", 18, 23]]], ["Next, the PCR products were diluted four times with ddH2O and mixed in a ratio of 1:1:1:1, incubated at RT for 1 h, and 10 \u00b5l of the mixture were used to transform Top10 OneShot\u2122 E. coli cells (Thermo Fisher Scientific).", [["cells", "ANATOMY", 187, 192], ["ddH2O", "SIMPLE_CHEMICAL", 52, 57], ["1:1:1:1", "SIMPLE_CHEMICAL", 82, 89], ["E. coli cells", "CELL", 179, 192], ["E. coli", "SPECIES", 179, 186], ["E. coli", "SPECIES", 179, 186], ["the PCR products", "TREATMENT", 6, 22], ["ddH2O", "TREATMENT", 52, 57], ["the mixture", "TREATMENT", 129, 140], ["coli cells", "OBSERVATION", 182, 192]]], ["MOv18 IgG1/k was expressed transiently in Expi293F\u2122 cells (Thermo Fisher Scientific), as described in Ref.", [["Expi293F\u2122 cells", "ANATOMY", 42, 57], ["IgG1", "GENE_OR_GENE_PRODUCT", 6, 10], ["Expi293F\u2122 cells", "CELL", 42, 57], ["MOv18 IgG1/k", "PROTEIN", 0, 12], ["Expi293F\u2122 cells", "CELL_LINE", 42, 57], ["IgG1/k", "TEST", 6, 12]]], ["Antibodies, secreted in the Expi293F\u2122 culture supernatant, were purified using a Protein A column (Thermo Fisher Scientific) and stored in PBS at 4\u00b0C.Workflow for Identification of Antibody-Expressing Single Cells Using Antigen-Conjugated Fluorescent Beads ::: ResultsWe designed a process to allow the identification of antigen-specific antibody-expressing B cells, which can be performed without prior ex vivo growth or secondary screening of B cells.", [["supernatant", "ANATOMY", 46, 57], ["Cells", "ANATOMY", 208, 213], ["B cells", "ANATOMY", 358, 365], ["B cells", "ANATOMY", 445, 452], ["Cells", "CELL", 208, 213], ["antigen", "GENE_OR_GENE_PRODUCT", 321, 328], ["B cells", "CELL", 358, 365], ["B cells", "CELL", 445, 452], ["Antibody", "PROTEIN", 181, 189], ["antigen-specific antibody", "PROTEIN", 321, 346], ["expressing B cells", "CELL_TYPE", 347, 365], ["B cells", "CELL_TYPE", 445, 452], ["Antibodies", "TEST", 0, 10], ["Antibody", "TEST", 181, 189], ["antigen", "TEST", 321, 328], ["specific antibody", "TEST", 329, 346], ["expressing B cells", "PROBLEM", 347, 365], ["prior ex vivo growth", "PROBLEM", 398, 418], ["B cells", "PROBLEM", 445, 452], ["B cells", "OBSERVATION", 445, 452]]], ["To establish this system, we selected Folate Receptor alpha (FR\u03b1) as a model antigen.", [["Folate", "CHEMICAL", 38, 44], ["Folate", "CHEMICAL", 38, 44], ["Folate Receptor alpha", "GENE_OR_GENE_PRODUCT", 38, 59], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 61, 64], ["Folate Receptor alpha", "PROTEIN", 38, 59], ["FR\u03b1", "PROTEIN", 61, 64], ["Folate Receptor alpha (FR\u03b1", "TREATMENT", 38, 64], ["a model antigen", "TEST", 69, 84]]], ["As the test antibody-expressing cells, we selected a B cell line expressing both the soluble and the membrane-bound [B cell receptor (BCR)] form of a human/mouse chimeric antibody (MOv18 IgG1 clone) specific for FR\u03b1.", [["cells", "ANATOMY", 32, 37], ["B cell line", "ANATOMY", 53, 64], ["membrane", "ANATOMY", 101, 109], ["B cell", "ANATOMY", 117, 123], ["cells", "CELL", 32, 37], ["B cell line", "CELL", 53, 64], ["membrane", "CELLULAR_COMPONENT", 101, 109], ["B cell receptor", "GENE_OR_GENE_PRODUCT", 117, 132], ["BCR", "GENE_OR_GENE_PRODUCT", 134, 137], ["human", "ORGANISM", 150, 155], ["mouse", "ORGANISM", 156, 161], ["IgG1", "GENE_OR_GENE_PRODUCT", 187, 191], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 212, 215], ["expressing cells", "CELL_TYPE", 21, 37], ["B cell line", "CELL_LINE", 53, 64], ["B cell receptor (BCR)] form", "PROTEIN", 117, 144], ["human/mouse chimeric antibody", "PROTEIN", 150, 179], ["MOv18 IgG1 clone", "PROTEIN", 181, 197], ["FR\u03b1", "PROTEIN", 212, 215], ["human", "SPECIES", 150, 155], ["mouse", "SPECIES", 156, 161], ["human", "SPECIES", 150, 155], ["mouse", "SPECIES", 156, 161], ["the test antibody", "TEST", 3, 20], ["expressing cells", "PROBLEM", 21, 37], ["a B cell line", "TREATMENT", 51, 64], ["B cell receptor (BCR", "TREATMENT", 117, 137], ["a human/mouse chimeric antibody", "TREATMENT", 148, 179], ["cell line", "OBSERVATION", 55, 64]]], ["The workflow (Figure 1) entails coupling of fluorescent polystyrene beads with the nominal antigen, Folate Receptor alpha (FR\u03b1), followed by binding of FR\u03b1-coated beads to anti-FR\u03b1 antibody-expressing B cells.", [["B cells", "ANATOMY", 201, 208], ["Folate", "CHEMICAL", 100, 106], ["polystyrene", "CHEMICAL", 56, 67], ["Folate", "CHEMICAL", 100, 106], ["Folate Receptor alpha", "GENE_OR_GENE_PRODUCT", 100, 121], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 123, 126], ["FR\u03b1", "SIMPLE_CHEMICAL", 152, 155], ["anti-FR\u03b1 antibody", "GENE_OR_GENE_PRODUCT", 172, 189], ["B cells", "CELL", 201, 208], ["nominal antigen", "PROTEIN", 83, 98], ["Folate Receptor alpha", "PROTEIN", 100, 121], ["FR\u03b1", "PROTEIN", 123, 126], ["FR\u03b1", "PROTEIN", 152, 155], ["anti-FR\u03b1 antibody", "PROTEIN", 172, 189], ["expressing B cells", "CELL_TYPE", 190, 208], ["The workflow (Figure 1) entails coupling of fluorescent polystyrene beads", "TREATMENT", 0, 73], ["the nominal antigen", "TEST", 79, 98], ["Folate Receptor alpha (FR\u03b1", "TREATMENT", 100, 126], ["anti-FR\u03b1 antibody", "TEST", 172, 189], ["polystyrene beads", "OBSERVATION", 56, 73]]], ["Single bead-conjugated cells were identified and isolated by FACS sorting directly onto microplates containing lysis buffer.", [["cells", "ANATOMY", 23, 28], ["cells", "CELL", 23, 28], ["Single bead-conjugated cells", "CELL_LINE", 0, 28], ["Single bead-conjugated cells", "PROBLEM", 0, 28], ["lysis buffer", "TREATMENT", 111, 123], ["bead", "OBSERVATION_MODIFIER", 7, 11], ["conjugated cells", "OBSERVATION", 12, 28], ["lysis", "OBSERVATION", 111, 116]]], ["RNA released from single cells was converted to cDNA using reverse transcription followed by a semi-nested RT-PCR with Ig specific primers.", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["Ig", "GENE_OR_GENE_PRODUCT", 119, 121], ["RNA", "RNA", 0, 3], ["cDNA", "DNA", 48, 52], ["Ig specific primers", "DNA", 119, 138], ["reverse transcription", "TREATMENT", 59, 80], ["a semi-nested RT-PCR", "TREATMENT", 93, 113], ["Ig specific primers", "TREATMENT", 119, 138]]], ["Matched variable H and L chains were sequenced and cloned into a single expression vector containing the H and L constant IgG1 region sequences as previously reported (25, 26).", [["variable H and L chains", "GENE_OR_GENE_PRODUCT", 8, 31], ["IgG1", "GENE_OR_GENE_PRODUCT", 122, 126], ["Matched variable H and L chains", "PROTEIN", 0, 31], ["H and L constant IgG1 region sequences", "DNA", 105, 143], ["Matched variable H and L chains", "TREATMENT", 0, 31], ["L", "ANATOMY_MODIFIER", 111, 112]]], ["The full antibody was then expressed in a human expression host.", [["human", "ORGANISM", 42, 47], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47]]], ["The antibody was purified and antibody specificity for the antigen was tested on target antigen-expressing cells.Antigen-Coupled Fluorescent Bead Recognition by Monoclonal Antibodies and by Specific Antibody-Expressing B Cells ::: ResultsWe first established the workflow using APC fluorochrome LumAvidin Microspheres of 5.6 \u00b5m diameter (LumAvidin 5.6 \u00b5m; Table S1 in Supplementary Material).", [["cells", "ANATOMY", 107, 112], ["Cells", "ANATOMY", 221, 226], ["LumAvidin", "CHEMICAL", 295, 304], ["antigen", "GENE_OR_GENE_PRODUCT", 88, 95], ["cells", "CELL", 107, 112], ["B Cells", "CELL", 219, 226], ["APC", "GENE_OR_GENE_PRODUCT", 278, 281], ["target antigen-expressing cells", "CELL_TYPE", 81, 112], ["Monoclonal Antibodies", "PROTEIN", 161, 182], ["Antibody", "PROTEIN", 199, 207], ["The antibody", "TEST", 0, 12], ["antibody specificity", "TEST", 30, 50], ["the antigen", "TEST", 55, 66], ["target antigen", "TEST", 81, 95], ["Antigen", "TEST", 113, 120], ["Monoclonal Antibodies", "TEST", 161, 182], ["Specific Antibody", "TEST", 190, 207], ["APC fluorochrome LumAvidin Microspheres", "TREATMENT", 278, 317], ["LumAvidin", "TREATMENT", 338, 347], ["Table S1 in Supplementary Material", "TREATMENT", 356, 390]]], ["Prior to interrogating the ability of these beads to bind antibody-expressing cells, we used flow cytometric evaluations to confirm that fluorescent beads could be successfully coupled to antigens.", [["cells", "ANATOMY", 78, 83], ["cells", "CELL", 78, 83], ["antibody-expressing cells", "CELL_TYPE", 58, 83], ["antigens", "PROTEIN", 188, 196], ["these beads", "TREATMENT", 38, 49], ["bind antibody", "TEST", 53, 66], ["expressing cells", "PROBLEM", 67, 83], ["flow cytometric evaluations", "TEST", 93, 120], ["fluorescent beads", "TREATMENT", 137, 154]]], ["We tested the antigens FR\u03b1 and HER2 conjugated to fluorescent beads.", [["FR\u03b1", "GENE_OR_GENE_PRODUCT", 23, 26], ["HER2", "GENE_OR_GENE_PRODUCT", 31, 35], ["antigens FR\u03b1", "PROTEIN", 14, 26], ["HER2", "PROTEIN", 31, 35], ["HER2", "TEST", 31, 35]]], ["The anti-FR\u03b1 antibody MOv18 IgG bound to FR\u03b1-conjugated beads, and the HER2-specific antibody trastuzumab bound to HER-2-conjugated beads.", [["trastuzumab", "CHEMICAL", 94, 105], ["anti-FR\u03b1", "GENE_OR_GENE_PRODUCT", 4, 12], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 41, 44], ["HER2", "GENE_OR_GENE_PRODUCT", 71, 75], ["trastuzumab", "SIMPLE_CHEMICAL", 94, 105], ["HER-2", "GENE_OR_GENE_PRODUCT", 115, 120], ["anti-FR\u03b1 antibody", "PROTEIN", 4, 21], ["MOv18 IgG", "PROTEIN", 22, 31], ["FR\u03b1", "PROTEIN", 41, 44], ["HER2", "PROTEIN", 71, 75], ["HER", "PROTEIN", 115, 118], ["The anti-FR\u03b1 antibody", "TEST", 0, 21], ["IgG", "TEST", 28, 31], ["conjugated beads", "TREATMENT", 45, 61], ["the HER2", "TEST", 67, 75], ["specific antibody trastuzumab", "TREATMENT", 76, 105]]], ["On the other hand, the hapten-specific monoclonal antibody NIP IgG showed only background binding to FR\u03b1-conjugated or to HER-2-conjugated beads, and no binding was detected on beads incubated with secondary antibody alone (Figure 2A).", [["HER", "CHEMICAL", 122, 125], ["hapten", "SIMPLE_CHEMICAL", 23, 29], ["HER-2", "GENE_OR_GENE_PRODUCT", 122, 127], ["monoclonal antibody", "PROTEIN", 39, 58], ["NIP IgG", "PROTEIN", 59, 66], ["FR\u03b1", "PROTEIN", 101, 104], ["HER", "PROTEIN", 122, 125], ["secondary antibody", "PROTEIN", 198, 216], ["the hapten", "TEST", 19, 29], ["specific monoclonal antibody NIP IgG", "TEST", 30, 66], ["background binding", "PROBLEM", 79, 97], ["FR\u03b1", "TEST", 101, 104], ["binding", "PROBLEM", 153, 160], ["no", "UNCERTAINTY", 150, 152]]], ["We also interrogated different coupling agents with varying biotin lengths (LC-biotin, 22.4 \u00c5; LC-LC-biotin, 30.5 \u00c5; PEG12-biotin, 56 \u00c5) to assess whether the distance between bead and antigen from the bead surface could affect antigen recognition by anti-FR\u03b1-expressing B cells.", [["bead surface", "ANATOMY", 202, 214], ["B cells", "ANATOMY", 271, 278], ["PEG12-biotin", "CHEMICAL", 117, 129], ["biotin", "CHEMICAL", 60, 66], ["biotin", "CHEMICAL", 79, 85], ["biotin", "CHEMICAL", 101, 107], ["PEG12-biotin", "CHEMICAL", 117, 129], ["biotin", "SIMPLE_CHEMICAL", 60, 66], ["LC-biotin", "SIMPLE_CHEMICAL", 76, 85], ["PEG12-biotin", "SIMPLE_CHEMICAL", 117, 129], ["bead", "CELLULAR_COMPONENT", 176, 180], ["antigen", "GENE_OR_GENE_PRODUCT", 185, 192], ["antigen", "GENE_OR_GENE_PRODUCT", 228, 235], ["anti-FR\u03b1", "GENE_OR_GENE_PRODUCT", 251, 259], ["B cells", "CELL", 271, 278], ["PEG12", "PROTEIN", 117, 122], ["anti-FR\u03b1", "PROTEIN", 251, 259], ["expressing B cells", "CELL_TYPE", 260, 278], ["different coupling agents", "TREATMENT", 21, 46], ["varying biotin lengths", "TREATMENT", 52, 74], ["LC", "TEST", 76, 78], ["biotin", "TEST", 79, 85], ["LC", "TEST", 95, 97], ["LC", "TEST", 98, 100], ["biotin", "TEST", 101, 107], ["PEG12", "TEST", 117, 122], ["biotin", "TEST", 123, 129], ["antigen recognition", "TEST", 228, 247], ["anti-FR\u03b1", "TEST", 251, 259]]], ["We found no significant differences in MOv18 IgG antibody binding to bead-conjugated FR\u03b1 with respect to any of these coupling agents (Figure 2B).Antigen-Coupled Fluorescent Bead Recognition by Monoclonal Antibodies and by Specific Antibody-Expressing B Cells ::: ResultsWe then established a model system using microsphere-coupled FR\u03b1 and anti-FR\u03b1 antibody-expressing B cells.", [["Cells", "ANATOMY", 254, 259], ["B cells", "ANATOMY", 369, 376], ["MOv18", "SIMPLE_CHEMICAL", 39, 44], ["bead-conjugated FR\u03b1", "SIMPLE_CHEMICAL", 69, 88], ["B Cells", "CELL", 252, 259], ["FR\u03b1", "SIMPLE_CHEMICAL", 332, 335], ["anti-FR\u03b1 antibody", "GENE_OR_GENE_PRODUCT", 340, 357], ["B cells", "CELL", 369, 376], ["MOv18 IgG antibody", "PROTEIN", 39, 57], ["bead-conjugated FR\u03b1", "PROTEIN", 69, 88], ["Monoclonal Antibodies", "PROTEIN", 194, 215], ["Antibody", "PROTEIN", 232, 240], ["FR\u03b1", "CELL_LINE", 332, 335], ["anti-FR\u03b1 antibody-expressing B cells", "CELL_LINE", 340, 376], ["significant differences", "PROBLEM", 12, 35], ["MOv18 IgG antibody binding", "PROBLEM", 39, 65], ["these coupling agents", "TREATMENT", 112, 133], ["Antigen", "TEST", 146, 153], ["Monoclonal Antibodies", "TEST", 194, 215], ["Specific Antibody", "TEST", 223, 240], ["microsphere", "TEST", 312, 323], ["coupled FR", "TEST", 324, 334], ["anti-FR\u03b1 antibody", "TEST", 340, 357], ["no", "UNCERTAINTY", 9, 11], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["B cells", "OBSERVATION", 369, 376]]], ["We confirmed that a small proportion of FR\u03b1+ LumAvidin 5.6 \u00b5m microspheres recognized single anti-FR\u03b1 antibody-expressing B cells (Sp2/0-MOv18) (Figure 3A).", [["B cells", "ANATOMY", 122, 129], ["anti-FR\u03b1 antibody", "GENE_OR_GENE_PRODUCT", 93, 110], ["B cells", "CELL", 122, 129], ["Sp2", "ORGANISM", 131, 134], ["anti-FR\u03b1 antibody", "PROTEIN", 93, 110], ["expressing B cells", "CELL_TYPE", 111, 129], ["Sp2", "PROTEIN", 131, 134], ["MOv18", "PROTEIN", 137, 142], ["FR\u03b1", "TREATMENT", 40, 43], ["LumAvidin", "TREATMENT", 45, 54], ["microspheres", "TEST", 62, 74], ["single anti-FR\u03b1 antibody", "TEST", 86, 110], ["Sp2", "TEST", 131, 134], ["small", "OBSERVATION_MODIFIER", 20, 25]]], ["When single bead-bound cells were isolated into lysis buffer-containing microplate wells by flow cytometric sorting, single cell PCR yielded matched H and L chain variable region DNA products were detected to be of the expected size (Figure 3B).", [["cells", "ANATOMY", 23, 28], ["cell", "ANATOMY", 124, 128], ["cells", "CELL", 23, 28], ["DNA", "CELLULAR_COMPONENT", 179, 182], ["single bead-bound cells", "CELL_LINE", 5, 28], ["single bead-bound cells", "TREATMENT", 5, 28], ["lysis buffer", "TREATMENT", 48, 60], ["microplate wells", "TEST", 72, 88], ["flow cytometric sorting", "TEST", 92, 115], ["single cell PCR", "TEST", 117, 132], ["matched H and L chain variable region DNA products", "TREATMENT", 141, 191], ["bound cells", "OBSERVATION", 17, 28], ["L", "ANATOMY_MODIFIER", 155, 156], ["size", "OBSERVATION_MODIFIER", 228, 232]]], ["Antibody variable region sequences were cloned into a pVITRO1 vector containing human IgG1/k constant region cassettes and the antibody was expressed in Expi293F\u2122 cells.", [["Expi293F\u2122 cells", "ANATOMY", 153, 168], ["pVITRO1", "GENE_OR_GENE_PRODUCT", 54, 61], ["human", "ORGANISM", 80, 85], ["IgG1", "GENE_OR_GENE_PRODUCT", 86, 90], ["Expi293F\u2122 cells", "CELL", 153, 168], ["Antibody variable region sequences", "DNA", 0, 34], ["pVITRO1 vector", "DNA", 54, 68], ["human IgG1/k constant region cassettes", "DNA", 80, 118], ["Expi293F\u2122 cells", "CELL_LINE", 153, 168], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["Antibody variable region sequences", "PROBLEM", 0, 34], ["a pVITRO1 vector", "TREATMENT", 52, 68], ["human IgG1/k constant region cassettes", "TREATMENT", 80, 118], ["the antibody", "TEST", 123, 135]]], ["Subsequently, the cloned IgG1 antibody was used to assess binding to IGROV1 cells, which express native cell surface human FR\u03b1.", [["IGROV1 cells", "ANATOMY", 69, 81], ["cell surface", "ANATOMY", 104, 116], ["IgG1", "GENE_OR_GENE_PRODUCT", 25, 29], ["IGROV1 cells", "CELL", 69, 81], ["cell", "CELL", 104, 108], ["human", "ORGANISM", 117, 122], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 123, 126], ["IgG1 antibody", "PROTEIN", 25, 38], ["IGROV1 cells", "CELL_LINE", 69, 81], ["native cell surface human FR\u03b1", "PROTEIN", 97, 126], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["the cloned IgG1 antibody", "TEST", 14, 38], ["IGROV1 cells", "PROBLEM", 69, 81], ["native cell", "OBSERVATION", 97, 108], ["surface human FR", "OBSERVATION", 109, 125]]], ["Flow cytometric evaluations confirmed that the anti-FR\u03b1 antibody cloned from a sorted single antibody-expressing B cell was able to specifically recognize antigen-expressing IGROV1 cells.", [["B cell", "ANATOMY", 113, 119], ["IGROV1 cells", "ANATOMY", 174, 186], ["anti-FR\u03b1 antibody", "GENE_OR_GENE_PRODUCT", 47, 64], ["B cell", "CELL", 113, 119], ["antigen", "GENE_OR_GENE_PRODUCT", 155, 162], ["IGROV1 cells", "CELL", 174, 186], ["anti-FR\u03b1 antibody", "PROTEIN", 47, 64], ["sorted single antibody-expressing B cell", "CELL_LINE", 79, 119], ["IGROV1 cells", "CELL_LINE", 174, 186], ["Flow cytometric evaluations", "TEST", 0, 27], ["the anti-FR\u03b1 antibody", "TEST", 43, 64], ["a sorted single antibody", "TEST", 77, 101], ["expressing B cell", "PROBLEM", 102, 119], ["antigen", "TEST", 155, 162], ["IGROV1 cells", "OBSERVATION", 174, 186]]], ["The cloned anti-FR\u03b1 antibody did not recognize MDA-MB-231 breast carcinoma cells that do not express FR\u03b1 (Figure 3C).Antigen-Coupled Fluorescent Bead Recognition by Monoclonal Antibodies and by Specific Antibody-Expressing B Cells ::: ResultsThese findings confirmed that it is possible to extract matched variable region sequences from single antibody-expressing cells selected by recognition of specific antigen-coated microspheres.", [["MDA-MB-231 breast carcinoma cells", "ANATOMY", 47, 80], ["Cells", "ANATOMY", 225, 230], ["cells", "ANATOMY", 364, 369], ["MDA-MB-231", "CHEMICAL", 47, 57], ["breast carcinoma", "DISEASE", 58, 74], ["anti-FR", "GENE_OR_GENE_PRODUCT", 11, 18], ["MDA-MB-231 breast carcinoma cells", "CELL", 47, 80], ["B Cells", "CELL", 223, 230], ["cells", "CELL", 364, 369], ["antigen", "GENE_OR_GENE_PRODUCT", 406, 413], ["anti-FR\u03b1 antibody", "PROTEIN", 11, 28], ["MDA-MB-231 breast carcinoma cells", "CELL_LINE", 47, 80], ["FR", "PROTEIN", 101, 103], ["Monoclonal Antibodies", "PROTEIN", 165, 186], ["Antibody", "PROTEIN", 203, 211], ["single antibody-expressing cells", "CELL_TYPE", 337, 369], ["The cloned anti-FR\u03b1 antibody", "TEST", 0, 28], ["MDA", "TEST", 47, 50], ["MB", "TEST", 51, 53], ["breast carcinoma cells", "PROBLEM", 58, 80], ["Antigen", "TEST", 117, 124], ["Monoclonal Antibodies", "TEST", 165, 186], ["Specific Antibody", "TEST", 194, 211], ["matched variable region sequences", "PROBLEM", 298, 331], ["single antibody", "TEST", 337, 352], ["specific antigen-coated microspheres", "TREATMENT", 397, 433], ["breast", "ANATOMY", 58, 64], ["carcinoma", "OBSERVATION", 65, 74]]], ["Selection of single B cells allowed the identification of the expected matched variable regions and permitted the cloning and production of the corresponding monoclonal antibody from a single cell.", [["B cells", "ANATOMY", 20, 27], ["cell", "ANATOMY", 192, 196], ["B cells", "CELL", 20, 27], ["cell", "CELL", 192, 196], ["single B cells", "CELL_TYPE", 13, 27], ["monoclonal antibody", "PROTEIN", 158, 177], ["single B cells", "PROBLEM", 13, 27], ["the corresponding monoclonal antibody", "PROBLEM", 140, 177], ["B cells", "OBSERVATION", 20, 27], ["monoclonal antibody", "OBSERVATION", 158, 177]]], ["This antibody was able to recognize natively expressed cell surface FR\u03b1.Influence of Microsphere Diameter and Biotin Length on Specific Recognition of Antigen-Expressing B Cells ::: ResultsSince we observed that FR\u03b1+ microspheres were able to bind only a small proportion of single anti-FR\u03b1 antibody-expressing B cells (Sp2/0-MOv18), we investigated whether microsphere diameter or the FR\u03b1-biotin on the beads could influence specific recognition of antibody-expressing cells.Influence of Microsphere Diameter and Biotin Length on Specific Recognition of Antigen-Expressing B Cells ::: ResultsWe confirmed that Sp2/0-MOv18 IgG cells expressing MOv18 IgG on the cell surface could be recognized by human recombinant FR\u03b1 (Figure 4A).", [["cell surface", "ANATOMY", 55, 67], ["B Cells", "ANATOMY", 170, 177], ["B cells", "ANATOMY", 311, 318], ["cells", "ANATOMY", 470, 475], ["B Cells", "ANATOMY", 574, 581], ["Sp2/0-MOv18 IgG cells", "ANATOMY", 611, 632], ["cell surface", "ANATOMY", 661, 673], ["FR\u03b1-biotin", "CHEMICAL", 386, 396], ["Biotin", "CHEMICAL", 110, 116], ["biotin", "CHEMICAL", 390, 396], ["Biotin", "CHEMICAL", 514, 520], ["cell", "CELL", 55, 59], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 68, 71], ["Biotin", "SIMPLE_CHEMICAL", 110, 116], ["B Cells", "CELL", 170, 177], ["FR\u03b1+ microspheres", "SIMPLE_CHEMICAL", 212, 229], ["anti-FR\u03b1 antibody", "GENE_OR_GENE_PRODUCT", 282, 299], ["B cells", "CELL", 311, 318], ["Sp2", "ORGANISM", 320, 323], ["MOv18", "GENE_OR_GENE_PRODUCT", 326, 331], ["FR\u03b1-", "SIMPLE_CHEMICAL", 386, 390], ["biotin", "SIMPLE_CHEMICAL", 390, 396], ["cells", "CELL", 470, 475], ["Biotin", "SIMPLE_CHEMICAL", 514, 520], ["B Cells", "CELL", 574, 581], ["MOv18 IgG", "GENE_OR_GENE_PRODUCT", 644, 653], ["cell surface", "CELLULAR_COMPONENT", 661, 673], ["human", "ORGANISM", 697, 702], ["FR\u03b1 (Figure 4A", "GENE_OR_GENE_PRODUCT", 715, 729], ["cell surface FR\u03b1", "PROTEIN", 55, 71], ["Antigen", "PROTEIN", 151, 158], ["FR\u03b1", "PROTEIN", 212, 215], ["anti-FR\u03b1 antibody", "PROTEIN", 282, 299], ["expressing B cells", "CELL_TYPE", 300, 318], ["Sp2", "PROTEIN", 320, 323], ["MOv18", "PROTEIN", 326, 331], ["FR\u03b1-biotin", "PROTEIN", 386, 396], ["antibody-expressing cells", "CELL_TYPE", 450, 475], ["Antigen", "PROTEIN", 555, 562], ["Sp2/0-MOv18 IgG cells", "CELL_LINE", 611, 632], ["MOv18 IgG", "PROTEIN", 644, 653], ["human recombinant FR\u03b1", "PROTEIN", 697, 718], ["Figure 4A", "PROTEIN", 720, 729], ["human", "SPECIES", 697, 702], ["human", "SPECIES", 697, 702], ["This antibody", "TEST", 0, 13], ["Influence of Microsphere Diameter and Biotin Length", "TREATMENT", 72, 123], ["FR\u03b1+ microspheres", "TEST", 212, 229], ["single anti-FR\u03b1 antibody", "TEST", 275, 299], ["Sp2", "TEST", 320, 323], ["microsphere diameter", "TEST", 358, 378], ["the FR\u03b1-biotin on the beads", "PROBLEM", 382, 409], ["antibody", "TEST", 450, 458], ["Influence of Microsphere Diameter and Biotin Length", "TREATMENT", 476, 527], ["ResultsWe", "TEST", 586, 595], ["Sp2", "TEST", 611, 614], ["IgG cells", "TEST", 623, 632], ["IgG", "TEST", 650, 653], ["cell surface", "OBSERVATION", 55, 67], ["Microsphere Diameter", "OBSERVATION_MODIFIER", 85, 105], ["Microsphere Diameter", "OBSERVATION_MODIFIER", 489, 509]]], ["As observed with recombinant antibody binding to FR\u03b1-coated microspheres (Figure 2), the distance between bead and antigen from the bead surface did not affect antigen recognition by anti-FR\u03b1 antibody-expressing Sp2/0-MOv18 cells (Figure 4B).", [["bead surface", "ANATOMY", 132, 144], ["Sp2/0-MOv18 cells", "ANATOMY", 212, 229], ["antigen", "GENE_OR_GENE_PRODUCT", 115, 122], ["antigen", "GENE_OR_GENE_PRODUCT", 160, 167], ["anti-FR\u03b1 antibody", "GENE_OR_GENE_PRODUCT", 183, 200], ["recombinant antibody", "PROTEIN", 17, 37], ["FR\u03b1", "PROTEIN", 49, 52], ["anti-FR\u03b1 antibody", "PROTEIN", 183, 200], ["Sp2/0-MOv18 cells", "CELL_LINE", 212, 229], ["recombinant antibody binding", "PROBLEM", 17, 45], ["FR\u03b1-coated microspheres", "TREATMENT", 49, 72], ["the bead surface", "TEST", 128, 144], ["antigen recognition", "TEST", 160, 179], ["anti-FR\u03b1 antibody", "TEST", 183, 200], ["Sp2", "TEST", 212, 215]]], ["However, the proportion of the Sp2/0-MOv18 cells recognized by fluorescent beads coated with FR\u03b1 differed with bead size or type: microspheres of smaller bead diameters (SA-Red 0.5 \u00b5m and SA-Blue 1.1 \u00b5m) appeared to bind a higher proportion of B cells (70.3 and 54.9%, respectively) compared to the LumAvidin 5.6 \u00b5m beads (1.4%) (Figures 4C,D).Influence of Microsphere Diameter and Biotin Length on Specific Recognition of Antigen-Expressing B Cells ::: ResultsThe length of the biotin arm had minor effects on the binding of the smaller sized (A-Red 0.8 \u00b5m and SA-Blue 1.1 \u00b5m) microspheres to Sp2/0-MOv18 cells.", [["Sp2/0-MOv18 cells", "ANATOMY", 31, 48], ["bead", "ANATOMY", 154, 158], ["B cells", "ANATOMY", 244, 251], ["B Cells", "ANATOMY", 442, 449], ["Sp2/0-MOv18 cells", "ANATOMY", 594, 611], ["biotin", "CHEMICAL", 479, 485], ["Biotin", "CHEMICAL", 382, 388], ["biotin", "CHEMICAL", 479, 485], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 93, 96], ["B cells", "CELL", 244, 251], ["Biotin", "SIMPLE_CHEMICAL", 382, 388], ["B Cells", "CELL", 442, 449], ["biotin", "SIMPLE_CHEMICAL", 479, 485], ["Sp2/0-MOv18 cells", "CELL_LINE", 31, 48], ["FR\u03b1", "PROTEIN", 93, 96], ["B cells", "CELL_TYPE", 244, 251], ["Antigen", "PROTEIN", 423, 430], ["Sp2/0-MOv18 cells", "CELL_LINE", 594, 611], ["the Sp2", "TEST", 27, 34], ["MOv18 cells", "TREATMENT", 37, 48], ["fluorescent beads", "TEST", 63, 80], ["SA", "TEST", 170, 172], ["SA", "TEST", 188, 190], ["the LumAvidin", "TEST", 295, 308], ["Influence of Microsphere Diameter and Biotin Length", "TREATMENT", 344, 395], ["SA", "TEST", 562, 564], ["microspheres", "TEST", 578, 590], ["Sp2", "TEST", 594, 597], ["fluorescent beads", "OBSERVATION", 63, 80], ["bead", "OBSERVATION_MODIFIER", 111, 115], ["size", "OBSERVATION_MODIFIER", 116, 120], ["microspheres", "OBSERVATION_MODIFIER", 130, 142], ["smaller", "OBSERVATION_MODIFIER", 146, 153], ["bead", "OBSERVATION_MODIFIER", 154, 158], ["diameters", "OBSERVATION_MODIFIER", 159, 168], ["B cells", "OBSERVATION", 244, 251], ["Microsphere Diameter", "OBSERVATION_MODIFIER", 357, 377], ["length", "OBSERVATION_MODIFIER", 465, 471], ["minor", "OBSERVATION_MODIFIER", 494, 499], ["effects", "OBSERVATION", 500, 507], ["smaller", "OBSERVATION_MODIFIER", 530, 537], ["sized", "OBSERVATION_MODIFIER", 538, 543]]], ["The PEG12-biotin arm showed a slightly higher proportion of microsphere-attached Sp2/0-MOv18 cells (69\u201371% of cells) compared with beads attached to FR\u03b1 via LC-LC-biotin (59\u201361%) or LC-biotin (54\u201364%) arms (Figure 4E).", [["Sp2/0-MOv18 cells", "ANATOMY", 81, 98], ["cells", "ANATOMY", 110, 115], ["beads", "ANATOMY", 131, 136], ["PEG12-biotin", "CHEMICAL", 4, 16], ["LC-LC-biotin", "CHEMICAL", 157, 169], ["LC-biotin", "CHEMICAL", 182, 191], ["biotin", "CHEMICAL", 10, 16], ["biotin", "CHEMICAL", 163, 169], ["biotin", "CHEMICAL", 185, 191], ["PEG12", "SIMPLE_CHEMICAL", 4, 9], ["biotin", "SIMPLE_CHEMICAL", 10, 16], ["Sp2/0-MOv18 cells", "CELL", 81, 98], ["cells", "CELL", 110, 115], ["FR\u03b1", "SIMPLE_CHEMICAL", 149, 152], ["biotin", "SIMPLE_CHEMICAL", 163, 169], ["LC-biotin", "SIMPLE_CHEMICAL", 182, 191], ["PEG12", "PROTEIN", 4, 9], ["Sp2/0-MOv18 cells", "CELL_LINE", 81, 98], ["The PEG12-biotin arm", "TEST", 0, 20], ["a slightly higher proportion of microsphere", "PROBLEM", 28, 71], ["cells", "TEST", 110, 115], ["beads", "TEST", 131, 136], ["LC", "TEST", 157, 159], ["LC", "TEST", 160, 162], ["biotin", "TEST", 163, 169], ["LC", "TEST", 182, 184], ["biotin", "TEST", 185, 191], ["LC", "ANATOMY", 157, 159], ["LC", "ANATOMY", 160, 162]]], ["Binding of FR\u03b1-coated fluorescent beads appeared to be specific for antibody-expressing B cells, since FR\u03b1-coated beads bound 54\u201371% of Sp2/0-MOv18 IgG cells, while FR\u03b1-coated beads bound 6\u20139% of Sp2/0 non-specific antibody-expressing cells used as controls (Figure 4E).Influence of Microsphere Diameter and Biotin Length on Specific Recognition of Antigen-Expressing B Cells ::: ResultsThese findings suggest that bead size or type could influence the proportion of possible antibody-expressing B cells recognized by antigen-conjugated fluorescent beads.Evaluation of Specific Detection of Antibody-Expressing B Cells in PBMC Samples by Antigen-Conjugated Fluorescent Beads ::: ResultsSince alongside specific binding of beads to antibody-expressing B cells, we also detected non-specific binding of FR\u03b1-coated beads to control Sp2/0 cells (Figure 4E), we further investigated the background binding of fluorescent beads to freshly isolated human PBMCs.", [["B cells", "ANATOMY", 88, 95], ["Sp2/0-MOv18 IgG cells", "ANATOMY", 136, 157], ["cells", "ANATOMY", 235, 240], ["B Cells", "ANATOMY", 368, 375], ["B cells", "ANATOMY", 496, 503], ["Cells", "ANATOMY", 613, 618], ["B cells", "ANATOMY", 751, 758], ["Sp2/0 cells", "ANATOMY", 829, 840], ["PBMCs", "ANATOMY", 948, 953], ["Biotin", "CHEMICAL", 308, 314], ["FR\u03b1", "SIMPLE_CHEMICAL", 11, 14], ["B cells", "CELL", 88, 95], ["FR\u03b1", "SIMPLE_CHEMICAL", 103, 106], ["cells", "CELL", 235, 240], ["Biotin", "SIMPLE_CHEMICAL", 308, 314], ["B Cells", "CELL", 368, 375], ["B cells", "CELL", 496, 503], ["antigen-conjugated fluorescent beads", "GENE_OR_GENE_PRODUCT", 518, 554], ["B Cells", "CELL", 611, 618], ["PBMC", "CELL", 622, 626], ["B cells", "CELL", 751, 758], ["Sp2/0 cells", "CELL", 829, 840], ["human", "ORGANISM", 942, 947], ["PBMCs", "CELL", 948, 953], ["FR\u03b1", "PROTEIN", 11, 14], ["antibody-expressing B cells", "CELL_TYPE", 68, 95], ["FR\u03b1", "PROTEIN", 103, 106], ["Sp2", "PROTEIN", 136, 139], ["MOv18 IgG cells", "CELL_LINE", 142, 157], ["FR\u03b1", "PROTEIN", 165, 168], ["Sp2/0 non-specific antibody", "PROTEIN", 196, 223], ["expressing cells", "CELL_TYPE", 224, 240], ["Antigen", "PROTEIN", 349, 356], ["antibody-expressing B cells", "CELL_TYPE", 476, 503], ["Antibody", "PROTEIN", 591, 599], ["PBMC", "CELL_TYPE", 622, 626], ["antibody-expressing B cells", "CELL_TYPE", 731, 758], ["FR\u03b1", "PROTEIN", 801, 804], ["Sp2/0 cells", "CELL_LINE", 829, 840], ["freshly isolated human PBMCs", "CELL_TYPE", 925, 953], ["human", "SPECIES", 942, 947], ["human", "SPECIES", 942, 947], ["FR\u03b1-coated fluorescent beads", "TREATMENT", 11, 39], ["antibody", "TEST", 68, 76], ["expressing B cells", "PROBLEM", 77, 95], ["FR\u03b1", "TEST", 103, 106], ["coated beads bound", "TEST", 107, 125], ["Sp2", "TEST", 136, 139], ["IgG cells", "TEST", 148, 157], ["FR", "TEST", 165, 167], ["coated beads bound", "TEST", 169, 187], ["Sp2", "TEST", 196, 199], ["non-specific antibody", "TEST", 202, 223], ["Influence of Microsphere Diameter and Biotin Length", "TREATMENT", 270, 321], ["bead size", "PROBLEM", 415, 424], ["antibody", "TEST", 476, 484], ["expressing B cells", "PROBLEM", 485, 503], ["Evaluation", "TEST", 555, 565], ["Specific Detection", "TEST", 569, 587], ["Antibody", "TEST", 591, 599], ["Expressing B Cells", "PROBLEM", 600, 618], ["PBMC Samples", "TEST", 622, 634], ["antibody", "TEST", 731, 739], ["expressing B cells", "PROBLEM", 740, 758], ["FR\u03b1-coated beads", "TREATMENT", 801, 817], ["freshly isolated human PBMCs", "TREATMENT", 925, 953], ["Microsphere Diameter", "OBSERVATION_MODIFIER", 283, 303], ["bead", "OBSERVATION_MODIFIER", 415, 419], ["size", "OBSERVATION_MODIFIER", 420, 424], ["fluorescent beads", "OBSERVATION", 537, 554]]], ["A proportion (~1%) of human PBMCs (top panel) and also of human B cells (CD19+ cells, lower panel) could bind to FR\u03b1-coated beads in most likely a non-specific manner (Figure 5A).", [["PBMCs", "ANATOMY", 28, 33], ["B cells", "ANATOMY", 64, 71], ["CD19+ cells", "ANATOMY", 73, 84], ["human", "ORGANISM", 22, 27], ["PBMCs", "CELL", 28, 33], ["human", "ORGANISM", 58, 63], ["B cells", "CELL", 64, 71], ["CD19", "GENE_OR_GENE_PRODUCT", 73, 77], ["cells", "CELL", 79, 84], ["human PBMCs", "CELL_TYPE", 22, 33], ["human B cells", "CELL_TYPE", 58, 71], ["CD19", "PROTEIN", 73, 77], ["FR\u03b1", "PROTEIN", 113, 116], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 58, 63], ["human PBMCs (top panel", "TEST", 22, 44], ["human B cells", "TEST", 58, 71], ["lower panel", "TEST", 86, 97], ["most likely", "UNCERTAINTY", 133, 144], ["non-specific", "OBSERVATION_MODIFIER", 147, 159]]], ["Different blocking agents did not appear to reduce the levels of background binding (Table S2 in Supplementary Material).", [["Different blocking agents", "TREATMENT", 0, 25], ["background binding", "PROBLEM", 65, 83]]], ["Furthermore, A-Red 0.8 \u00b5m, SA-Blue 1.1 \u00b5m, and LumAvidin 5.6 \u00b5m FR\u03b1-coupled (PEG12-biotin) beads were incubated with PBMCs and binding was directly compared to recognition of Sp2/0-MOv18 IgG cells (used as positive controls).", [["PBMCs", "ANATOMY", 117, 122], ["cells", "ANATOMY", 191, 196], ["PEG12-biotin", "CHEMICAL", 77, 89], ["biotin", "CHEMICAL", 83, 89], ["SA-Blue", "SIMPLE_CHEMICAL", 27, 34], ["PEG12-biotin", "SIMPLE_CHEMICAL", 77, 89], ["PBMCs", "CELL", 117, 122], ["LumAvidin 5.6 \u00b5m FR\u03b1-coupled (PEG12-biotin) beads", "CELL_LINE", 47, 96], ["PBMCs", "CELL_TYPE", 117, 122], ["Sp2/0-MOv18 IgG cells", "CELL_LINE", 175, 196], ["A", "TEST", 13, 14], ["SA", "TEST", 27, 29], ["LumAvidin", "TREATMENT", 47, 56], ["PEG12-biotin) beads", "TREATMENT", 77, 96], ["PBMCs", "TREATMENT", 117, 122], ["Sp2", "TEST", 175, 178], ["IgG cells", "TEST", 187, 196]]], ["FR\u03b1-coupled A-Red 0.8 \u00b5m microspheres showed 54.3% specific and 0.56% non-specific B cell recognition, while SA-Blue 1.1 \u00b5m microspheres showed 53.4% specific and 1.36% non-specific recognition of B cells.", [["B cell", "ANATOMY", 83, 89], ["B cells", "ANATOMY", 197, 204], ["FR\u03b1", "SIMPLE_CHEMICAL", 0, 3], ["A-Red", "GENE_OR_GENE_PRODUCT", 12, 17], ["B cell", "CELL", 83, 89], ["B cells", "CELL", 197, 204], ["FR\u03b1", "PROTEIN", 0, 3], ["B cells", "CELL_TYPE", 197, 204], ["\u00b5m microspheres", "TEST", 22, 37], ["non-specific B cell recognition", "TEST", 70, 101], ["SA", "TEST", 109, 111], ["\u00b5m microspheres", "TEST", 121, 136], ["non-specific recognition of B cells", "PROBLEM", 169, 204], ["B cells", "OBSERVATION", 197, 204]]], ["On the other hand, the larger sized LumAvidin 5.6 \u00b5m microspheres showed 8.7% specific and 0.07% non-specific binding (Figure 5B).", [["the larger sized LumAvidin", "TREATMENT", 19, 45], ["microspheres", "TEST", 53, 65], ["larger", "OBSERVATION_MODIFIER", 23, 29], ["sized", "OBSERVATION_MODIFIER", 30, 35]]], ["This suggested that the smaller diameter beads were more likely to select antibody-expressing cells.Evaluation of Specific Detection of Antibody-Expressing B Cells in PBMC Samples by Antigen-Conjugated Fluorescent Beads ::: ResultsIn order to analyze whether, and at what frequency, anti-FR\u03b1 antibody-expressing B cells in PBMC samples may be detected by FR\u03b1-coupled beads, we spiked human PBMC with Sp2/0-MOv18 cells at different frequencies and we detected double-positive (FR\u03b1+/Sp2/0+) events by flow cytometry (Figure 6A).", [["cells", "ANATOMY", 94, 99], ["Cells", "ANATOMY", 158, 163], ["B cells", "ANATOMY", 312, 319], ["PBMC samples", "ANATOMY", 323, 335], ["PBMC", "ANATOMY", 390, 394], ["Sp2/0-MOv18 cells", "ANATOMY", 400, 417], ["\u03b1+/Sp2/0+", "ANATOMY", 478, 487], ["cells", "CELL", 94, 99], ["B Cells", "CELL", 156, 163], ["PBMC", "CELL", 167, 171], ["anti-FR\u03b1 antibody", "GENE_OR_GENE_PRODUCT", 283, 300], ["B cells", "CELL", 312, 319], ["PBMC samples", "CELL", 323, 335], ["human", "ORGANISM", 384, 389], ["PBMC", "CELL", 390, 394], ["Sp2/0-MOv18 cells", "CELL", 400, 417], ["antibody-expressing cells", "CELL_TYPE", 74, 99], ["Antibody", "PROTEIN", 136, 144], ["PBMC", "CELL_TYPE", 167, 171], ["anti-FR\u03b1 antibody", "PROTEIN", 283, 300], ["expressing B cells", "CELL_TYPE", 301, 319], ["PBMC", "CELL_TYPE", 323, 327], ["FR\u03b1", "PROTEIN", 355, 358], ["human PBMC", "CELL_TYPE", 384, 394], ["Sp2/0-MOv18 cells", "CELL_LINE", 400, 417], ["Sp2", "PROTEIN", 481, 484], ["human", "SPECIES", 384, 389], ["human", "SPECIES", 384, 389], ["the smaller diameter beads", "PROBLEM", 20, 46], ["Evaluation", "TEST", 100, 110], ["Specific Detection", "TEST", 114, 132], ["Antibody", "TEST", 136, 144], ["Expressing B Cells", "PROBLEM", 145, 163], ["PBMC Samples", "TEST", 167, 179], ["anti-FR\u03b1 antibody", "TEST", 283, 300], ["PBMC samples", "TEST", 323, 335], ["human PBMC", "TEST", 384, 394], ["Sp2", "TEST", 400, 403], ["double", "TEST", 459, 465], ["FR\u03b1", "TEST", 476, 479], ["Sp2", "TEST", 481, 484], ["flow cytometry", "TEST", 499, 513], ["smaller", "OBSERVATION_MODIFIER", 24, 31], ["diameter", "OBSERVATION_MODIFIER", 32, 40], ["beads", "OBSERVATION_MODIFIER", 41, 46], ["more likely", "UNCERTAINTY", 52, 63], ["expressing cells", "OBSERVATION", 83, 99]]], ["FR\u03b1-coupled A-Red 0.8 \u00b5m fluorescent beads were incubated with PBMC (1 \u00b5l beads/106 PBMC, Table S1 in Supplementary Material) in the presence of serially diluted (1:50, 1:500, 1:5,000) Sp2/0-MOv18 cells pre-labeled with an anti-CD45 antibody.", [["PBMC", "ANATOMY", 63, 67], ["PBMC", "ANATOMY", 84, 88], ["Sp2/0-MOv18 cells", "ANATOMY", 185, 202], ["FR\u03b1", "SIMPLE_CHEMICAL", 0, 3], ["A-Red", "GENE_OR_GENE_PRODUCT", 12, 17], ["PBMC", "CELL", 63, 67], ["anti-CD45", "GENE_OR_GENE_PRODUCT", 223, 232], ["FR\u03b1", "PROTEIN", 0, 3], ["PBMC", "CELL_TYPE", 63, 67], ["PBMC", "CELL_TYPE", 84, 88], ["serially diluted (1:50, 1:500, 1:5,000) Sp2/0-MOv18 cells", "CELL_LINE", 145, 202], ["anti-CD45 antibody", "PROTEIN", 223, 241], ["Red 0.8 \u00b5m fluorescent beads", "TREATMENT", 14, 42], ["PBMC (1 \u00b5l beads", "TREATMENT", 63, 79], ["PBMC", "TEST", 84, 88], ["Sp2", "TEST", 185, 188], ["an anti-CD45 antibody", "TEST", 220, 241]]], ["The actual dilution was calculated post acquisition (Figure 6B).", [["The actual dilution", "TEST", 0, 19]]], ["Actual positive events were defined as anti-FR\u03b1 antibody-expressing B cells among all bead-bound cells and used to evaluate potential specific selection of real antigen-specific cells.", [["B cells", "ANATOMY", 68, 75], ["cells", "ANATOMY", 97, 102], ["cells", "ANATOMY", 178, 183], ["anti-FR\u03b1 antibody", "GENE_OR_GENE_PRODUCT", 39, 56], ["B cells", "CELL", 68, 75], ["cells", "CELL", 97, 102], ["antigen", "GENE_OR_GENE_PRODUCT", 161, 168], ["cells", "CELL", 178, 183], ["anti-FR\u03b1 antibody", "PROTEIN", 39, 56], ["expressing B cells", "CELL_TYPE", 57, 75], ["bead-bound cells", "CELL_LINE", 86, 102], ["Actual positive events", "PROBLEM", 0, 22], ["anti-FR\u03b1 antibody", "TEST", 39, 56], ["expressing B cells", "PROBLEM", 57, 75], ["bound cells", "OBSERVATION", 91, 102]]], ["The Actual true events were defined as antigen-specific B cells bound to beads among all possible antibody-specific Sp2/0+ events and used to estimate the selection of antigen-binding cells compared to all specific cells in a sample.", [["B cells", "ANATOMY", 56, 63], ["cells", "ANATOMY", 184, 189], ["cells", "ANATOMY", 215, 220], ["sample", "ANATOMY", 226, 232], ["B cells", "CELL", 56, 63], ["Sp2", "GENE_OR_GENE_PRODUCT", 116, 119], ["antigen", "GENE_OR_GENE_PRODUCT", 168, 175], ["cells", "CELL", 184, 189], ["cells", "CELL", 215, 220], ["B cells", "CELL_TYPE", 56, 63], ["Sp2", "PROTEIN", 116, 119], ["antigen-binding cells", "CELL_TYPE", 168, 189], ["The Actual true events", "PROBLEM", 0, 22], ["antigen", "TEST", 39, 46], ["antibody", "TEST", 98, 106], ["antigen-binding cells", "PROBLEM", 168, 189], ["binding cells", "OBSERVATION", 176, 189]]], ["We observed that FR\u03b1+ beads were able to identify 49% actual positive events (B cells) when the specific B cell frequency was ~1:50.", [["B cells", "ANATOMY", 78, 85], ["B cell", "ANATOMY", 105, 111], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 17, 20], ["B cells", "CELL", 78, 85], ["B cell", "CELL", 105, 111], ["FR\u03b1", "PROTEIN", 17, 20], ["B cells", "CELL_TYPE", 78, 85], ["FR\u03b1+ beads", "TEST", 17, 27], ["actual positive events (B cells", "PROBLEM", 54, 85], ["the specific B cell frequency", "TEST", 92, 121]]], ["The proportion of actual positive events (anti-FR\u03b1 antibody-expressing B cells) was lower when the specific B cell frequencies in the PBMC pool were reduced (Figures 6B,C).", [["B cells", "ANATOMY", 71, 78], ["B cell", "ANATOMY", 108, 114], ["PBMC", "ANATOMY", 134, 138], ["anti-FR\u03b1 antibody", "GENE_OR_GENE_PRODUCT", 42, 59], ["B cells", "CELL", 71, 78], ["B cell", "CELL", 108, 114], ["PBMC", "CELL", 134, 138], ["anti-FR\u03b1 antibody", "PROTEIN", 42, 59], ["expressing B cells", "CELL_TYPE", 60, 78], ["PBMC", "CELL_TYPE", 134, 138], ["actual positive events", "PROBLEM", 18, 40], ["anti-FR\u03b1 antibody", "TEST", 42, 59], ["expressing B cells", "PROBLEM", 60, 78], ["the specific B cell frequencies", "TEST", 95, 126], ["the PBMC pool", "TEST", 130, 143], ["positive events", "OBSERVATION", 25, 40], ["PBMC", "ANATOMY", 134, 138]]], ["The actual true events (B cells bound to beads among all possible antibody-expressing Sp2/0+ events) ranged between 9.4 and 18% (Figures 6B,C).", [["B cells", "ANATOMY", 24, 31], ["B cells", "CELL", 24, 31], ["B cells", "CELL_TYPE", 24, 31], ["antibody", "PROTEIN", 66, 74], ["Sp2", "PROTEIN", 86, 89], ["The actual true events", "PROBLEM", 0, 22], ["B cells bound", "PROBLEM", 24, 37], ["antibody", "TEST", 66, 74], ["Sp2", "TEST", 86, 89]]], ["Beads of different types and diameter sizes varied in ability to detect Actual positive events, and the proportion of Actual positive events (among all bead-bound cells) decreased when the frequencies of FR\u03b1+/Sp2/0+ B cells were lower among PBMCs.", [["cells", "ANATOMY", 163, 168], ["FR\u03b1+/Sp2/0+ B cells", "ANATOMY", 204, 223], ["PBMCs", "ANATOMY", 241, 246], ["cells", "CELL", 163, 168], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 204, 207], ["PBMCs", "CELL", 241, 246], ["FR\u03b1", "PROTEIN", 204, 207], ["Sp2", "PROTEIN", 209, 212], ["B cells", "CELL_TYPE", 216, 223], ["PBMCs", "CELL_TYPE", 241, 246], ["diameter sizes", "PROBLEM", 29, 43], ["Actual positive events", "PROBLEM", 72, 94], ["Actual positive events", "PROBLEM", 118, 140], ["all bead-bound cells", "TEST", 148, 168], ["the frequencies", "TEST", 185, 200], ["FR\u03b1", "TEST", 204, 207], ["Sp2", "TEST", 209, 212], ["B cells", "PROBLEM", 216, 223], ["different types", "OBSERVATION_MODIFIER", 9, 24], ["diameter", "OBSERVATION_MODIFIER", 29, 37], ["sizes", "OBSERVATION_MODIFIER", 38, 43], ["varied", "OBSERVATION_MODIFIER", 44, 50], ["positive", "OBSERVATION", 79, 87]]], ["Between 5 and 75% of antibody-expressing B cells recognized by beads were antigen-specific when B cells were found in high frequencies (\u22651:100) in human blood.", [["B cells", "ANATOMY", 41, 48], ["beads", "ANATOMY", 63, 68], ["B cells", "ANATOMY", 96, 103], ["blood", "ANATOMY", 153, 158], ["B cells", "CELL", 41, 48], ["B cells", "CELL", 96, 103], ["human", "ORGANISM", 147, 152], ["blood", "ORGANISM_SUBSTANCE", 153, 158], ["antibody-expressing B cells", "CELL_TYPE", 21, 48], ["B cells", "CELL_TYPE", 96, 103], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 147, 152], ["antibody", "TEST", 21, 29], ["expressing B cells", "PROBLEM", 30, 48], ["antigen", "TEST", 74, 81], ["B cells", "TEST", 96, 103], ["human blood", "TEST", 147, 158], ["high frequencies", "OBSERVATION_MODIFIER", 118, 134]]], ["SA-Blue 1.1 \u00b5m LC-LC biotin beads detected the highest proportion (75%) when B cells were found at a frequency of 1:43 (Figure 6D; Table S3 in Supplementary Material).Evaluation of Specific Detection of Antibody-Expressing B Cells in PBMC Samples by Antigen-Conjugated Fluorescent Beads ::: ResultsTo confirm selection of antibody-expressing cells by specific antibody, PBMC spiking showed that FR\u03b1-coated beads were more likely than HER2-coated beads to be recognized by FR\u03b1-specific Sp2/0-MOv18 cells (Figure 7A; Figure S1 in Supplementary Material).", [["B cells", "ANATOMY", 77, 84], ["Cells", "ANATOMY", 225, 230], ["cells", "ANATOMY", 342, 347], ["PBMC", "ANATOMY", 370, 374], ["Sp2/0-MOv18 cells", "ANATOMY", 485, 502], ["biotin", "CHEMICAL", 21, 27], ["B cells", "CELL", 77, 84], ["B Cells", "CELL", 223, 230], ["PBMC", "CELL", 234, 238], ["cells", "CELL", 342, 347], ["PBMC", "CELL", 370, 374], ["FR\u03b1", "SIMPLE_CHEMICAL", 395, 398], ["HER2", "GENE_OR_GENE_PRODUCT", 434, 438], ["B cells", "CELL_TYPE", 77, 84], ["Antibody", "PROTEIN", 203, 211], ["PBMC", "CELL_TYPE", 234, 238], ["antibody-expressing cells", "CELL_LINE", 322, 347], ["PBMC", "CELL_TYPE", 370, 374], ["FR\u03b1", "PROTEIN", 395, 398], ["HER2", "PROTEIN", 434, 438], ["FR\u03b1-specific Sp2/0-MOv18 cells", "CELL_LINE", 472, 502], ["SA", "TEST", 0, 2], ["LC", "TEST", 15, 17], ["LC biotin beads", "TEST", 18, 33], ["B cells", "PROBLEM", 77, 84], ["Table S3 in Supplementary Material", "TREATMENT", 131, 165], ["Evaluation", "TEST", 167, 177], ["Specific Detection", "TEST", 181, 199], ["Antibody", "TEST", 203, 211], ["Expressing B Cells", "PROBLEM", 212, 230], ["PBMC Samples", "TEST", 234, 246], ["selection of antibody", "TEST", 309, 330], ["expressing cells", "PROBLEM", 331, 347], ["specific antibody", "TEST", 351, 368], ["PBMC spiking", "TEST", 370, 382], ["FR\u03b1-coated beads", "TREATMENT", 395, 411], ["HER2-coated beads", "TREATMENT", 434, 451], ["highest", "OBSERVATION_MODIFIER", 47, 54], ["more likely", "UNCERTAINTY", 417, 428]]], ["Anti-SF25 antibody-expressing Sp2/0 cells were also less likely to be detected by FR\u03b1-coated beads in PBMC samples (Figure 7A).", [["Sp2/0 cells", "ANATOMY", 30, 41], ["PBMC samples", "ANATOMY", 102, 114], ["SF25", "GENE_OR_GENE_PRODUCT", 5, 9], ["SF25 antibody", "PROTEIN", 5, 18], ["Sp2/0 cells", "CELL_LINE", 30, 41], ["FR\u03b1", "PROTEIN", 82, 85], ["PBMC", "CELL_TYPE", 102, 106], ["Anti-SF25 antibody", "TEST", 0, 18], ["expressing Sp2/0 cells", "PROBLEM", 19, 41], ["PBMC samples", "TEST", 102, 114]]], ["Similarly, HER2-coated beads were more likely to bind anti-HER2 (trastuzumab)-expressing Expi293F cells compared with anti-CSPG4 control antibody-expressing Expi293F cells.", [["Expi293F cells", "ANATOMY", 89, 103], ["Expi293F cells", "ANATOMY", 157, 171], ["trastuzumab", "CHEMICAL", 65, 76], ["HER2", "GENE_OR_GENE_PRODUCT", 11, 15], ["anti-HER2", "GENE_OR_GENE_PRODUCT", 54, 63], ["trastuzumab", "SIMPLE_CHEMICAL", 65, 76], ["Expi293F cells", "CELL", 89, 103], ["anti-CSPG4", "GENE_OR_GENE_PRODUCT", 118, 128], ["Expi293F cells", "CELL", 157, 171], ["HER2", "PROTEIN", 11, 15], ["anti-HER2 (trastuzumab)-expressing Expi293F cells", "CELL_LINE", 54, 103], ["anti-CSPG4 control antibody-expressing Expi293F cells", "CELL_LINE", 118, 171], ["HER2-coated beads", "TREATMENT", 11, 28], ["anti-HER2 (trastuzumab", "TREATMENT", 54, 76], ["expressing Expi293F cells", "PROBLEM", 78, 103], ["anti-CSPG4 control antibody", "TEST", 118, 145]]], ["HER2-coated beads were also more likely to bind anti-HER2 (trastuzumab)-expressing Expi293F cells compared with FR\u03b1-coated beads, which showed low binding to anti-HER2 (trastuzumab)-expressing Expi293F cells (Figure 7B).", [["Expi293F cells", "ANATOMY", 83, 97], ["Expi293F cells", "ANATOMY", 193, 207], ["trastuzumab", "CHEMICAL", 59, 70], ["trastuzumab", "CHEMICAL", 169, 180], ["HER2", "GENE_OR_GENE_PRODUCT", 0, 4], ["anti-HER2", "GENE_OR_GENE_PRODUCT", 48, 57], ["trastuzumab", "SIMPLE_CHEMICAL", 59, 70], ["Expi293F cells", "CELL", 83, 97], ["anti-HER2", "GENE_OR_GENE_PRODUCT", 158, 167], ["trastuzumab", "SIMPLE_CHEMICAL", 169, 180], ["Expi293F cells", "CELL", 193, 207], ["HER2", "PROTEIN", 0, 4], ["anti-HER2 (trastuzumab)-expressing Expi293F cells", "CELL_LINE", 48, 97], ["FR\u03b1", "PROTEIN", 112, 115], ["anti-HER2 (trastuzumab)-expressing Expi293F cells", "CELL_LINE", 158, 207], ["HER2-coated beads", "TREATMENT", 0, 17], ["anti-HER2 (trastuzumab", "TREATMENT", 48, 70], ["expressing Expi293F cells", "PROBLEM", 72, 97], ["FR\u03b1-coated beads", "TREATMENT", 112, 128], ["low binding", "PROBLEM", 143, 154], ["anti-HER2 (trastuzumab", "TREATMENT", 158, 180]]], ["Human Ig expression on the surface of Expi293F cells is shown in Figure S1 in Supplementary Material.", [["surface", "ANATOMY", 27, 34], ["Expi293F cells", "ANATOMY", 38, 52], ["Human", "ORGANISM", 0, 5], ["Ig", "GENE_OR_GENE_PRODUCT", 6, 8], ["surface", "CELLULAR_COMPONENT", 27, 34], ["Expi293F cells", "CELL", 38, 52], ["Ig", "PROTEIN", 6, 8], ["Expi293F cells", "CELL_LINE", 38, 52], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human Ig expression", "TREATMENT", 0, 19]]], ["Together, these data suggest that antibody-expressing cells in PBMC preparations are able to recognize beads conjugated to their specific antigens.Evaluation of Specific Detection of Antibody-Expressing B Cells in PBMC Samples by Antigen-Conjugated Fluorescent Beads ::: ResultsTo interrogate this approach in the human setting, we evaluated whether fluorescent beads conjugated to melanoma cell surface antigens were able to identify antigen-reactive B cells.", [["cells", "ANATOMY", 54, 59], ["PBMC", "ANATOMY", 63, 67], ["Cells", "ANATOMY", 205, 210], ["melanoma cell surface", "ANATOMY", 382, 403], ["B cells", "ANATOMY", 452, 459], ["melanoma", "DISEASE", 382, 390], ["cells", "CELL", 54, 59], ["PBMC", "CELL", 63, 67], ["B Cells", "CELL", 203, 210], ["PBMC", "CELL", 214, 218], ["human", "ORGANISM", 314, 319], ["melanoma cell", "CELL", 382, 395], ["B cells", "CELL", 452, 459], ["antibody-expressing cells", "CELL_LINE", 34, 59], ["PBMC", "CELL_TYPE", 63, 67], ["Antibody", "PROTEIN", 183, 191], ["PBMC", "CELL_TYPE", 214, 218], ["melanoma cell surface antigens", "PROTEIN", 382, 412], ["antigen-reactive B cells", "CELL_TYPE", 435, 459], ["human", "SPECIES", 314, 319], ["human", "SPECIES", 314, 319], ["these data", "TEST", 10, 20], ["antibody", "TEST", 34, 42], ["expressing cells", "PROBLEM", 43, 59], ["PBMC preparations", "TREATMENT", 63, 80], ["Evaluation", "TEST", 147, 157], ["Specific Detection", "TEST", 161, 179], ["Antibody", "TEST", 183, 191], ["Expressing B Cells", "PROBLEM", 192, 210], ["PBMC Samples", "TEST", 214, 226], ["fluorescent beads", "TREATMENT", 350, 367], ["melanoma cell surface antigens", "TEST", 382, 412], ["antigen", "TEST", 435, 442], ["reactive B cells", "OBSERVATION", 443, 459]]], ["We prepared fluorescent beads coated with antigens extracted from human melanoma SK-MEL-28 cells, which natively express the tumor-associated antigen chondroitin sulfate proteoglycan 4 (CSPG4).", [["melanoma SK-MEL-28 cells", "ANATOMY", 72, 96], ["tumor", "ANATOMY", 125, 130], ["tumor", "DISEASE", 125, 130], ["chondroitin sulfate", "CHEMICAL", 150, 169], ["human", "ORGANISM", 66, 71], ["melanoma SK-MEL-28 cells", "CELL", 72, 96], ["tumor", "CANCER", 125, 130], ["chondroitin sulfate proteoglycan 4", "GENE_OR_GENE_PRODUCT", 150, 184], ["CSPG4", "GENE_OR_GENE_PRODUCT", 186, 191], ["human melanoma SK-MEL-28 cells", "CELL_LINE", 66, 96], ["tumor-associated antigen chondroitin sulfate proteoglycan 4", "PROTEIN", 125, 184], ["CSPG4", "PROTEIN", 186, 191], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["human melanoma SK", "TEST", 66, 83], ["the tumor", "PROBLEM", 121, 130], ["antigen chondroitin sulfate proteoglycan", "TREATMENT", 142, 182], ["tumor", "OBSERVATION", 125, 130]]], ["Melanoma antigen-coated beads were recognized by an anti-CSPG4 antibody but not by MOv18 antibody specific for the antigen FR\u03b1 not expressed by SK-MEL-28 cells (Figure S2 in Supplementary Material), suggesting that antigen-reactive antibodies can specifically recognize antigen bound on these beads.", [["Melanoma", "ANATOMY", 0, 8], ["SK-MEL-28 cells", "ANATOMY", 144, 159], ["Melanoma antigen", "GENE_OR_GENE_PRODUCT", 0, 16], ["anti-CSPG4", "GENE_OR_GENE_PRODUCT", 52, 62], ["MOv18 antibody", "GENE_OR_GENE_PRODUCT", 83, 97], ["antigen FR\u03b1", "GENE_OR_GENE_PRODUCT", 115, 126], ["SK-MEL-28 cells", "CELL", 144, 159], ["anti-CSPG4 antibody", "PROTEIN", 52, 71], ["MOv18 antibody", "PROTEIN", 83, 97], ["antigen FR\u03b1", "PROTEIN", 115, 126], ["SK-MEL-28 cells", "CELL_LINE", 144, 159], ["antigen-reactive antibodies", "PROTEIN", 215, 242], ["Melanoma antigen-coated beads", "PROBLEM", 0, 29], ["an anti-CSPG4 antibody", "TEST", 49, 71], ["MOv18 antibody", "TEST", 83, 97], ["the antigen FR", "TEST", 111, 125], ["SK", "TEST", 144, 146], ["Figure S2 in Supplementary Material", "TEST", 161, 196], ["antigen", "TEST", 215, 222], ["reactive antibodies", "PROBLEM", 223, 242], ["coated beads", "OBSERVATION", 17, 29], ["reactive antibodies", "OBSERVATION", 223, 242]]], ["We then screened for antigen-reactive antibodies from human B cells.", [["B cells", "ANATOMY", 60, 67], ["human", "ORGANISM", 54, 59], ["B cells", "CELL", 60, 67], ["antigen-reactive antibodies", "PROTEIN", 21, 48], ["human B cells", "CELL_TYPE", 54, 67], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["antigen", "TEST", 21, 28], ["reactive antibodies", "PROBLEM", 29, 48], ["reactive antibodies", "OBSERVATION", 29, 48]]], ["PBMCs from patients with melanoma incubated with melanoma antigen-coated beads were screened to identify mature CD19/CD22+ B cells recognizing antigen-coated beads.", [["PBMCs", "ANATOMY", 0, 5], ["melanoma", "ANATOMY", 25, 33], ["melanoma", "ANATOMY", 49, 57], ["B cells", "ANATOMY", 123, 130], ["melanoma", "DISEASE", 25, 33], ["PBMCs", "CELL", 0, 5], ["patients", "ORGANISM", 11, 19], ["melanoma", "CANCER", 25, 33], ["melanoma antigen", "GENE_OR_GENE_PRODUCT", 49, 65], ["CD19", "GENE_OR_GENE_PRODUCT", 112, 116], ["CD22", "GENE_OR_GENE_PRODUCT", 117, 121], ["B cells", "CELL", 123, 130], ["antigen", "GENE_OR_GENE_PRODUCT", 143, 150], ["PBMCs", "CELL_TYPE", 0, 5], ["melanoma antigen", "PROTEIN", 49, 65], ["CD19", "PROTEIN", 112, 116], ["CD22", "PROTEIN", 117, 121], ["B cells", "CELL_TYPE", 123, 130], ["patients", "SPECIES", 11, 19], ["PBMCs", "PROBLEM", 0, 5], ["melanoma", "PROBLEM", 25, 33], ["melanoma antigen", "PROBLEM", 49, 65], ["coated beads", "TEST", 66, 78], ["antigen-coated beads", "TREATMENT", 143, 163], ["melanoma", "OBSERVATION", 25, 33], ["coated beads", "OBSERVATION", 151, 163]]], ["Single bead-bound B cells were isolated by single cell sorting Ig heavy and light chain sequences were amplified, sequenced, and antibodies were cloned (Figures 8A,B).", [["B cells", "ANATOMY", 18, 25], ["cell", "ANATOMY", 50, 54], ["B cells", "CELL", 18, 25], ["cell", "CELL", 50, 54], ["Ig heavy", "GENE_OR_GENE_PRODUCT", 63, 71], ["B", "GENE_OR_GENE_PRODUCT", 164, 165], ["B cells", "CELL_TYPE", 18, 25], ["Ig heavy and light chain sequences", "DNA", 63, 97], ["antibodies", "PROTEIN", 129, 139], ["Single bead-bound B cells", "TEST", 0, 25], ["light chain sequences", "TEST", 76, 97], ["antibodies", "TEST", 129, 139]]], ["An antibody derived from a single bead-bound B cell could recognize melanoma antigen-coated fluorescent beads compared with secondary only or a non-specific antibody control.", [["B cell", "ANATOMY", 45, 51], ["melanoma", "ANATOMY", 68, 76], ["B cell", "CELL", 45, 51], ["melanoma antigen", "GENE_OR_GENE_PRODUCT", 68, 84], ["B cell", "CELL_TYPE", 45, 51], ["melanoma antigen", "PROTEIN", 68, 84], ["An antibody", "TEST", 0, 11], ["a single bead-bound B cell", "TREATMENT", 25, 51], ["melanoma antigen", "PROBLEM", 68, 84], ["coated fluorescent beads", "TREATMENT", 85, 109], ["a non-specific antibody control", "TREATMENT", 142, 173], ["melanoma", "OBSERVATION", 68, 76]]], ["The B cell-derived clone showed binding comparable to that of a monoclonal antibody specific for the melanoma-associated antigen CSPG4 (Figure 8C).Evaluation of Specific Detection of Antibody-Expressing B Cells in PBMC Samples by Antigen-Conjugated Fluorescent Beads ::: ResultsTaken together, these findings suggest that antigen-reactive B cells in human blood could be recognized by antigen-conjugated fluorescent beads and could be sorted by flow cytometry for the expression of monoclonal antibodies.DiscussionIn this report, we present the development of a fluorescent bead method for the selection of single antigen-reactive B cell clones and the production of the cloned antigen-specific antibodies for downstream testing.", [["B cell", "ANATOMY", 4, 10], ["clone", "ANATOMY", 19, 24], ["melanoma", "ANATOMY", 101, 109], ["Cells", "ANATOMY", 205, 210], ["B cells", "ANATOMY", 339, 346], ["blood", "ANATOMY", 356, 361], ["B cell clones", "ANATOMY", 631, 644], ["melanoma", "DISEASE", 101, 109], ["B cell", "CELL", 4, 10], ["clone", "CELL", 19, 24], ["melanoma", "CANCER", 101, 109], ["CSPG4", "GENE_OR_GENE_PRODUCT", 129, 134], ["B Cells", "CELL", 203, 210], ["PBMC", "CELL", 214, 218], ["antigen", "GENE_OR_GENE_PRODUCT", 322, 329], ["B cells", "CELL", 339, 346], ["human", "ORGANISM", 350, 355], ["blood", "ORGANISM_SUBSTANCE", 356, 361], ["B cell clones", "CELL", 631, 644], ["B cell-derived clone", "CELL_LINE", 4, 24], ["monoclonal antibody", "PROTEIN", 64, 83], ["melanoma-associated antigen", "PROTEIN", 101, 128], ["CSPG4", "PROTEIN", 129, 134], ["Figure 8C", "PROTEIN", 136, 145], ["Antibody", "PROTEIN", 183, 191], ["PBMC", "CELL_TYPE", 214, 218], ["reactive B cells", "CELL_TYPE", 330, 346], ["monoclonal antibodies", "PROTEIN", 482, 503], ["single antigen-reactive B cell clones", "CELL_LINE", 607, 644], ["cloned antigen-specific antibodies", "PROTEIN", 671, 705], ["human", "SPECIES", 350, 355], ["human", "SPECIES", 350, 355], ["The B cell", "TEST", 0, 10], ["a monoclonal antibody", "TEST", 62, 83], ["the melanoma", "PROBLEM", 97, 109], ["Evaluation", "TEST", 147, 157], ["Specific Detection", "TEST", 161, 179], ["Antibody", "TEST", 183, 191], ["Expressing B Cells", "PROBLEM", 192, 210], ["PBMC Samples", "TEST", 214, 226], ["antigen", "TEST", 322, 329], ["reactive B cells in human blood", "PROBLEM", 330, 361], ["conjugated fluorescent beads", "TREATMENT", 393, 421], ["flow cytometry", "TEST", 445, 459], ["monoclonal antibodies", "PROBLEM", 482, 503], ["a fluorescent bead method", "TREATMENT", 560, 585], ["single antigen", "TEST", 607, 621], ["reactive B cell clones", "PROBLEM", 622, 644], ["the cloned antigen", "TEST", 667, 685], ["downstream testing", "TEST", 710, 728], ["melanoma", "OBSERVATION", 101, 109], ["reactive B cells", "OBSERVATION", 330, 346], ["monoclonal antibodies", "OBSERVATION", 482, 503], ["reactive B cell clones", "OBSERVATION", 622, 644]]], ["The workflow comprises: (a) conjugation of fluorescent microspheres with a recombinant antigen of interest; (b) identification of fluorescently labeled single antibody-expressing B cells by flow cytometry using antigen-conjugated beads; (c) flow cytometric sorting of bead-bound single cells directly into lysis buffer; (d) single cell retrotranscription and sequencing of matched heavy and light chain antibody variable regions; (e) cloning and expression using a vector containing human constant region cassettes; (f) confirmation of antigen reactivity of the produced full-length antibody.", [["B cells", "ANATOMY", 179, 186], ["cells", "ANATOMY", 286, 291], ["cell", "ANATOMY", 331, 335], ["B cells", "CELL", 179, 186], ["cells", "CELL", 286, 291], ["cell", "CELL", 331, 335], ["human", "ORGANISM", 483, 488], ["recombinant antigen", "PROTEIN", 75, 94], ["fluorescently labeled single antibody", "PROTEIN", 130, 167], ["expressing B cells", "CELL_TYPE", 168, 186], ["bead-bound single cells", "CELL_TYPE", 268, 291], ["human constant region cassettes", "DNA", 483, 514], ["full-length antibody", "PROTEIN", 571, 591], ["human", "SPECIES", 483, 488], ["human", "SPECIES", 483, 488], ["a) conjugation of fluorescent microspheres", "TREATMENT", 25, 67], ["single antibody", "TEST", 152, 167], ["flow cytometry", "TEST", 190, 204], ["antigen", "TEST", 211, 218], ["bead-bound single cells", "TREATMENT", 268, 291], ["lysis buffer", "TREATMENT", 306, 318], ["single cell retrotranscription", "TREATMENT", 324, 354], ["matched heavy and light chain antibody variable regions", "PROBLEM", 373, 428], ["a vector containing human constant region cassettes", "TREATMENT", 463, 514], ["antigen reactivity", "TEST", 536, 554]]], ["We designed this process to allow the identification of antigen-specific antibody-expressing B cells without the requirement of prior ex vivo growth or secondary screening of B cells, and we aimed to conduct the workflow from clone identification to antibody production and characterization in a timeframe of approximately 23 days.DiscussionTo design this protocol, we employed a model system featuring human recombinant Folate Receptor alpha (FR\u03b1) as the target antigen, a B cell line expressing both the soluble and the membrane-bound forms of MOv18 IgG1, a human/mouse chimeric antibody specific for FR\u03b1.", [["B cells", "ANATOMY", 93, 100], ["B cells", "ANATOMY", 175, 182], ["B cell line", "ANATOMY", 474, 485], ["membrane", "ANATOMY", 522, 530], ["Folate", "CHEMICAL", 421, 427], ["Folate", "CHEMICAL", 421, 427], ["antigen", "GENE_OR_GENE_PRODUCT", 56, 63], ["B cells", "CELL", 93, 100], ["B cells", "CELL", 175, 182], ["clone", "CELL", 226, 231], ["human", "ORGANISM", 403, 408], ["Folate Receptor alpha", "GENE_OR_GENE_PRODUCT", 421, 442], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 444, 447], ["B cell line", "CELL", 474, 485], ["membrane", "CELLULAR_COMPONENT", 522, 530], ["MOv18", "GENE_OR_GENE_PRODUCT", 546, 551], ["IgG1", "GENE_OR_GENE_PRODUCT", 552, 556], ["human", "ORGANISM", 560, 565], ["mouse", "ORGANISM", 566, 571], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 603, 606], ["antigen-specific antibody", "PROTEIN", 56, 81], ["expressing B cells", "CELL_TYPE", 82, 100], ["B cells", "CELL_TYPE", 175, 182], ["human recombinant Folate Receptor alpha", "PROTEIN", 403, 442], ["FR\u03b1", "PROTEIN", 444, 447], ["B cell line", "CELL_LINE", 474, 485], ["membrane-bound forms", "PROTEIN", 522, 542], ["MOv18 IgG1", "PROTEIN", 546, 556], ["human/mouse chimeric antibody", "PROTEIN", 560, 589], ["FR\u03b1", "PROTEIN", 603, 606], ["human", "SPECIES", 403, 408], ["human", "SPECIES", 560, 565], ["mouse", "SPECIES", 566, 571], ["human", "SPECIES", 403, 408], ["human", "SPECIES", 560, 565], ["mouse", "SPECIES", 566, 571], ["antigen", "TEST", 56, 63], ["specific antibody", "TEST", 64, 81], ["expressing B cells", "PROBLEM", 82, 100], ["prior ex vivo growth", "PROBLEM", 128, 148], ["B cells", "PROBLEM", 175, 182], ["clone identification", "TEST", 226, 246], ["antibody production", "TEST", 250, 269], ["this protocol", "TREATMENT", 351, 364], ["human recombinant Folate Receptor alpha (FR\u03b1", "TREATMENT", 403, 447], ["the target antigen", "PROBLEM", 452, 470], ["a B cell line", "TREATMENT", 472, 485], ["a human/mouse chimeric antibody", "TREATMENT", 558, 589], ["cell line", "OBSERVATION", 476, 485]]], ["We showed that fluorescent microspheres can be coupled with the recombinant antigen via biotin\u2013streptavidin/avidin bridging, and that immobilized antigens could be readily detected by antigen-specific monoclonal antibodies.", [["biotin\u2013streptavidin", "CHEMICAL", 88, 107], ["fluorescent microspheres", "SIMPLE_CHEMICAL", 15, 39], ["biotin\u2013streptavidin", "SIMPLE_CHEMICAL", 88, 107], ["avidin", "GENE_OR_GENE_PRODUCT", 108, 114], ["antigen", "GENE_OR_GENE_PRODUCT", 184, 191], ["recombinant antigen", "PROTEIN", 64, 83], ["biotin\u2013streptavidin", "PROTEIN", 88, 107], ["antigen-specific monoclonal antibodies", "PROTEIN", 184, 222], ["fluorescent microspheres", "PROBLEM", 15, 39], ["biotin\u2013streptavidin/avidin bridging", "TREATMENT", 88, 123], ["immobilized antigens", "TEST", 134, 154], ["monoclonal antibodies", "OBSERVATION", 201, 222]]], ["Recognition of the epitope on FR\u03b1 by the test antibody MOv18 is thought to be dependent on the native folding of the target antigen.", [["MOv18", "CHEMICAL", 55, 60], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 30, 33], ["FR\u03b1", "PROTEIN", 30, 33], ["MOv18", "PROTEIN", 55, 60], ["target antigen", "PROTEIN", 117, 131], ["the test antibody MOv18", "TEST", 37, 60], ["thought to be", "UNCERTAINTY", 64, 77], ["dependent", "OBSERVATION_MODIFIER", 78, 87]]], ["Here, we demonstrated that it is possible to use antigen-coupled fluorescent beads of different sizes to identify and isolate single B cells expressing cell surface-expressed antibodies that recognize this conformational epitope.", [["B cells", "ANATOMY", 133, 140], ["cell surface", "ANATOMY", 152, 164], ["B cells", "CELL", 133, 140], ["cell", "CELL", 152, 156], ["B cells", "CELL_TYPE", 133, 140], ["cell surface-expressed antibodies", "PROTEIN", 152, 185], ["conformational epitope", "PROTEIN", 206, 228], ["antigen", "TEST", 49, 56], ["cell surface", "TEST", 152, 164], ["expressed antibodies", "PROBLEM", 165, 185], ["this conformational epitope", "PROBLEM", 201, 228]]], ["Antigen-antibody recognition could be improved by evaluating beads with different characteristics and diameters, while varying the lengths of the avidin coupling agents did not significantly influence antibody-expressing cell recognition by the beads.", [["cell", "ANATOMY", 221, 225], ["avidin", "GENE_OR_GENE_PRODUCT", 146, 152], ["cell", "CELL", 221, 225], ["Antigen-antibody recognition", "TEST", 0, 28], ["the avidin coupling agents", "TREATMENT", 142, 168], ["diameters", "OBSERVATION_MODIFIER", 102, 111]]], ["The latter observation also suggested that engagement of the antigen to the bead surface via different biotins did not mask epitope recognition by specific antibody either in solution or when the antibody was expressed on the surface of a B cell.DiscussionA key feature of this streptavidin\u2013biotin bead-based approach is that, in principle, it may enable the coupling of virtually any known native or recombinant antigen to fluorescent beads and facilitate the detection of B cells reactive to this antigen.", [["bead surface", "ANATOMY", 76, 88], ["surface", "ANATOMY", 226, 233], ["B cell", "ANATOMY", 239, 245], ["B cells", "ANATOMY", 474, 481], ["streptavidin\u2013biotin", "CHEMICAL", 278, 297], ["biotins", "SIMPLE_CHEMICAL", 103, 110], ["surface", "CELLULAR_COMPONENT", 226, 233], ["B cell", "CELL", 239, 245], ["streptavidin\u2013biotin", "SIMPLE_CHEMICAL", 278, 297], ["B cells", "CELL", 474, 481], ["specific antibody", "PROTEIN", 147, 164], ["B cell", "CELL_TYPE", 239, 245], ["recombinant antigen", "PROTEIN", 401, 420], ["B cells", "CELL_TYPE", 474, 481], ["different biotins", "PROBLEM", 93, 110], ["the antibody", "TEST", 192, 204], ["this streptavidin\u2013biotin bead", "TREATMENT", 273, 302], ["the detection", "TEST", 457, 470], ["B cells", "PROBLEM", 474, 481], ["this antigen", "PROBLEM", 494, 506], ["B cell", "OBSERVATION", 239, 245]]], ["For instance, antibodies used for detection of BCR on B cells may also interact not only with BCRs but also with Fc receptors on human B cells (30).", [["B cells", "ANATOMY", 54, 61], ["B cells", "ANATOMY", 135, 142], ["BCR", "GENE_OR_GENE_PRODUCT", 47, 50], ["B cells", "CELL", 54, 61], ["BCRs", "GENE_OR_GENE_PRODUCT", 94, 98], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 113, 125], ["human", "ORGANISM", 129, 134], ["B cells", "CELL", 135, 142], ["antibodies", "PROTEIN", 14, 24], ["BCR", "PROTEIN", 47, 50], ["B cells", "CELL_TYPE", 54, 61], ["BCRs", "PROTEIN", 94, 98], ["Fc receptors", "PROTEIN", 113, 125], ["human B cells", "CELL_TYPE", 129, 142], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["antibodies", "TEST", 14, 24], ["BCR on B cells", "PROBLEM", 47, 61], ["BCRs", "PROBLEM", 94, 98], ["human B cells", "TEST", 129, 142]]], ["Tetramer technologies may be applicable to the selection of antigen-specific B cells, but fluorophores have been known to be released from antigen complexes and to bind non-specifically to immune cells, yielding false positive events (31).", [["B cells", "ANATOMY", 77, 84], ["immune cells", "ANATOMY", 189, 201], ["antigen", "GENE_OR_GENE_PRODUCT", 60, 67], ["B cells", "CELL", 77, 84], ["immune cells", "CELL", 189, 201], ["B cells", "CELL_TYPE", 77, 84], ["antigen complexes", "PROTEIN", 139, 156], ["immune cells", "CELL_TYPE", 189, 201], ["Tetramer technologies", "TREATMENT", 0, 21], ["specific B cells", "PROBLEM", 68, 84], ["fluorophores", "PROBLEM", 90, 102], ["false positive events", "PROBLEM", 212, 233]]], ["Our protocol is also specifically designed to avoid the requirement for B cell culture and ex vivo expansion or for antibody selection from culture supernatants prior to sub-cloning, limiting dilution and isolation of antigen-specific B cell clones.", [["B cell", "ANATOMY", 72, 78], ["supernatants", "ANATOMY", 148, 160], ["B cell clones", "ANATOMY", 235, 248], ["B cell", "CELL", 72, 78], ["antigen", "GENE_OR_GENE_PRODUCT", 218, 225], ["B cell clones", "CELL", 235, 248], ["B cell culture", "CELL_LINE", 72, 86], ["antigen-specific B cell clones", "CELL_LINE", 218, 248], ["B cell culture", "TEST", 72, 86], ["ex vivo expansion", "TEST", 91, 108], ["antibody selection", "PROBLEM", 116, 134], ["culture supernatants", "TEST", 140, 160], ["antigen", "TEST", 218, 225], ["specific B cell clones", "PROBLEM", 226, 248], ["B cell clones", "OBSERVATION", 235, 248]]], ["As well as being laborious and lengthy, these steps may also be limited by specific expansion of distinct B cell populations not always representative of the original B cell repertoire, and which could suffer from potential loss of the antigen-specific clone during the cell ex vivo culture processes (17).DiscussionFollowing flow sorting of single cells directly into lysis buffer, we confirmed that it is possible to extract matched H and L chain variable region sequences from single antibody-expressing cells selected by specific antigen-coated beads.", [["B cell", "ANATOMY", 106, 112], ["B cell", "ANATOMY", 167, 173], ["clone", "ANATOMY", 253, 258], ["cell", "ANATOMY", 270, 274], ["cells", "ANATOMY", 349, 354], ["cells", "ANATOMY", 507, 512], ["B cell populations", "CELL", 106, 124], ["B cell", "CELL", 167, 173], ["clone", "CELL", 253, 258], ["cell", "CELL", 270, 274], ["cells", "CELL", 349, 354], ["cells", "CELL", 507, 512], ["antigen", "GENE_OR_GENE_PRODUCT", 534, 541], ["B cell populations", "CELL_TYPE", 106, 124], ["single cells", "CELL_TYPE", 342, 354], ["H and L chain variable region sequences", "DNA", 435, 474], ["single antibody-expressing cells", "CELL_TYPE", 480, 512], ["distinct B cell populations", "PROBLEM", 97, 124], ["potential loss of the antigen", "PROBLEM", 214, 243], ["specific clone", "PROBLEM", 244, 258], ["the cell ex vivo culture processes", "TEST", 266, 300], ["lysis buffer", "TREATMENT", 369, 381], ["matched H and L chain variable region sequences", "PROBLEM", 427, 474], ["single antibody", "TEST", 480, 495], ["distinct B cell populations", "OBSERVATION", 97, 124]]], ["Employing the FR\u03b1-MOv18 Sp2/0 B cell model, we confirmed that B cell selection by FR\u03b1+ fluorescent beads allowed the identification of the matched variable regions and permitted the cloning and production of the corresponding monoclonal antibody from a single cell.", [["Sp2/0 B cell", "ANATOMY", 24, 36], ["B cell", "ANATOMY", 62, 68], ["cell", "ANATOMY", 260, 264], ["B cell", "CELL", 62, 68], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 82, 85], ["cell", "CELL", 260, 264], ["FR\u03b1-MOv18 Sp2/0 B cell model", "CELL_LINE", 14, 42], ["FR\u03b1", "PROTEIN", 82, 85], ["monoclonal antibody", "PROTEIN", 226, 245], ["the FR", "TEST", 10, 16], ["B cell model", "TEST", 30, 42], ["B cell selection", "TREATMENT", 62, 78], ["fluorescent beads", "TREATMENT", 87, 104], ["the matched variable regions", "PROBLEM", 135, 163], ["the corresponding monoclonal antibody", "PROBLEM", 208, 245], ["B cell selection", "OBSERVATION", 62, 78], ["fluorescent beads", "OBSERVATION", 87, 104], ["monoclonal antibody", "OBSERVATION", 226, 245]]], ["This was greatly expedited with the use of a single vector Expi293F\u2122 cell line-based expression system, which permitted antibody production within a few days (25, 26).", [["cell line", "ANATOMY", 69, 78], ["Expi293F\u2122 cell line", "CELL", 59, 78], ["a single vector Expi293F\u2122 cell line", "TREATMENT", 43, 78], ["cell line", "OBSERVATION", 69, 78]]], ["While the vector used in this study contained the constant regions of human IgG1, in principle, this platform could be used for engineering of B cell-derived antibodies with constant regions of any isotype or species desired, potentially facilitating a wide range of downstream applications for this technology.", [["B cell", "ANATOMY", 143, 149], ["human", "ORGANISM", 70, 75], ["IgG1", "GENE_OR_GENE_PRODUCT", 76, 80], ["B cell", "CELL", 143, 149], ["human IgG1", "PROTEIN", 70, 80], ["B cell-derived antibodies", "PROTEIN", 143, 168], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["the vector", "TREATMENT", 6, 16], ["this study", "TEST", 25, 35], ["human IgG1", "TREATMENT", 70, 80], ["B cell-derived antibodies", "PROBLEM", 143, 168], ["any isotype or species", "PROBLEM", 194, 216], ["this technology", "TREATMENT", 295, 310], ["human IgG1", "OBSERVATION", 70, 80]]], ["Importantly, we showed that cloned and expressed full-length antibody with variable regions extracted from a single B cell could recognize native cell surface-expressed human FR\u03b1.", [["B cell", "ANATOMY", 116, 122], ["cell surface", "ANATOMY", 146, 158], ["B cell", "CELL", 116, 122], ["cell", "CELL", 146, 150], ["human", "ORGANISM", 169, 174], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 175, 178], ["full-length antibody", "PROTEIN", 49, 69], ["B cell", "CELL_TYPE", 116, 122], ["human FR\u03b1", "PROTEIN", 169, 178], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 169, 174], ["variable regions", "PROBLEM", 75, 91], ["a single B cell", "PROBLEM", 107, 122], ["native cell surface", "OBSERVATION", 139, 158]]], ["The specificity of an identified antibody could ultimately be confirmed only by the expression of the antibody and subsequent testing against the natively expressed antigen.", [["natively expressed antigen", "PROTEIN", 146, 172], ["an identified antibody", "PROBLEM", 19, 41], ["the antibody", "TEST", 98, 110], ["subsequent testing", "TEST", 115, 133], ["antibody", "OBSERVATION", 33, 41]]], ["Previous published studies report the number of detected B cells and the antigenic reactivity of antibodies secreted in supernatants of ex vivo B cell cultures without cloning, production, or testing of the derived antibody clones (16, 32).", [["B cells", "ANATOMY", 57, 64], ["supernatants", "ANATOMY", 120, 132], ["B cell cultures", "ANATOMY", 144, 159], ["B cells", "CELL", 57, 64], ["B cell cultures", "CELL", 144, 159], ["B cells", "CELL_TYPE", 57, 64], ["antibodies", "PROTEIN", 97, 107], ["ex vivo B cell cultures", "CELL_LINE", 136, 159], ["derived antibody clones", "CELL_LINE", 207, 230], ["Previous published studies", "TEST", 0, 26], ["B cells", "PROBLEM", 57, 64], ["the antigenic reactivity of antibodies", "TEST", 69, 107], ["ex vivo B cell cultures", "TEST", 136, 159], ["cloning", "PROBLEM", 168, 175], ["the derived antibody clones", "PROBLEM", 203, 230], ["antibody clones", "OBSERVATION", 215, 230]]], ["A similar B cell identification process to the one reported in our study described the frequency of antigen-specific B cells detected using a modified bead-based method (31).", [["B cell", "ANATOMY", 10, 16], ["B cells", "ANATOMY", 117, 124], ["B cell", "CELL", 10, 16], ["antigen", "GENE_OR_GENE_PRODUCT", 100, 107], ["B cells", "CELL", 117, 124], ["B cells", "CELL_TYPE", 117, 124], ["A similar B cell identification process", "PROBLEM", 0, 39], ["our study", "TEST", 63, 72], ["a modified bead-based method", "TREATMENT", 140, 168], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["B cell", "OBSERVATION", 10, 16]]], ["With this tool, it was possible to monitor the frequencies of anti-HLA, anti-tetanus toxin-, and anti-EBNA1-committed B cells in different individuals.", [["B cells", "ANATOMY", 118, 125], ["anti-HLA", "GENE_OR_GENE_PRODUCT", 62, 70], ["anti-tetanus toxin", "SIMPLE_CHEMICAL", 72, 90], ["anti-EBNA1", "SIMPLE_CHEMICAL", 97, 107], ["B cells", "CELL", 118, 125], ["anti-HLA", "PROTEIN", 62, 70], ["anti-tetanus toxin", "PROTEIN", 72, 90], ["anti-EBNA1", "PROTEIN", 97, 107], ["committed B cells", "CELL_TYPE", 108, 125], ["anti-HLA", "TEST", 62, 70], ["anti-tetanus toxin", "TEST", 72, 90], ["anti-EBNA1", "TEST", 97, 107]]], ["However, antibodies from selected B cells are often not cloned and expressed subsequently in order to analyze their ability to recognize natively expressed cognate antigens.", [["B cells", "ANATOMY", 34, 41], ["B cells", "CELL", 34, 41], ["antibodies", "PROTEIN", 9, 19], ["B cells", "CELL_TYPE", 34, 41], ["cognate antigens", "PROTEIN", 156, 172], ["antibodies", "TEST", 9, 19]]], ["Our data confirming antibody sequencing, cloning, expression, and antigen recognition provide an early proof of principle that functional Ig sequences could be recovered with this methodology.DiscussionWe ascertained that binding of FR\u03b1-coated fluorescent beads can specifically single out antibody-expressing B cells.", [["B cells", "ANATOMY", 310, 317], ["Ig", "GENE_OR_GENE_PRODUCT", 138, 140], ["B cells", "CELL", 310, 317], ["Ig sequences", "DNA", 138, 150], ["FR\u03b1", "PROTEIN", 233, 236], ["antibody-expressing B cells", "CELL_TYPE", 290, 317], ["Our data", "TEST", 0, 8], ["antibody sequencing", "TEST", 20, 39], ["Ig sequences", "TEST", 138, 150], ["FR\u03b1-coated fluorescent beads", "TREATMENT", 233, 261]]], ["We found that FR\u03b1-coated beads bound up to 71% of possible Sp2/0-MOv18 IgG cells.", [["Sp2/0-MOv18 IgG cells", "ANATOMY", 59, 80], ["FR\u03b1", "PROTEIN", 14, 17], ["Sp2/0-MOv18 IgG cells", "CELL_LINE", 59, 80], ["FR\u03b1", "TEST", 14, 17], ["coated beads bound", "PROBLEM", 18, 36], ["Sp2", "TEST", 59, 62], ["MOv18 IgG cells", "PROBLEM", 65, 80], ["IgG cells", "OBSERVATION", 71, 80]]], ["However, alongside enhanced recognition of possible antigen-reactive B cells, FR\u03b1-coated beads also bound to 6\u20139% of non-specific Sp2/0 B cells.", [["B cells", "ANATOMY", 69, 76], ["Sp2/0 B cells", "ANATOMY", 130, 143], ["antigen", "GENE_OR_GENE_PRODUCT", 52, 59], ["B cells", "CELL", 69, 76], ["Sp2/0 B cells", "CELL", 130, 143], ["reactive B cells", "CELL_TYPE", 60, 76], ["FR\u03b1", "PROTEIN", 78, 81], ["Sp2/0 B cells", "CELL_LINE", 130, 143], ["antigen", "TEST", 52, 59], ["reactive B cells", "PROBLEM", 60, 76], ["non-specific Sp2/0 B cells", "PROBLEM", 117, 143], ["possible", "UNCERTAINTY", 43, 51], ["reactive B cells", "OBSERVATION", 60, 76]]], ["Furthermore, a proportion (~1%) of human circulating B cells could bind to FR\u03b1-coated beads in most likely a non-specific manner.", [["B cells", "ANATOMY", 53, 60], ["human", "ORGANISM", 35, 40], ["B cells", "CELL", 53, 60], ["human circulating B cells", "CELL_TYPE", 35, 60], ["FR\u03b1", "PROTEIN", 75, 78], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["human circulating B cells", "TREATMENT", 35, 60], ["FR\u03b1-coated beads", "TREATMENT", 75, 91], ["coated beads", "OBSERVATION_MODIFIER", 79, 91], ["most likely", "UNCERTAINTY", 95, 106], ["non-specific", "OBSERVATION_MODIFIER", 109, 121]]], ["Together, these suggest that background non-specific binding of beads to cells may be a limitation of this methodology.", [["cells", "ANATOMY", 73, 78], ["cells", "CELL", 73, 78], ["background non-specific binding of beads to cells", "PROBLEM", 29, 78], ["non-specific", "OBSERVATION_MODIFIER", 40, 52]]], ["We employed two approaches to evaluate whether antigen-coupled beads could detect antigen-reactive antibody-expressing cells in PBMC samples.DiscussionOur first approach was to \u201cspike\u201d human PBMC with Sp2/0-MOv18 B cells at different frequencies.", [["cells", "ANATOMY", 119, 124], ["PBMC samples", "ANATOMY", 128, 140], ["PBMC", "ANATOMY", 191, 195], ["Sp2/0-MOv18 B cells", "ANATOMY", 201, 220], ["antigen-reactive antibody", "GENE_OR_GENE_PRODUCT", 82, 107], ["cells", "CELL", 119, 124], ["PBMC samples", "CELL", 128, 140], ["human", "ORGANISM", 185, 190], ["PBMC", "CELL", 191, 195], ["Sp2/0-MOv18 B cells", "CELL", 201, 220], ["antigen-reactive antibody", "PROTEIN", 82, 107], ["expressing cells", "CELL_TYPE", 108, 124], ["PBMC", "CELL_TYPE", 128, 132], ["human PBMC", "CELL_TYPE", 185, 195], ["Sp2/0-MOv18 B cells", "CELL_LINE", 201, 220], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 185, 190], ["antigen", "TEST", 47, 54], ["coupled beads", "TEST", 55, 68], ["antigen", "TEST", 82, 89], ["reactive antibody", "TEST", 90, 107], ["PBMC samples", "TEST", 128, 140], ["human PBMC", "TEST", 185, 195], ["Sp2", "TEST", 201, 204], ["reactive antibody", "OBSERVATION", 90, 107]]], ["We demonstrated that FR\u03b1+ fluorescent beads could identify antibody-expressing cells among PBMC populations when these antigen-reactive cells were present at higher frequencies in human blood.", [["cells", "ANATOMY", 79, 84], ["PBMC", "ANATOMY", 91, 95], ["cells", "ANATOMY", 136, 141], ["blood", "ANATOMY", 186, 191], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 21, 24], ["cells", "CELL", 79, 84], ["PBMC populations", "CELL", 91, 107], ["antigen", "GENE_OR_GENE_PRODUCT", 119, 126], ["cells", "CELL", 136, 141], ["human", "ORGANISM", 180, 185], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["FR\u03b1", "PROTEIN", 21, 24], ["antibody-expressing cells", "CELL_TYPE", 59, 84], ["PBMC populations", "CELL_TYPE", 91, 107], ["antigen-reactive cells", "CELL_TYPE", 119, 141], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["FR\u03b1", "TEST", 21, 24], ["fluorescent beads", "TEST", 26, 43], ["antibody", "TEST", 59, 67], ["expressing cells", "PROBLEM", 68, 84], ["PBMC populations", "PROBLEM", 91, 107], ["these antigen", "TEST", 113, 126], ["reactive cells", "PROBLEM", 127, 141], ["fluorescent beads", "OBSERVATION", 26, 43], ["reactive cells", "OBSERVATION", 127, 141]]], ["We also found that different bead types had different specific recognition and background recognition profiles.", [["different", "OBSERVATION_MODIFIER", 19, 28], ["bead types", "OBSERVATION", 29, 39]]], ["The proportion of actual positive B cells among all bead-bound cells decreased with lower frequencies of FR\u03b1+/Sp2/0+ B cells among PBMCs.", [["B cells", "ANATOMY", 34, 41], ["cells", "ANATOMY", 63, 68], ["FR\u03b1+/Sp2/0+ B cells", "ANATOMY", 105, 124], ["PBMCs", "ANATOMY", 131, 136], ["B cells", "CELL", 34, 41], ["cells", "CELL", 63, 68], ["FR\u03b1", "GENE_OR_GENE_PRODUCT", 105, 108], ["PBMCs", "CELL", 131, 136], ["positive B cells", "CELL_TYPE", 25, 41], ["bead-bound cells", "CELL_LINE", 52, 68], ["FR\u03b1", "PROTEIN", 105, 108], ["Sp2", "PROTEIN", 110, 113], ["B cells", "CELL_TYPE", 117, 124], ["PBMCs", "CELL_TYPE", 131, 136], ["actual positive B cells", "PROBLEM", 18, 41], ["all bead-bound cells", "TEST", 48, 68], ["FR\u03b1", "TEST", 105, 108], ["Sp2", "TEST", 110, 113], ["PBMCs", "TEST", 131, 136], ["positive B cells", "OBSERVATION", 25, 41], ["bound cells", "OBSERVATION", 57, 68], ["lower frequencies", "OBSERVATION_MODIFIER", 84, 101]]], ["When B cells were found in high frequencies (\u22651:100) in human blood, the proportion of Actual positive events, the specific B cells recognized by the beads, ranged from 5 to 75% of the total bound cells, with the SA-Blue 1.1 \u00b5m LC-LC biotin beads able to detect the highest proportion (75%).", [["B cells", "ANATOMY", 5, 12], ["blood", "ANATOMY", 62, 67], ["B cells", "ANATOMY", 124, 131], ["beads", "ANATOMY", 150, 155], ["cells", "ANATOMY", 197, 202], ["biotin", "CHEMICAL", 234, 240], ["B cells", "CELL", 5, 12], ["human", "ORGANISM", 56, 61], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["B cells", "CELL", 124, 131], ["cells", "CELL", 197, 202], ["B cells", "CELL_TYPE", 5, 12], ["B cells", "CELL_TYPE", 124, 131], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["B cells", "PROBLEM", 5, 12], ["high frequencies", "PROBLEM", 27, 43], ["human blood", "TEST", 56, 67], ["Actual positive events", "PROBLEM", 87, 109], ["the specific B cells", "PROBLEM", 111, 131], ["the SA", "TEST", 209, 215], ["LC biotin beads", "TREATMENT", 231, 246], ["high frequencies", "OBSERVATION_MODIFIER", 27, 43], ["positive events", "OBSERVATION", 94, 109]]], ["Although fluorescent activated cell sorting could enable separating a single cell from a heterogeneous population, the detection of cell populations with a low frequency remains challenging and presents a technical limitation with different protocols (33, 34).", [["cell", "ANATOMY", 31, 35], ["cell", "ANATOMY", 77, 81], ["cell", "ANATOMY", 132, 136], ["cell", "CELL", 31, 35], ["cell", "CELL", 77, 81], ["cell populations", "CELL", 132, 148], ["fluorescent activated cell sorting", "PROBLEM", 9, 43], ["a heterogeneous population", "PROBLEM", 87, 113], ["cell populations", "PROBLEM", 132, 148], ["different protocols", "TEST", 231, 250], ["activated cell", "OBSERVATION", 21, 35], ["heterogeneous", "OBSERVATION_MODIFIER", 89, 102], ["population", "OBSERVATION", 103, 113], ["cell populations", "OBSERVATION", 132, 148], ["low frequency", "OBSERVATION_MODIFIER", 156, 169]]], ["Consistent with previous studies, here, we observed great variability in the acquired numbers of cells when analyzing samples with very low antigen-specific B cell frequencies.", [["cells", "ANATOMY", 97, 102], ["samples", "ANATOMY", 118, 125], ["B cell", "ANATOMY", 157, 163], ["cells", "CELL", 97, 102], ["antigen", "GENE_OR_GENE_PRODUCT", 140, 147], ["B cell", "CELL", 157, 163], ["previous studies", "TEST", 16, 32], ["great variability", "PROBLEM", 52, 69], ["analyzing samples", "TEST", 108, 125], ["very low antigen", "PROBLEM", 131, 147], ["great", "OBSERVATION_MODIFIER", 52, 57], ["variability", "OBSERVATION_MODIFIER", 58, 69], ["cell frequencies", "OBSERVATION", 159, 175]]], ["This implies that only active and high frequency humoral responses may be readily studied in the present context, while the detection of low frequency B cells represents an inherent limitation of this methodology and requires further optimization.", [["B cells", "ANATOMY", 151, 158], ["B cells", "CELL", 151, 158], ["low frequency B cells", "CELL_TYPE", 137, 158], ["low frequency B cells", "PROBLEM", 137, 158], ["this methodology", "TREATMENT", 196, 212], ["further optimization", "TREATMENT", 226, 246], ["active", "OBSERVATION_MODIFIER", 23, 29]]], ["As a next step, we asked whether using this protocol, fluorescent beads coated with melanoma cell line antigens may be able to identify antigen-reactive B cells in individuals suffering of malignant melanoma.", [["melanoma cell line", "ANATOMY", 84, 102], ["B cells", "ANATOMY", 153, 160], ["malignant melanoma", "ANATOMY", 189, 207], ["malignant melanoma", "DISEASE", 189, 207], ["melanoma cell line antigens", "CELL", 84, 111], ["B cells", "CELL", 153, 160], ["malignant melanoma", "CANCER", 189, 207], ["melanoma cell line antigens", "CELL_LINE", 84, 111], ["antigen-reactive B cells", "CELL_TYPE", 136, 160], ["this protocol", "TREATMENT", 39, 52], ["fluorescent beads coated", "TREATMENT", 54, 78], ["melanoma cell line antigens", "TREATMENT", 84, 111], ["antigen", "TEST", 136, 143], ["reactive B cells", "PROBLEM", 144, 160], ["malignant melanoma", "PROBLEM", 189, 207], ["melanoma cell line", "OBSERVATION", 84, 102], ["reactive B cells", "OBSERVATION", 144, 160], ["malignant", "OBSERVATION_MODIFIER", 189, 198], ["melanoma", "OBSERVATION", 199, 207]]], ["Using melanoma cell line surface antigen-coated fluorescent beads, we expressed a monoclonal antibody that bound to melanoma cell line protein-coated beads.", [["melanoma cell line surface", "ANATOMY", 6, 32], ["melanoma cell line", "ANATOMY", 116, 134], ["beads", "ANATOMY", 150, 155], ["melanoma", "DISEASE", 6, 14], ["melanoma", "DISEASE", 116, 124], ["melanoma cell line", "CELL", 6, 24], ["surface antigen", "GENE_OR_GENE_PRODUCT", 25, 40], ["melanoma cell line", "CELL", 116, 134], ["melanoma cell line", "CELL_LINE", 6, 24], ["monoclonal antibody", "PROTEIN", 82, 101], ["melanoma cell line protein", "CELL_LINE", 116, 142], ["melanoma cell line surface antigen", "TREATMENT", 6, 40], ["coated fluorescent beads", "PROBLEM", 41, 65], ["a monoclonal antibody", "PROBLEM", 80, 101], ["melanoma cell line protein-coated beads", "TREATMENT", 116, 155], ["melanoma cell line", "OBSERVATION", 6, 24], ["surface", "OBSERVATION_MODIFIER", 25, 32], ["fluorescent beads", "OBSERVATION", 48, 65], ["monoclonal antibody", "OBSERVATION", 82, 101], ["melanoma cell line", "OBSERVATION", 116, 134], ["coated beads", "OBSERVATION", 143, 155]]], ["This suggested that antigen-reactive B cells in human blood may be singled out using fluorescent beads.DiscussionThe selection of single antigen-specific B cells and the identification of their expressed antibodies is critical to gaining a deeper understanding of the nature and functions of active human humoral immune responses.", [["antigen-reactive B cells", "ANATOMY", 20, 44], ["blood", "ANATOMY", 54, 59], ["B cells", "ANATOMY", 154, 161], ["antigen", "GENE_OR_GENE_PRODUCT", 20, 27], ["B cells", "CELL", 37, 44], ["human", "ORGANISM", 48, 53], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["antigen", "GENE_OR_GENE_PRODUCT", 137, 144], ["B cells", "CELL", 154, 161], ["human", "ORGANISM", 299, 304], ["antigen-reactive B cells", "CELL_TYPE", 20, 44], ["B cells", "CELL_TYPE", 154, 161], ["antibodies", "PROTEIN", 204, 214], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 299, 304], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 299, 304], ["antigen", "TEST", 20, 27], ["reactive B cells in human blood", "PROBLEM", 28, 59], ["fluorescent beads", "TREATMENT", 85, 102], ["reactive B cells", "OBSERVATION", 28, 44]]], ["Identification of B cells, as well as cloning and production of their heavy and light chain matched antigen-specific monoclonal antibodies thus remain highly desirable in immunology research and antibody discovery.", [["B cells", "ANATOMY", 18, 25], ["B cells", "CELL", 18, 25], ["antigen", "GENE_OR_GENE_PRODUCT", 100, 107], ["B cells", "CELL_TYPE", 18, 25], ["heavy and light chain", "PROTEIN", 70, 91], ["monoclonal antibodies", "PROTEIN", 117, 138], ["B cells", "PROBLEM", 18, 25], ["light chain matched antigen", "TEST", 80, 107], ["specific monoclonal antibodies", "PROBLEM", 108, 138], ["B cells", "OBSERVATION", 18, 25], ["monoclonal antibodies", "OBSERVATION", 117, 138]]], ["Consequently, discovery of antigen-specific B cell clones forms the focus of numerous high- and low-throughput approaches (12\u201314).", [["B cell clones", "ANATOMY", 44, 57], ["antigen", "GENE_OR_GENE_PRODUCT", 27, 34], ["B cell clones", "CELL", 44, 57], ["antigen-specific B cell clones", "CELL_LINE", 27, 57], ["antigen", "TEST", 27, 34], ["specific B cell clones", "PROBLEM", 35, 57], ["B cell clones", "OBSERVATION", 44, 57], ["focus", "OBSERVATION_MODIFIER", 68, 73], ["numerous", "OBSERVATION_MODIFIER", 77, 85], ["high", "OBSERVATION_MODIFIER", 86, 90], ["low", "OBSERVATION_MODIFIER", 96, 99]]], ["Our bead-based protocol may provide an alternative, readily applicable means for exploring human B cells by facilitating the study of single B cell-derived antibodies and their functional profiles.", [["B cells", "ANATOMY", 97, 104], ["B cell", "ANATOMY", 141, 147], ["human", "ORGANISM", 91, 96], ["B cells", "CELL", 97, 104], ["B cell", "CELL", 141, 147], ["human B cells", "CELL_TYPE", 91, 104], ["B cell", "CELL_TYPE", 141, 147], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["Our bead-based protocol", "TREATMENT", 0, 23], ["human B cells", "TREATMENT", 91, 104], ["the study", "TEST", 121, 130]]], ["Since the frequency of antigen-specific B cells in the human circulation remains \u22641% of the total B cell populations (35), increasing the probability for more specific selection of such low-frequency B cells remains a major challenge with this and many other available technologies.", [["B cells", "ANATOMY", 40, 47], ["B cell", "ANATOMY", 98, 104], ["B cells", "ANATOMY", 200, 207], ["antigen", "GENE_OR_GENE_PRODUCT", 23, 30], ["B cells", "CELL", 40, 47], ["human", "ORGANISM", 55, 60], ["B cell populations", "CELL", 98, 116], ["B cells", "CELL", 200, 207], ["B cells", "CELL_TYPE", 40, 47], ["B cell populations", "CELL_TYPE", 98, 116], ["low-frequency B cells", "CELL_TYPE", 186, 207], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["antigen", "TEST", 23, 30], ["the human circulation", "TEST", 51, 72], ["the total B cell populations", "TEST", 88, 116], ["such low-frequency B cells", "PROBLEM", 181, 207]]], ["Future efforts may help improve specific selection by incorporating additional selection markers such as beads of multiple fluorophores (31), or B cell activation markers to single out BCR-activated cells more likely to be matured antibody-expressing clones (36, 37).", [["B cell", "ANATOMY", 145, 151], ["cells", "ANATOMY", 199, 204], ["B cell", "CELL", 145, 151], ["BCR", "GENE_OR_GENE_PRODUCT", 185, 188], ["cells", "CELL", 199, 204], ["clones", "CELL", 251, 257], ["B cell activation markers", "PROTEIN", 145, 170], ["BCR", "PROTEIN", 185, 188], ["matured antibody-expressing clones", "CELL_LINE", 223, 257], ["additional selection markers", "TREATMENT", 68, 96], ["multiple fluorophores", "TREATMENT", 114, 135], ["B cell activation markers", "TEST", 145, 170], ["activated cells", "PROBLEM", 189, 204]]], ["An alternative strategy may entail an additional imaging tool to verify selection of single antigen-reactive B cells subsequent to cell sorting (38).", [["B cells", "ANATOMY", 109, 116], ["cell", "ANATOMY", 131, 135], ["B cells", "CELL", 109, 116], ["cell", "CELL", 131, 135], ["single antigen-reactive B cells", "CELL_TYPE", 85, 116], ["an additional imaging tool", "TEST", 35, 61], ["single antigen", "TEST", 85, 99], ["cell sorting", "TEST", 131, 143], ["reactive B cells", "OBSERVATION", 100, 116]]], ["Furthermore, adjusting the cloning process to identify antibodies of different subclasses or specificities or from specific B cell subsets could improve the chance of detecting clones and clonal families in certain diseases, in which immunological conditions may promote specific antibody profiles (39\u201342).", [["B cell", "ANATOMY", 124, 130], ["clones", "ANATOMY", 177, 183], ["B cell", "CELL", 124, 130], ["clones", "CELL", 177, 183], ["antibodies", "PROTEIN", 55, 65], ["B cell subsets", "CELL_TYPE", 124, 138], ["the cloning process", "TREATMENT", 23, 42], ["different subclasses", "PROBLEM", 69, 89], ["specific B cell subsets", "PROBLEM", 115, 138], ["clonal families in certain diseases", "PROBLEM", 188, 223], ["specific antibody profiles", "TEST", 271, 297], ["cell subsets", "OBSERVATION", 126, 138]]], ["Individually or combined, such approaches may help increase the chances of clonal selection.DiscussionIn summary, we describe the establishment of a methodology to identify single antibody-expressing cells and to produce and test their sequenced recombinant antibodies in a workflow that may be readily applicable in any basic and translational immunology laboratory setting.", [["cells", "ANATOMY", 200, 205], ["clonal", "CELL", 75, 81], ["cells", "CELL", 200, 205], ["single antibody-expressing cells", "CELL_TYPE", 173, 205], ["recombinant antibodies", "PROTEIN", 246, 268], ["clonal selection", "PROBLEM", 75, 91], ["single antibody-expressing cells", "PROBLEM", 173, 205], ["clonal selection", "OBSERVATION", 75, 91]]], ["This single cell-to-functional antibody strategy may open the way for new opportunities to analyze B cells and their antibody profiles at the single cell level and may be potentially applied to help unravel diverse humoral immune repertoires in blood and tissues and in different health and disease conditions.Ethics StatementHuman immune cells were isolated from the venous blood of human volunteers.", [["cell", "ANATOMY", 12, 16], ["B cells", "ANATOMY", 99, 106], ["cell", "ANATOMY", 149, 153], ["blood", "ANATOMY", 245, 250], ["tissues", "ANATOMY", 255, 262], ["immune cells", "ANATOMY", 332, 344], ["venous blood", "ANATOMY", 368, 380], ["cell", "CELL", 12, 16], ["B cells", "CELL", 99, 106], ["single cell", "CELL", 142, 153], ["blood", "ORGANISM_SUBSTANCE", 245, 250], ["tissues", "TISSUE", 255, 262], ["StatementHuman immune cells", "CELL", 317, 344], ["venous blood", "ORGANISM_SUBSTANCE", 368, 380], ["human", "ORGANISM", 384, 389], ["volunteers", "ORGANISM", 390, 400], ["B cells", "CELL_TYPE", 99, 106], ["StatementHuman immune cells", "CELL_LINE", 317, 344], ["human", "SPECIES", 384, 389], ["human", "SPECIES", 384, 389], ["functional antibody strategy", "TREATMENT", 20, 48], ["their antibody profiles", "TEST", 111, 134], ["disease conditions", "PROBLEM", 291, 309], ["Ethics StatementHuman immune cells", "TREATMENT", 310, 344], ["humoral immune repertoires", "OBSERVATION", 215, 241], ["tissues", "ANATOMY", 255, 262], ["venous", "ANATOMY", 368, 374]]], ["Specimens were collected with informed written consent in accordance with the Declaration of Helsinki.Author ContributionsSK, PK, KL, and FN conceived the study, and IC, KI, SC, PK, KL, FN, AT, and SK designed the methodology.", [["Specimens", "ANATOMY", 0, 9], ["FN", "PROTEIN", 138, 140], ["FN", "PROTEIN", 186, 188], ["the study", "TEST", 151, 160], ["IC", "TEST", 166, 168]]], ["IC, KI, PK, SC, SL, MF, and AC acquired data, generated materials, or helped with the data analysis and interpretation.", [["IC, KI, PK, SC, SL, MF, and AC acquired data", "TEST", 0, 44], ["the data analysis", "TEST", 82, 99], ["SC", "ANATOMY", 12, 14], ["SL", "ANATOMY", 16, 18]]], ["SK, PK, KI, IC, and SC wrote the manuscript.", [["SK", "CHEMICAL", 0, 2], ["PK", "GENE_OR_GENE_PRODUCT", 4, 6], ["SC", "ANATOMY", 20, 22]]], ["IC, KI, SC, SL, MF, AC, JS, AT, FN, PK, KL, and SK discussed and interpreted the data and edited the manuscript.", [["SC", "ANATOMY", 8, 10]]], ["SK supervised the study, led and coordinated the project.Conflict of Interest StatementSK and JS are founders and shareholders of IGEM Therapeutics Ltd.", [["SK", "CHEMICAL", 0, 2], ["the study", "TEST", 14, 23]]], ["FN is an employee of Sanofi US.", [["FN", "PROTEIN", 0, 2]]]], "PMC7300872": [["Case series ::: INTRODUCTIONOn April 30, a 58\u2010year old female patient presented to the hospital with a 1 hr acute onset chest pain on the background of recently positive SARS\u2010CoV\u20102 nose swab.", [["chest", "ANATOMY", 120, 125], ["chest pain", "DISEASE", 120, 130], ["SARS", "DISEASE", 170, 174], ["female", "ORGANISM", 55, 61], ["patient", "ORGANISM", 62, 69], ["chest", "ORGANISM_SUBDIVISION", 120, 125], ["patient", "SPECIES", 62, 69], ["a 1 hr acute onset chest pain", "PROBLEM", 101, 130], ["recently positive SARS", "PROBLEM", 152, 174], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["chest", "ANATOMY", 120, 125], ["pain", "OBSERVATION", 126, 130]]], ["ECG revealed infero\u2010posterior STEMI and, the patient immediately received loading doses of dual antiplatelet therapy (ticagrelor 180 mg and aspirin 300 mg) and 2.5 mg of subcutaneous fondaparinux.", [["subcutaneous", "ANATOMY", 170, 182], ["STEMI", "DISEASE", 30, 35], ["ticagrelor", "CHEMICAL", 118, 128], ["aspirin", "CHEMICAL", 140, 147], ["fondaparinux", "CHEMICAL", 183, 195], ["ticagrelor", "CHEMICAL", 118, 128], ["aspirin", "CHEMICAL", 140, 147], ["fondaparinux", "CHEMICAL", 183, 195], ["patient", "ORGANISM", 45, 52], ["ticagrelor", "SIMPLE_CHEMICAL", 118, 128], ["aspirin", "SIMPLE_CHEMICAL", 140, 147], ["fondaparinux", "SIMPLE_CHEMICAL", 183, 195], ["patient", "SPECIES", 45, 52], ["ECG", "TEST", 0, 3], ["infero\u2010posterior STEMI", "PROBLEM", 13, 35], ["dual antiplatelet therapy", "TREATMENT", 91, 116], ["ticagrelor", "TREATMENT", 118, 128], ["aspirin", "TREATMENT", 140, 147], ["subcutaneous fondaparinux", "TREATMENT", 170, 195], ["infero\u2010posterior", "OBSERVATION_MODIFIER", 13, 29], ["STEMI", "OBSERVATION", 30, 35]]], ["Revascularization was planned through primary PCI, and the patient was immediately transferred to the catheterization lab.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["Revascularization", "TREATMENT", 0, 17], ["primary PCI", "TREATMENT", 38, 49]]], ["Coronary angiography showed a massive thrombus occluding right coronary artery (Figure 1).", [["Coronary", "ANATOMY", 0, 8], ["thrombus", "ANATOMY", 38, 46], ["right coronary artery", "ANATOMY", 57, 78], ["thrombus", "DISEASE", 38, 46], ["Coronary", "MULTI-TISSUE_STRUCTURE", 0, 8], ["thrombus", "PATHOLOGICAL_FORMATION", 38, 46], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 63, 78], ["Coronary angiography", "TEST", 0, 20], ["a massive thrombus occluding right coronary artery", "PROBLEM", 28, 78], ["massive", "OBSERVATION_MODIFIER", 30, 37], ["thrombus", "OBSERVATION", 38, 46], ["right coronary artery", "ANATOMY", 57, 78]]], ["An intra\u2010arterial weight\u2010adjusted dose of heparin was administrated.", [["heparin", "CHEMICAL", 42, 49], ["heparin", "SIMPLE_CHEMICAL", 42, 49], ["An intra\u2010arterial weight\u2010adjusted dose of heparin", "TREATMENT", 0, 49]]], ["Wiring was successfully performed; however, multiple balloon dilatation failed to restore blood flow (Figure 2).", [["balloon", "ANATOMY", 53, 60], ["blood", "ANATOMY", 90, 95], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["multiple balloon dilatation", "TREATMENT", 44, 71], ["blood flow", "TEST", 90, 100], ["balloon", "OBSERVATION_MODIFIER", 53, 60], ["dilatation", "OBSERVATION", 61, 71]]], ["Therefore, aspiration thrombectomy was performed thorough aspiration catheter (export catheter), but also failed despite severe attempts.", [["aspiration thrombectomy", "TREATMENT", 11, 34], ["thorough aspiration catheter (export catheter", "TREATMENT", 49, 94], ["aspiration thrombectomy", "OBSERVATION", 11, 34], ["catheter", "OBSERVATION", 86, 94], ["severe", "OBSERVATION_MODIFIER", 121, 127]]], ["Intravenous bolus dose injection of GP IIb/IIIa inhibitor (eptifibatide) followed by continuous infusion due to heavy thrombotic burden.", [["Intravenous", "ANATOMY", 0, 11], ["GP IIb/IIIa inhibitor", "CHEMICAL", 36, 57], ["eptifibatide", "CHEMICAL", 59, 71], ["thrombotic", "DISEASE", 118, 128], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["GP IIb/IIIa", "GENE_OR_GENE_PRODUCT", 36, 47], ["eptifibatide", "SIMPLE_CHEMICAL", 59, 71], ["Intravenous bolus dose injection", "TREATMENT", 0, 32], ["GP IIb/IIIa inhibitor (eptifibatide)", "TREATMENT", 36, 72], ["continuous infusion", "TREATMENT", 85, 104], ["heavy thrombotic burden", "PROBLEM", 112, 135], ["heavy", "OBSERVATION_MODIFIER", 112, 117], ["thrombotic", "OBSERVATION", 118, 128]]], ["Finally, a trial of thrombus aspiration was attempted using 6Fr Guideliner but was unfortunately unsuccessful (Figure 3).", [["thrombus", "ANATOMY", 20, 28], ["thrombus", "DISEASE", 20, 28], ["thrombus", "PATHOLOGICAL_FORMATION", 20, 28], ["thrombus aspiration", "PROBLEM", 20, 39], ["6Fr Guideliner", "TREATMENT", 60, 74], ["thrombus", "OBSERVATION", 20, 28]]], ["The decision was made to abandon the procedure and transfer the patient back to the intensive therapeutic unit (ITU) with continuous 48 hr intravenous infusion of eptifibatide as well as activated coagulation time guided therapeutic intravenous heparin followed by repeat coronary angiography.", [["intravenous", "ANATOMY", 139, 150], ["intravenous", "ANATOMY", 233, 244], ["coronary", "ANATOMY", 272, 280], ["eptifibatide", "CHEMICAL", 163, 175], ["heparin", "CHEMICAL", 245, 252], ["eptifibatide", "CHEMICAL", 163, 175], ["patient", "ORGANISM", 64, 71], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 139, 150], ["eptifibatide", "SIMPLE_CHEMICAL", 163, 175], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 233, 244], ["heparin", "SIMPLE_CHEMICAL", 245, 252], ["coronary", "MULTI-TISSUE_STRUCTURE", 272, 280], ["patient", "SPECIES", 64, 71], ["the procedure", "TREATMENT", 33, 46], ["continuous 48 hr intravenous infusion of eptifibatide", "TREATMENT", 122, 175], ["activated coagulation time", "TREATMENT", 187, 213], ["therapeutic intravenous heparin", "TREATMENT", 221, 252], ["repeat coronary angiography", "TEST", 265, 292], ["coronary", "ANATOMY", 272, 280]]], ["Also, ticagrelor was replaced by prasugrel (with a 60 mg loading dose).", [["ticagrelor", "CHEMICAL", 6, 16], ["prasugrel", "CHEMICAL", 33, 42], ["ticagrelor", "CHEMICAL", 6, 16], ["prasugrel", "CHEMICAL", 33, 42], ["ticagrelor", "SIMPLE_CHEMICAL", 6, 16], ["prasugrel", "SIMPLE_CHEMICAL", 33, 42], ["ticagrelor", "TREATMENT", 6, 16], ["prasugrel", "TREATMENT", 33, 42]]], ["In the ITU intravenous fluids were commenced for low blood pressure.Case series ::: INTRODUCTIONAdditionally, patient's ECG showed atrial tachycardia for which amiodarone infusion was started.", [["intravenous", "ANATOMY", 11, 22], ["blood", "ANATOMY", 53, 58], ["atrial", "ANATOMY", 131, 137], ["atrial tachycardia", "DISEASE", 131, 149], ["amiodarone", "CHEMICAL", 160, 170], ["amiodarone", "CHEMICAL", 160, 170], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["patient", "ORGANISM", 110, 117], ["atrial", "MULTI-TISSUE_STRUCTURE", 131, 137], ["amiodarone", "SIMPLE_CHEMICAL", 160, 170], ["patient", "SPECIES", 110, 117], ["the ITU intravenous fluids", "TREATMENT", 3, 29], ["low blood pressure", "PROBLEM", 49, 67], ["patient's ECG", "TEST", 110, 123], ["atrial tachycardia", "PROBLEM", 131, 149], ["amiodarone infusion", "TREATMENT", 160, 179], ["atrial", "ANATOMY", 131, 137], ["tachycardia", "OBSERVATION", 138, 149]]], ["Left ventricular ejection fraction was estimated at 40%.", [["Left ventricular", "ANATOMY", 0, 16], ["Left ventricular", "MULTI-TISSUE_STRUCTURE", 0, 16], ["Left ventricular ejection fraction", "TEST", 0, 34], ["ventricular", "ANATOMY", 5, 16], ["ejection fraction", "OBSERVATION", 17, 34]]], ["Blood results illustrated acute kidney injury (eGFR 28 ml/min, urea 32 mmol/L and creatinine 164 mmol/L), elevated C\u2010reactive protein elevation (225 mg/L) and mild leucocytosis (12.3 G/L, N < 10).", [["Blood", "ANATOMY", 0, 5], ["kidney", "ANATOMY", 32, 38], ["acute kidney injury", "DISEASE", 26, 45], ["urea", "CHEMICAL", 63, 67], ["creatinine", "CHEMICAL", 82, 92], ["leucocytosis", "DISEASE", 164, 176], ["urea", "CHEMICAL", 63, 67], ["creatinine", "CHEMICAL", 82, 92], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["kidney", "ORGAN", 32, 38], ["C\u2010reactive protein", "PROTEIN", 115, 133], ["Blood results", "TEST", 0, 13], ["acute kidney injury", "PROBLEM", 26, 45], ["eGFR", "TEST", 47, 51], ["urea", "TEST", 63, 67], ["creatinine", "TEST", 82, 92], ["elevated C\u2010reactive protein elevation", "PROBLEM", 106, 143], ["mild leucocytosis", "PROBLEM", 159, 176], ["G/L", "TEST", 183, 186], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["kidney", "ANATOMY", 32, 38], ["injury", "OBSERVATION", 39, 45], ["elevation", "OBSERVATION_MODIFIER", 134, 143], ["mild", "OBSERVATION_MODIFIER", 159, 163], ["leucocytosis", "OBSERVATION", 164, 176]]], ["Unfortunately, the patient finally died 48 hr later from hemodynamic and respiratory deterioration.DISCUSSIONPrevious observational studies have illustrated that severe bacterial or viral infection may be associated with intravascular disseminated coagulopathy with thrombocytopenia.2NETS are an extracellular web of chromatin, oxidant enzymes and mitochondrial proteins released by neutrophils to contain the infection; however, it might induce microvascular thrombosis and therefore have an impact on patients' coagulation.4Nevertheless, there is no evidence of direct action for COVID\u201019 on platelet function.", [["intravascular", "ANATOMY", 221, 234], ["extracellular", "ANATOMY", 296, 309], ["chromatin", "ANATOMY", 317, 326], ["mitochondrial", "ANATOMY", 348, 361], ["neutrophils", "ANATOMY", 383, 394], ["microvascular", "ANATOMY", 446, 459], ["platelet", "ANATOMY", 594, 602], ["bacterial or viral infection", "DISEASE", 169, 197], ["intravascular disseminated coagulopathy", "DISEASE", 221, 260], ["infection", "DISEASE", 410, 419], ["thrombosis", "DISEASE", 460, 470], ["patient", "ORGANISM", 19, 26], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 221, 234], ["2NETS", "GENE_OR_GENE_PRODUCT", 283, 288], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 296, 309], ["chromatin", "CELLULAR_COMPONENT", 317, 326], ["mitochondrial", "CELLULAR_COMPONENT", 348, 361], ["neutrophils", "CELL", 383, 394], ["microvascular", "TISSUE", 446, 459], ["patients", "ORGANISM", 503, 511], ["platelet", "CELL", 594, 602], ["2NETS", "PROTEIN", 283, 288], ["chromatin", "DNA", 317, 326], ["oxidant enzymes", "PROTEIN", 328, 343], ["mitochondrial proteins", "PROTEIN", 348, 370], ["neutrophils", "CELL_TYPE", 383, 394], ["patient", "SPECIES", 19, 26], ["patients", "SPECIES", 503, 511], ["observational studies", "TEST", 118, 139], ["severe bacterial or viral infection", "PROBLEM", 162, 197], ["intravascular disseminated coagulopathy", "PROBLEM", 221, 260], ["thrombocytopenia.", "PROBLEM", 266, 283], ["oxidant enzymes", "TEST", 328, 343], ["mitochondrial proteins", "PROBLEM", 348, 370], ["the infection", "PROBLEM", 406, 419], ["microvascular thrombosis", "PROBLEM", 446, 470], ["patients' coagulation", "TREATMENT", 503, 524], ["COVID\u2010", "TEST", 582, 588], ["platelet function", "TEST", 594, 611], ["respiratory", "ANATOMY", 73, 84], ["severe", "OBSERVATION_MODIFIER", 162, 168], ["bacterial", "OBSERVATION", 169, 178], ["viral", "OBSERVATION_MODIFIER", 182, 187], ["infection", "OBSERVATION", 188, 197], ["may be associated with", "UNCERTAINTY", 198, 220], ["intravascular", "OBSERVATION_MODIFIER", 221, 234], ["disseminated", "OBSERVATION_MODIFIER", 235, 247], ["coagulopathy", "OBSERVATION", 248, 260], ["extracellular", "OBSERVATION_MODIFIER", 296, 309], ["web", "OBSERVATION", 310, 313], ["infection", "OBSERVATION", 410, 419], ["microvascular", "ANATOMY", 446, 459], ["thrombosis", "OBSERVATION", 460, 470], ["no evidence of", "UNCERTAINTY", 549, 563]]], ["NETS were noticed in patients with severe ARDS and COVID\u201019; it is associated with the worst prognosis.", [["ARDS", "DISEASE", 42, 46], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["severe ARDS", "PROBLEM", 35, 46], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["ARDS", "OBSERVATION", 42, 46]]], ["It was observed that high levels of NETS' highly specific markers were in the sera of COVID\u201019 patients.4Both arterial and venous thrombosis will significantly increase as a result of NETS; therefore, we assume that infection with SARS\u2010CoV\u20102 has exerted a significant role in this massive intracoronary thrombosis and unfavorable outcome.5The acute viral infection is associated with a significant rise in the incidence of acute myocardial infarction as a result of the acute inflammatory response and endothelial dysfunction.6, 7 Besides, with surging numbers of COVID\u201019 patients worldwide, concomitantly with the high prevalence of coronary artery disease, it is expected to experience a significant rise in the numbers of patients with combined STEMI and COVID\u201019.8", [["sera", "ANATOMY", 78, 82], ["arterial", "ANATOMY", 110, 118], ["venous", "ANATOMY", 123, 129], ["intracoronary", "ANATOMY", 289, 302], ["myocardial", "ANATOMY", 429, 439], ["endothelial", "ANATOMY", 502, 513], ["coronary artery", "ANATOMY", 635, 650], ["arterial and venous thrombosis", "DISEASE", 110, 140], ["NETS", "DISEASE", 184, 188], ["infection", "DISEASE", 216, 225], ["SARS", "DISEASE", 231, 235], ["CoV\u20102", "CHEMICAL", 236, 241], ["intracoronary thrombosis", "DISEASE", 289, 313], ["viral infection", "DISEASE", 349, 364], ["acute myocardial infarction", "DISEASE", 423, 450], ["endothelial dysfunction", "DISEASE", 502, 525], ["coronary artery disease", "DISEASE", 635, 658], ["STEMI", "DISEASE", 749, 754], ["COVID", "DISEASE", 759, 764], ["NETS", "GENE_OR_GENE_PRODUCT", 36, 40], ["sera", "ORGANISM_SUBSTANCE", 78, 82], ["patients", "ORGANISM", 95, 103], ["arterial", "MULTI-TISSUE_STRUCTURE", 110, 118], ["venous", "MULTI-TISSUE_STRUCTURE", 123, 129], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 236, 241], ["intracoronary", "IMMATERIAL_ANATOMICAL_ENTITY", 289, 302], ["myocardial", "MULTI-TISSUE_STRUCTURE", 429, 439], ["endothelial", "TISSUE", 502, 513], ["patients", "ORGANISM", 573, 581], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 635, 650], ["patients", "ORGANISM", 726, 734], ["NETS", "PROTEIN", 36, 40], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 573, 581], ["patients", "SPECIES", 726, 734], ["high levels of NETS'", "PROBLEM", 21, 41], ["4Both arterial and venous thrombosis", "PROBLEM", 104, 140], ["NETS", "PROBLEM", 184, 188], ["infection", "PROBLEM", 216, 225], ["SARS", "PROBLEM", 231, 235], ["this massive intracoronary thrombosis", "PROBLEM", 276, 313], ["The acute viral infection", "PROBLEM", 339, 364], ["acute myocardial infarction", "PROBLEM", 423, 450], ["the acute inflammatory response", "PROBLEM", 466, 497], ["endothelial dysfunction", "PROBLEM", 502, 525], ["coronary artery disease", "PROBLEM", 635, 658], ["a significant rise", "PROBLEM", 689, 707], ["combined STEMI", "PROBLEM", 740, 754], ["COVID", "TEST", 759, 764], ["high", "OBSERVATION_MODIFIER", 21, 25], ["arterial", "ANATOMY", 110, 118], ["venous", "ANATOMY", 123, 129], ["thrombosis", "OBSERVATION", 130, 140], ["increase", "OBSERVATION_MODIFIER", 160, 168], ["infection", "OBSERVATION", 216, 225], ["significant", "OBSERVATION_MODIFIER", 256, 267], ["massive", "OBSERVATION_MODIFIER", 281, 288], ["intracoronary", "ANATOMY", 289, 302], ["thrombosis", "OBSERVATION", 303, 313], ["acute", "OBSERVATION_MODIFIER", 343, 348], ["viral", "OBSERVATION_MODIFIER", 349, 354], ["infection", "OBSERVATION", 355, 364], ["significant", "OBSERVATION_MODIFIER", 386, 397], ["rise", "OBSERVATION_MODIFIER", 398, 402], ["acute", "OBSERVATION_MODIFIER", 423, 428], ["myocardial", "ANATOMY", 429, 439], ["infarction", "OBSERVATION", 440, 450], ["acute", "OBSERVATION_MODIFIER", 470, 475], ["inflammatory", "OBSERVATION", 476, 488], ["endothelial dysfunction", "OBSERVATION", 502, 525], ["coronary artery", "ANATOMY", 635, 650], ["disease", "OBSERVATION", 651, 658], ["significant", "OBSERVATION_MODIFIER", 691, 702], ["rise", "OBSERVATION_MODIFIER", 703, 707]]]], "PMC7526849": [["In the context of this medical crisis, we here exemplify the rapidity by which dissemination of scientific data impacts real-life medical prescriptions.LETTERIn Strasbourg University Hospital, France, which was severely affected by the SARS-CoV-2 epidemic at the beginning of March 2020, we analyzed the consumption of antiviral agents according to the emergence of relevant scientific data.", [["SARS", "DISEASE", 236, 240], ["this medical crisis", "PROBLEM", 18, 37], ["severely affected", "PROBLEM", 211, 228], ["the SARS", "TEST", 232, 240], ["CoV", "TEST", 241, 244], ["antiviral agents", "TREATMENT", 319, 335]]], ["At this time, no medically evaluated standard treatment was available, and so, the need for information was vital.", [["standard treatment", "TREATMENT", 37, 55]]], ["The treatment strategies in our center, outside clinical trials, included standard of care alone or in combination with lopinavir-ritonavir or hydroxychloroquine (HCQ) in off-label utilization and without grading of the recommendations.", [["lopinavir-ritonavir", "CHEMICAL", 120, 139], ["hydroxychloroquine", "CHEMICAL", 143, 161], ["HCQ", "CHEMICAL", 163, 166], ["lopinavir", "CHEMICAL", 120, 129], ["ritonavir", "CHEMICAL", 130, 139], ["hydroxychloroquine", "CHEMICAL", 143, 161], ["HCQ", "CHEMICAL", 163, 166], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 120, 139], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 143, 161], ["HCQ", "SIMPLE_CHEMICAL", 163, 166], ["The treatment strategies", "TREATMENT", 0, 24], ["lopinavir", "TREATMENT", 120, 129], ["ritonavir", "TREATMENT", 130, 139], ["hydroxychloroquine", "TREATMENT", 143, 161], ["HCQ", "TREATMENT", 163, 166]]], ["This strategy was in accordance with the French recommendations.LETTERThe first patients were treated with standard care alone or in combination with lopinavir-ritonavir (Fig. 1).", [["lopinavir-ritonavir", "CHEMICAL", 150, 169], ["lopinavir", "CHEMICAL", 150, 159], ["ritonavir", "CHEMICAL", 160, 169], ["patients", "ORGANISM", 80, 88], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 150, 169], ["patients", "SPECIES", 80, 88], ["standard care", "TREATMENT", 107, 120], ["lopinavir", "TREATMENT", 150, 159], ["ritonavir (Fig", "TREATMENT", 160, 174]]], ["This treatment had shown some efficacy in nonrandomized trials on SARS-CoV and Middle East respiratory syndrome (1).", [["SARS-CoV", "DISEASE", 66, 74], ["Middle East respiratory syndrome", "DISEASE", 79, 111], ["SARS-CoV", "ORGANISM", 66, 74], ["SARS-CoV", "SPECIES", 66, 74], ["This treatment", "TREATMENT", 0, 14], ["SARS", "PROBLEM", 66, 70], ["CoV", "PROBLEM", 71, 74], ["Middle East respiratory syndrome", "PROBLEM", 79, 111], ["Middle", "ANATOMY_MODIFIER", 79, 85], ["respiratory syndrome", "OBSERVATION", 91, 111]]], ["Data on the first randomized clinical trial appeared online on 18 March and showed no benefit of lopinavir\u2013ritonavir (2).", [["lopinavir\u2013ritonavir", "CHEMICAL", 97, 116], ["lopinavir\u2013ritonavir", "CHEMICAL", 97, 116], ["lopinavir\u2013ritonavir", "SIMPLE_CHEMICAL", 97, 116], ["lopinavir\u2013ritonavir", "TREATMENT", 97, 116]]], ["This information triggered a quick decrease in our prescriptions, despite the increase of COVID-19 cases.LETTEROn 20 March, a nonrandomized open-label study on 26 patients treated with hydroxychloroquine (6 patients also received azithromycin) showed some efficacy in decreasing viral load compared with controls (3).", [["hydroxychloroquine", "CHEMICAL", 185, 203], ["azithromycin", "CHEMICAL", 230, 242], ["hydroxychloroquine", "CHEMICAL", 185, 203], ["azithromycin", "CHEMICAL", 230, 242], ["patients", "ORGANISM", 163, 171], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 185, 203], ["patients", "ORGANISM", 207, 215], ["azithromycin", "SIMPLE_CHEMICAL", 230, 242], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 207, 215], ["the increase of COVID", "TREATMENT", 74, 95], ["label study", "TEST", 145, 156], ["hydroxychloroquine", "TREATMENT", 185, 203], ["azithromycin", "TREATMENT", 230, 242], ["decreasing viral load", "PROBLEM", 268, 289], ["decreasing", "OBSERVATION_MODIFIER", 268, 278], ["viral load", "OBSERVATION", 279, 289]]], ["This study was widely shared in the French media.", [["This study", "TEST", 0, 10]]], ["Despite the major limitations of this study\u2014including no outcome data on clinical efficacy or safety, the small number of patients enrolled, and the absence of randomization\u2014we experienced a dramatic increase in our HCQ prescriptions following this publication (Fig. 1).", [["HCQ", "CHEMICAL", 216, 219], ["HCQ", "CHEMICAL", 216, 219], ["patients", "ORGANISM", 122, 130], ["HCQ", "SIMPLE_CHEMICAL", 216, 219], ["patients", "SPECIES", 122, 130], ["this study", "TEST", 33, 43], ["a dramatic increase", "PROBLEM", 189, 208], ["our HCQ prescriptions", "TREATMENT", 212, 233], ["small", "OBSERVATION_MODIFIER", 106, 111], ["number", "OBSERVATION_MODIFIER", 112, 118], ["dramatic", "OBSERVATION_MODIFIER", 191, 199], ["increase", "OBSERVATION_MODIFIER", 200, 208]]], ["The use of azithromycin had the same trend (data not shown).LETTERIn April, HCQ prescriptions decreased for several reasons, including the publication of \u201cnegative\u201d studies, the increase in serious adverse events reported, inclusion of some of our patients in clinical trials, and a decrease of new COVID-19 cases (4, 5).", [["azithromycin", "CHEMICAL", 11, 23], ["HCQ", "CHEMICAL", 76, 79], ["azithromycin", "CHEMICAL", 11, 23], ["HCQ", "CHEMICAL", 76, 79], ["azithromycin", "SIMPLE_CHEMICAL", 11, 23], ["HCQ", "SIMPLE_CHEMICAL", 76, 79], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 248, 256], ["azithromycin", "TREATMENT", 11, 23], ["HCQ prescriptions", "TREATMENT", 76, 93], ["serious adverse events", "PROBLEM", 190, 212], ["new COVID", "TEST", 295, 304], ["increase", "OBSERVATION_MODIFIER", 178, 186]]], ["Following the publication of a large observational study on 22 May showing no beneficial effect of HCQ, this treatment regimen is not authorized anymore in France outside clinical trials (6).", [["HCQ", "CHEMICAL", 99, 102], ["HCQ", "CHEMICAL", 99, 102], ["HCQ", "SIMPLE_CHEMICAL", 99, 102], ["a large observational study", "TEST", 29, 56], ["HCQ", "TREATMENT", 99, 102], ["this treatment regimen", "TREATMENT", 104, 126]]], ["Two weeks later, this article was retracted.LETTERDuring the emergence of this life-threatening pandemic, developing treatment strategies for COVID-19 is challenging with so little relevant scientifically supported data at hand.", [["hand", "ORGANISM_SUBDIVISION", 223, 227], ["treatment strategies", "TREATMENT", 117, 137], ["COVID", "TEST", 142, 147]]], ["Remarkably, we observed that all relevant scientific publications, even if they had important limitations, had rapid and major impacts on the prescription of antivirals.", [["antivirals", "TREATMENT", 158, 168]]], ["Decisively, the results of ongoing randomized clinical trials are urgently needed to define standard treatment as well as novel approaches (7).", [["standard treatment", "TREATMENT", 92, 110]]]]}